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Abstract
Retroviral vectors have been successfully used in the clinic for the correction of 
inherited immunodeficiencies. However, in 2 recent gene therapy trials for X- 
linked Severe Combined Immunodeficiency, 5 patients developed leukaemia. 
This was associated with vector integration near cellular proto-oncogenes, 
leading to their activation; a process known as insertional mutagenesis.
This thesis describes the development of a cell line assay that allows us to 
quantify insertional mutagenesis by retroviral and lentiviral vectors and to analyse 
the mechanisms by which this occurs. The interleukin-3 (IL-3) dependent cell line 
BCL15 is derived from the mouse bone marrow cell line BAF3 and over­
expresses human Bcl2. The frequency at which IL-3 independent mutants are 
obtained following vector transduction is measured. Lentiviral and retroviral 
vectors transform BCL15 cells at similar integrant frequencies of 4.3 x 10"8 and 
1.2 x 10-7, respectively. However, they cause insertional mutagenesis in this 
assay by different mechanisms. The human immunodeficiency virus-1 (HIV-1)- 
derived lentiviral vector HV transforms BCL15 cells by insertional activation of the 
growth hormone receptor (Ghr) gene. An HIV-Ghr fusion transcript was detected. 
It originates from the HIV-1 5’-LTR; it then splices from the HIV-1 major splice 
donor to the splice acceptor of Ghr exon 2. The mutants express GHR and grow 
in response to bovine growth hormone in the foetal calf serum of the culture 
medium. Deletion of the HIV-1 enhancer/promoter in a self-inactivating vector 
prevents this mechanism of transformation. Retroviral vector transformation of 
the BCL15 cell line does not occur via Ghr gene activation. Retroviral vectors up- 
regulate expression of the cytokine IL-3, either by insertion into the IL-3 gene or 
by insertion into other genes, which may act as upstream activators of IL-3 
expression. This assay is a general method to quantitate insertional 
mutagenesis. It may inform the design of safer vectors and can be used in initial 
safety testing of (pre-) clinical vectors.
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Chapter 1
1. Introduction
1.1. Retrovirus Biology
Retroviruses (Retroviridae family) are a unique class of viruses that have single 
stranded (ss) RNA genomes, which serve as templates for reverse transcription 
into double stranded (ds) DNA by an RNA-dependent DNA polymerase known as 
reverse transcriptase. A further distinctive feature of retrovirus replication is, that 
this reverse transcribed dsDNA genome becomes integrated into the host cell 
genome. This property makes vectors derived from these viruses particularly 
suitable for use in gene therapy.
In this thesis, vectors derived from the genomes of Murine Leukaemia Virus 
(MLV) and Human Immunodeficiency Virus-1 (HIV-1) were used. In the ensuing 
text I shall therefore focus on distinctive features of these two viruses. As we 
believe these may play a role in vector-mediated pathogenesis, two stages of the 
retroviral life cycle will receive particular attention: integration and long terminal 
repeat (LTR)-driven gene expression.
1.1.1. Retrovirus Taxonomy
The retroviridae family can be subdivided into seven genera, based on both 
genome structure (See section 1.1.2.) and virion morphology (Table 1.1). MLV is 
a gammaretrovirus; HIV-1 is a lentivirus.
21.
1.1.2. Retroviral genome structure
The RNA genome structures of Moloney MLV (Mo-MLV) and HIV-1 are depicted 
in Figure 1.1. They are 8332bp and 9181 nt in size, respectively.
Gene regulatory sequences are found at the 5’ and 3’ ends of all retroviral 
genomes. In the RNA genome, at the 5’ end, R (repeat) and U5 (unique 5) 
segments are found; the 3’end is made up of a U3 (unique 3) and an identical R 
segment. Simple retroviruses such as Mo-MLV contain 3 genes: gag, pol and 
env. The MLV gag gene encodes the 3 viral structural proteins: matrix (MA), 
capsid (CA) and nucleocapsid (NC) and the polypeptide p12. The pol gene 
encodes the viral enzymes necessary for replication: protease (PR), reverse 
transcriptase (RT)/ RNase H and integrase (IN).
The env gene encodes transmembrane (TM) and surface (SU) glycoproteins. 
They are found in the viral envelope, a lipid bilayer derived from the cell 
membrane, and mediate virus entry into a cell by interacting with specific 
receptors on a cell surface. HIV-1 is a complex retrovirus. Its genome contains 
an additional 6 genes: the regulatory genes tat and rev, and the accessory genes 
nef, vpu, vpr and vif. The functions of these genes will be discussed. In addition 
to MA, CA and NC, HIV-1 gag encodes the polypeptide p6.
1.1.3. Retroviral virion structure
Figure 1.2. depicts the structure of an HIV-1 virion. Two copies of genomic RNA 
with associated primer tRNAs (tRNA(Pro) for MLV (Harada et al. 1979); 
tRNA(3Lys) for HIV-1 (Jiang et al. 1993)) are complexed with nucleocapsid 
protein. This RNA/protein complex is packaged together with the viral enzymes 
(PR, RT, IN) and cellular proteins in a protein shell made up of capsid protein. 
MLV has a roughly spherical core, whereas the HIV-1 core is elongated and 
conical. Matrix protein is found between the capsid and the lipid membrane, in 
which envelope glycoproteins are embedded.
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Figure 1.1. MLV and HIV-1 genome organisation
The RNA genom e structures of MLV (a) and HIV-1 (b) are shown. The gag, pol and env genes are common to 
all retroviruses. HIV-1 regulatory genes tat and rev and accessory genes vif, vpr, vpu and nef are located down­
stream of pol. They partially overlap with env, U3 or each other. Tat and rev are each made up of 2 exons which 
are found in different reading frames. The organisation of Gag, Gag-Pol and Env polyprotein precursors is 
shown below each genom e structure.
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Figure 1.2. Morphology of Retroviridae virions
a. Morphology of betaretrovirus, lentivirus and gammaretrovirus particles. Betaretroviruses have an eccentrically placed round core (formerly known as type B morpho­
logy); lentiviruses have an elongated cone-shaped core and gammaretroviruses have a round core centred in the middle of the particle (formerly known as type C 
morphology). (Reproduced with permission from Principles of Virology 2nd edition, SJ Flint; LW Enquist;VR Racaniello; AM Skalka, ASM Press, Washington DC).
b. Morphology of HIV-1 virions before and after maturation. Immature HIV-1 virions resemble gammaretroviral particles; mature HIV-1 virions have an elongated cone- 
shaped core. (Image obtained from the International Committee on Taxonomy of Viruses database (ICTVdb) with kind permission from Dr Cornelia Buechen-Osmond.This 
image was modified from a model by Drs Louis Henderson and Larry Arthur obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, 
NIH.)
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Figure 1.3.The retrovirus life cycle
The retrovirus life cycle is described in detail in section 1.1. of the introduction. An overview of the early and late events of the retrovirus life cycle is shown here for HIV-1. 
(Reproduced from Freed eta\, Retrovirology 3 :77,2006, with kind permission from the publisher BioMed Central Ltd).
1.1.4. The retroviral life cycle
The retroviral life cycle can be divided into two phases: the early phase 
comprises those steps from attachment of the virus to the cell, to integration of 
the viral genome into host cell DNA. The late phase starts with the transcription 
of viral genes and continues through to the release of new virions. An overview of 
the retroviral life cycle is shown in Figure 1.3 (Freed and Mouland 2006).
1.1.5. Entry
The retroviral life cycle starts with non-specific adsorption of the virus to the cell, 
mediated by cell surface lectins and proteoglycans. Entry occurs through 
interactions between viral envelope glycoproteins with proteins on the cell 
surface, which act as specific receptors. Receptor-usage is one determinant of 
cell tropism i.e. which host species and cell types a particular retrovirus is able to 
infect.
1.1.5.1. MLV tropism
Murine leukaemia viruses have been subclassified into four different host range 
subgroups: ecotropic (MLV-E, infects mouse cells); xenotropic (MLV-X, infects 
cells from species other than mouse), amphotropic (MLV-A, infects cells from 
mice and many other species) and polytropic (MLV-P, infects cells from mice and 
many other species). The receptors used by these different subgroups of MLV 
are multiple transmembrane spanning proteins that function as transporters 
(Table 1.2.). The MLV-A envelope glycoprotein is frequently used in gene therapy 
to pseudotype retroviral cores, because it allows efficient entry into human cells.
1.1.5.2. HIV-1 tropism
The primary attachment receptor used by HIV-1 and its close relatives has been 
identified as CD4, a cell surface marker of helper T cells and also expressed on 
monocytes, macrophages and dendritic cells (Dalgleish et al. 1984; Klatzmann et 
al. 1984). In addition, the chemokine receptors CXCR4 (Feng et al. 1996) or 
CCR5 (Deng et al. 1996; Dragic et al. 1996) are required as co-receptors to 
mediate membrane fusion.
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1.1.5.3. pH-dependent versus pH-independent fusion
HIV-1 and MLV-A enter cells by fusion with the plasma membrane, which is pH-
independent (McClure et al. 1988). Whereas the surface unit (SU) of the viral 
envelope glycoprotein is responsible for recognising a specific receptor, fusion is 
mediated by the transmembrane (TM) domain. It occurs as a result of 
conformational changes in the envelope glycoprotein following receptor binding. 
MLV-E enters cells by fusion with endosomal membranes (McClure et al. 1990). 
This process is pH-dependent, as low pH drives the conformational changes in 
envelope proteins needed for fusion. Vesicular Stomatis Virus (VSV), whose G 
protein is frequently used to pseudotype retroviral particles also gains entry by 
endocytosis (Fan and Sefton 1978).
1.1.6.Uncoating
Following membrane fusion, the retroviral capsid is released into the cytoplasm. 
Subsequent early post-entry events are considered the least well-understood of 
the retroviral life cycle. Uncoating, the (partial) disintegration of the retroviral 
capsid, is necessary for the generation of a reverse transcription complex (RTC). 
Capsid remains tightly associated with MLV RTC (Fassati and Goff 1999), 
whereas HIV-1 sheds its capsid shell rapidly after entry (Fassati and Goff 2001). 
Other viral proteins associated with the two copies of ssRNA genome in the RTC 
include RT and IN (plus NC, MA and Vpr in the case of HIV-1). Several cellular 
proteins have also been shown to be associated with MLV and HIV-1 RTCs.
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Table 1.1. Genera of the Retroviridae family
Genus Typical species Genome
1. Alpharetrovirus Avian Leukosis Virus (ALV) Simple
2. Beta retrovirus Mouse Mammary Tumour Virus (MMTV) Simple
3. Gammaretrovirus Murine Leukaemia Virus (MLV) Simple
4. Delta retrovirus Bovine Leukaemia Virus Complex
5. Epsilonretrovirus Walleye Dermal Sarcoma Virus Simple
6. Lentivirus Human Immunodeficiency Virus Type I (HIV-1) Complex
7. Spumavirus Simian Spumavirus Complex
Table 1.2. Tropism of MLV subgroups and receptor usage
Subgroup Receptor Examples
Ecotropic
Cationic amino acid 
transporter 1 (CAT-1) 
(Kim etal. 1991)
Moloney MLV, Friend 
MLV, AKR MLV (AKV)
Xenotropic
Rmc1 (XPR) (Battini et 
al. 1999; Tailor et al. 
1999; Yang etal. 1999)
Endogenous MLVs
Amphotropic
Inorganic phosphate 
transporter 2 (Pit-2)
(van Zeijl et al. 1994)
Exogenous MLVs
Polytropic
Rmc1 (XPR) (Battini et 
al. 1999; Tailor et al. 
1999; Yang etal. 1999)
Endogenous MLVs 
Mink Cell Focus-inducing 
(MCF) viruses
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1.1.7. Reverse transcription
Reverse transcriptase (RT) is a unique enzyme; it not only has RNA- and DNA- 
dependent DNA polymerase activity (Baltimore 1970; Temin and Mizutani 1970), 
but also possesses an RNase H domain that degrades genomic RNA after it has 
been copied into DNA. An overview of reverse transcription is shown in Figure 
1.4 (Katz and Skalka 1994).
It starts near the 5’end of the retroviral genome. Minus strand synthesis is 
initiated from a tRNA primer bound to the primer binding site (PBS), located just 
downstream of U5. Minus strand (-) strong stop DNA approximately 100bp in 
length is generated, followed by RNase H digestion of the RNA portion of the 
RNA:DNA duplex. Complementary hybridisation of (-) strong stop R sequence to 
the 3’ R sequence on the same or on the other RNA strand then occurs (1st 
template exchange). Extension of minus strand synthesis follows. RNaseH 
digestion removes most plus strand RNA, except at the polypurine tract (PPT) 
which is highly resistant to RNaseH digestion. PPT RNA serves as a primer for 
plus strand (+) strong stop DNA synthesis. HIV also contains a central PPT 
(cPPT) for priming plus strand synthesis. The tRNA primer is removed. (+) strong 
stop DNA then hybridises to the complementary PBS on the minus strand (2nd 
template exchange), leading to the completion of reverse transcription and 
generation of long terminal repeats (LTRs) at both ends of the dsDNA genome. 
The LTRs are essential for the subsequent integration reaction (Panganiban and 
Temin 1983) and for transcription of viral genes thereafter.
The template exchanges during reverse transcription are thought to be 
responsible for the high rate of recombination seen in retroviruses. Also, the RT 
enzyme has no proof reading activity. Whereas cellular DNA polymerase has an 
error rate of 1 misincorporation per 107 to 1011 nucleotides polymerised, the error 
rate of RT is thought to be as high as 1 in 104 to 1 in 106. The low fidelity of RT is 
responsible for the high in vivo mutation rate of retroviruses (Reviewed in: 
(Williams and Loeb 1992)).
The cellular protein APOBEC3G can interfere with HIV-1 reverse transcription. 
One mechanism by which it can do this is by inducing cytidine deamination in the
29.
minus strand, resulting in hypermutation of reverse transcribed DNA (Reviewed 
in: (Holmes et al. 2007)). APOBEC3G is targeted for degradation by the HIV-1 
encoded accessory protein Vif (Sheehy et al. 2003).
1.1.8. Nuclear import
Following the completion of reverse transcription the RTC becomes known as the 
pre-integration complex (PIC). Retroviral RTC/PIC are thought to be transported 
through the cytoplasm via the actin and microtubule cytoskeleton; passive 
diffusion cannot be responsible for their intracellular movement (Suzuki and 
Craigie 2007). The manner by which a PIC enters the nucleus has not as yet 
been completely resolved. Gammaretroviruses such as MLV can only infect 
dividing cells; breakdown of the nuclear membrane during mitosis therefore 
seems to be required for MLV PIC to access host chromatin. Lentiviruses such 
as HIV infect dividing and non-dividing cells equally well (Lewis et al. 1992). 
Import of HIV PICs into the nucleus most likely involves traversing the nuclear 
pore complex (NPC), although Vpr-mediated disruption of the nuclear envelope 
has also been proposed (de Noronha et al. 2001). All proteins in the cell that are 
destined for the nucleus contain nuclear localisation signals (NLS). The HIV PIC 
contain proteins such as MA, IN and Vpr in which NLS have been identified. The 
cPPT in the HIV genome has also been shown to facilitate nuclear entry (Zennou 
et al. 2000). However, the importance of these NLS has been called into question 
since it was shown that mutation or complete deletion of the four known NLS did 
not abolish HIV-Ts ability to infect non-dividing cells (Dvorin et al. 2002; 
Yamashita and Emerman 2005). Capsid is now thought to be the main viral 
determinant of retroviral infectivity of non dividing cells (Yamashita et al. 2007). 
Cellular factors involved in the nuclear import of HIV-1 include importin 7 (Fassati 
et al. 2003) and a 3’ CCA deficient tRNA species that is incorporated into HIV-1 
virions (Zaitseva et al. 2006).
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1.1.9. Retroviral integration
1.1.9.1. The integration mechanism and the viral integrase enzyme
Retroviral integration is catalysed by the viral integrase enzyme. The integrase
enzyme possesses 3 structural domains: the N terminal domain, the central core 
domain and the C terminal domain. The central core domain is the catalytic 
domain of the enzyme. The core domain contains a catalytic triad of 3 highly 
conserved residues. (D64, D116 and E152 in HIV-1 IN (Engelman and Craigie
1992)). Mutation of any of these critical residues results in a loss of integrase 
catalytic activity.
The integration reaction comprises two well-defined steps, end-processing and 
joining (Described for HIV-1 by: (Engelman et al. 1991); reviewed in: (Hindmarsh 
and Leis 1999)). During end-processing, the integrase enzyme removes two 
nucleotides from 3’ends of both plus and minus strands. This exposes recessed 
3’OH groups, whose oxygen is used as a nucleophile to attack host cell DNA. 
During the joining reaction, the 3’ends of the viral cDNA are inserted into host cell 
DNA. Depending on viral species, 4-6 nucleotides of host cell DNA immediately 
flanking the LTRs are duplicated (5nt in the case of HIV-1; 4nt in case of MLV). 
Host DNA repair enzymes remove the two nucleotide overhangs and repair the 
gaps in the DNA.
1.1.9.2. Retroviral integration site distribution
For a long time it was thought that retroviral integration occurred essentially 
randomly throughout the genome. In recent years however, it was found that 
retroviral integration favours particular chromosomal features and these differ 
among different retroviruses. The completion of the draft sequence of the human 
genome in the year 2000 allowed for the systematic large scale analysis of 
retroviral integration sites. Genome wide mapping studies of HIV, MLV, ASLV 
and foamy virus integration sites have been conducted. Below follows a summary 
of the distinct target sites favoured by these different retroviruses.
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1.1.9.2.1. Lentiviruses (HIV-1 and SIV)
The first genome wide mapping study of HIV-1 integration sites in the SupT1 T 
cell line revealed that genes are favoured targets of HIV-1 integration (Schroder 
et al. 2002). 69% of HIV-1 integration sites were found to be in transcription units 
(TU), compared to 35% of control in vitro integration sites into naked DNA. 
Integration site selection was also influenced by transcriptional activity. 
Microarray analysis showed that the median expression levels of genes hosting 
HIV-1 integration sites were consistently higher than the median expression 
levels of all genes on the array. Genes transcribed as a result of HIV-1 infection 
were particularly favoured targets for HIV-1 integration.
These preferences were confirmed by a study that analysed HIV-1 vector 
integration sites in human primary cells (Mitchell et al. 2004). Simian 
immunodeficiency (SIV) vector integration sites were analysed in the progeny of 
transduced rhesus macaque haematopoietic stem cells (Hematti et al. 2004). SIV 
like HIV favoured integration into TU.
1.1.9.2.2. Murine Leukaemia Virus (MLV)
20.2% of MLV integrations occurred 5kb upstream or downstream of transcription 
start sites compared to 4.3% of random integration sites (Wu et al. 2003). CpG 
islands are regions abundant in the CpG dinucleotide, which are 
undermethylated and associated with gene regulatory regions. MLV strongly 
favours integration near CpG islands, but HIV does not. Microarray analysis 
revealed that MLV preferentially integrates near transcription start sites of 
actively transcribed genes. MLV, unlike HIV or ASLV, also has a strong 
preference for integration near DNase I hypersensitive sites (Lewinski et al. 
2006). These are nucleosome depleted chromosomal regions associated with 
gene regulatory elements. They are enriched near promoters, the 5’ends of TU 
and CpG islands.
1.1.9.3. Integration target site selection
Several models have been proposed to account for the distinct integration target 
site preferences of different retroviruses (Ciuffi and Bushman 2006).
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The chromosome accessibility model proposes that open chromatin is a favoured 
target for PICs because it is most accessible. This model might account for the 
fact that centromeric heterochromatin is a consistently unfavourable environment 
for retroviral integration. DNAse I hypersensitive sites are markers for accessible 
chromatin, yet these sites are only favoured by MLV. It was thought that maybe 
cell cycle effects could explain the differences in integration preferences between 
HIV and MLV. However, no difference in HIV integration site selection was seen 
between dividing and cell cycle arrested cells (Ciuffi et al. 2006). The tethering 
model proposes that the PICs of different retroviruses interact with different 
cellular factors that guide them to specific sites on chromosomal DNA. This could 
account for integration preference in the proximity of transcription start sites 
(MLV), within genes (HIV) and in transcriptionally active regions (HIV and MLV). 
Although host cell DNA primary sequence seems of little importance in target site 
selection, distinct base preferences at the sites of integration and proximal 
sequences were observed in one study (Holman and Coffin 2005). This would 
suggest that integrase does recognise a sequence pattern upon integration.
1.1.9.4. Viral and cellular factors involved in retroviral integration and 
their possible role in target site selection
1.1.9.4.1. Viral determinants
Not surprisingly, integrase as the catalyst of the retroviral integration process is 
the main viral determinant of target site selection. A recent study by the Bushman 
lab demonstrated this very convincingly (Lewinski et al. 2006). Emerman’s group 
had previously generated a set of chimeric HIV viruses, one in which HIV IN was 
replaced by MLV IN (HIVmlN); another one in which HIV Gag and IN were 
replaced by their MLV counterparts (HIVmGagmlN); and a third one in which only 
HIV Gag was replaced by MLV Gag (HIVmGag)(Yamashita and Emerman 2004; 
Yamashita and Emerman 2005). Only HIVmlN could infect non-dividing cells, 
meaning MLV Gag imposes the requirement for cell division on the HIVmGag 
and HIVmGagmlN chimeras. The integration site preferences of the different 
chimeric viruses were compared. The HIVmGagmlN pattern most closely 
resembled that of MLV, followed by that of HIVmlN; the integration site
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preference of HIVmGag differed from that of both MLV and HIV. In conclusion, 
integrase is thus the main viral determinant of integration specificity, but Gag 
derived proteins also have some influence.
1.1.9.4.2. Cellular determinants
Several cellular factors such as HMGA1(high-mobility-group protein A1), BAF 
(Barrier to Autointegration Factor), EED, p300, lni-1 (Integrase Interactor 1) and 
LEDGF/p75 are known to be associated with PICs and these in turn could 
influence retroviral integration and target site selection (Ciuffi and Bushman
2006). Recently, it was reported that HIV-1 integration is dependent on the 
integral inner-nuclear-membrane protein emerin and its LEM (LAP, emerin, MAN) 
binding partner BAF (Jacque and Stevenson 2006). Emerin and BAF are 
required for the association of HIV-1 PICs with chromatin. When emerin or BAF 
are knocked down by RNA interference, HIV-1 PICs are sequestered in the 
nuclear matrix where they are present as episomal 1’LTR and 2’LTR circles. 
Infection by MLV, which is restricted to dividing cells, is dependent on Lap2a and 
BAF (Suzuki et al. 2004), but not emerin (Jacque and Stevenson 2006). MLV and 
HIV thus use different inner nuclear membrane proteins to co-localise with 
chromatin. Lap2a is only required for integration by HIV-1 carrying wild-type 
envelope proteins, but not when it is pseudotyped with VSV-G. The route of entry 
into the cell thus also seems to play a role in the requirement for different nuclear 
proteins mediating integration. Lap2a & BAF and emerin & BAF are required for 
chromatin association of MLV PICs and HIV PICs, respectively, but they are not 
known to influence integration target site selection by the two different viruses. In 
this study it was also found that HMGA1 was not required for MLV or HIV 
integration.
So far, the only cellular factor known to influence integration site selection is lens 
epithelium-derived growth factor LEDGF/p75 (Ciuffi et al. 2005). LEDGF/p75 is 
specific for lentiviral targeting. It strongly binds to lentiviral integrase as well as 
chromosomal DNA. Ciuffi et al knocked down LEDGF/p75 expression in 3 
different cell types (293T, Jurkat, HOS) and investigated whether this altered 
HIV-1 integration site preferences in these cells (Ciuffi et al. 2005). HIV
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integration was still favoured in transcription units in LEDGF/p75 depleted cells, 
but it was markedly reduced (56% of HIV integration sites were in TU in 
LEDGF/p75 depleted cells versus 67% in control cells). These data suggest that 
LEDGF/p75 does contribute to targeting HIV to transcription units but is not the 
sole factor in doing so.
1.1.10. Retroviral gene expression
In both simple and complex retroviruses gene expression is initiated from the 5’ 
long terminal repeat (LTR). The LTRs are subdivided into three regions, namely 
the U3, R and U5 regions. Transcription is initiated from the U3/R boundary 
(designated at +1 in Figure 1.5.). Retroviral gene expression relies on host cell 
transcriptional machinery; the RNA polymerase II (RNAPII) complex assembles 
at the TATAA box, located 30bp upstream of the transcription start site in both 
the MLV and HIV-1 LTRs. The LTR U3 region in particular contains binding sites 
for many different cellular transcription factors that regulate activity of the viral 
promoter. Regulation of MLV and HIV-1 LTR activity shall be discussed in detail.
1.1.10.1. MLV LTR activity
The Moloney MLV (Mo-MLV) enhancer is located in the U3 region, 342 to 154bp 
upstream of the transcription start site. It consists of two 75bp direct repeats plus 
an additional upstream glucocorticoid response element (GRE) and downstream 
mammalian type-C retrovirus enhancer factor 1 (MCREF-1) binding site (Manley 
et al. 1993). The Mo-MLV enhancer not only controls transcriptional activity of its 
own promoter, it can also trans-activate nearby cellular promoters. The 
implications of this will be discussed in the section on MLV pathogenesis.
The Mo-MLV enhancer contains numerous binding sites for cellular transcription 
factors. Some of these overlap, so a particular enhancer sequence can bind 
multiple proteins. This property allows tissue specific regulation of Mo-MLV LTR 
activity. The two most important binding sites in the Mo-MLV direct repeats are 
the Core Binding Factor (CBF) site (Wang etal. 1993) and the two Ets-1 binding 
sites (LVb and LVc) (Gunther and Graves 1994) that flank it. Both these proteins 
are highly enriched in haematopoietic cells. The CBF, LVb and LVc sites are
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highly conserved among Type C retroviruses (Golemis et al. 1990). Mutations in 
the CBF site reduces LTR transcriptional activity in T and B cells, but not in 
fibroblasts (Speck et al. 1990). Two NF-1 sites are also contained within the 
direct repeat (Reisman 1990), mutations of these sites affect transcription in 
fibroblasts but not in haematopoietic cells. Furthermore, one GRE, an E box motif 
which binds basic helix-loop-helix (HLH) transcription factors such as ALF-1 
(Corneliussen et al. 1991; Nielsen et al. 1994) and an MCREF-1 (Manley et al.
1993) binding site are present in each Mo-MLV direct repeat.
1.1.10.2. HIV-1 LTR activity
The following reviews on HIV-1 transcription were consulted to write this section: 
(Fred C. Krebs 2001); (Stevens et al. 2006); (Williams and Greene 2007). HIV-1 
LTR gene expression relies both on cellular transcription factors whose 
expression is enriched in T cells and monocytes/macrophages, as well as a virus 
encoded transactivator protein Tat. The contribution of both these factors shall be 
discussed in turn.
1.1.10.2.1. Cellular transcription factors
The HIV-1 U3 region can be subdivided into three functional regions: the core 
promoter; the basal enhancer and the modulatory region (Figure 1.5.b.). The core 
promoter contains the TATAA box and three Sp1 binding sites. Sp1 is a 
ubiquitously expressed cellular transcription factor; it is thought to direct 
components of RNAPII to the TATAA box. The HIV-1 basal enhancer contains an 
AP-2 (Perkins et al. 1994) and two NFkB binding sites (Nabel and Baltimore 
1987). Nuclear factor k B (NFkB) is the most important cellular transcription factor 
in HIV-1 gene expression; its role shall be discussed in detail below.
The modulatory region contains an extraordinary number of transcription factor 
binding sites, including those for Ets-1, GATA-3, LEF-1/TCF-1a; NF-IL6 (C/EBP), 
AP-1 and NFAT. The latter two are inducible T cell transcription factors; they 
were shown to synergise/cooperate with NFkB in activating HIV-1 gene 
expression (Kinoshita et al. 1997; Yang et al. 1999). The effect of most of these 
transcription factors has only been assessed by quantifying HIV-1 driven reporter
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gene expression in transient systems and their role in HIV-1 viral gene 
expression in vivo is unknown.
In HIV-1, cellular transcription factors are required for basal transcription, Tat- 
dependent transcription and the reactivation of HIV-1 from latency. HIV-1 
reproduces most efficiently in activated T cells, suggesting the transcription 
factors present in this cell subset is required for efficient HIV-1 gene expression.
In unstimulated T cells, NFkB (p65/p50) is sequestered in the cytoplasm by IkB. 
Upon T cell stimulation by e.g. T cell receptor ligation, cytokine signalling by IL- 
1 p, IL-7 or TNF-a or mitogen stimulation with phorbol myristate acetate (PMA), 
IkB is phosphorylated and targeted for degradation, whereupon NFkB p65/p50 
translocates to the nucleus. In unstimulated cells, NFkB p50 homodimers occupy 
the NFkB binding sites in the basal enhancer. Histone deacetylase 1 (HDAC-1) is 
bound to p50 homodimers; this enzyme maintains the histones nucleosome 1 
(nuc-1) and nuc-0 in a deacetylated state (Zhong et al. 2002; Williams et al.
2006). These nucleosomes inhibit the binding of transcription factors and RNAPII 
components to the HIV-1 promoter. When the p65/p50 NFkB heterodimer enters 
the nucleus following T cell stimulation, it displaces the p50 homodimer from the 
NFkB core enhancer sites. p65/p50 binds the histone acetyl transferase (HAT) 
p300. p300 acetylates nuc-1. This leads to the recruitment of chromatin 
remodelling complexes that disrupt nuc-1, enabling the initiation of transcription 
(Verdin etal. 1993; Van Lint et al. 1996).
In the absence of Tat, transcription is successfully initiated by cellular 
transcription factors. However, elongation is very inefficient with 90% of 
transcripts terminating within 60bp of the transcription start site. NFkB not only 
directs transcriptional initiation, it also has a role in elongation in the absence of 
Tat (West et al. 2001). NFkB p65/p50 recruits TFIIH, which phosphorylates the C 
terminal domain (CTD) of RNAPII on serine 5 (Kim et al. 2006). NFkB directed 
elongation is crucial in the reactivation of HIV-1 from latency (Williams et al.
2007).
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Figure 1.5.a. Transcription factor binding sites in the Moloney Murine Leukaemia Virus enhancer
The 594 bp Moloney Murine Leukaemia Virus long terminal repeat is depicted here. The enhancer is 
located in the U3 region, 342 to 154 bp upstream of the transcription start site at the U3/R boundary 
(indicated by + 1 and the arrow). It consists of two 75 bp direct repeats plus an upstream 
glucocorticoid response element (GRE) and downstream mammalian type-C retrovirus enhancer factor 
1 (MCREF-1) binding site. Individual transcription factor binding sites in the direct repeat are shown in 
the enlargement.This diagram was adapted from Figure 7 in Manley etalJ. Virol. 1993 67(4): 1967-1975. 
(Ets-1 is Ets binding site; CBF is core binding factor; bHLH is basic Helix Loop Helix; NF-1 nuclear factor 
1).The TATA and CAAT elements are found at 30 and 81 bp upstream of the transcription start site, 
respectively.
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Figure 1.5.b. Transcription factor binding sites in the Human Immunodeficiency Virus-1 (HIV-1) 
U3 region
The 633 bp HIV-1 LTR consists of U3, R and U5 regions. Transcription is initiated from the U3/R 
boundary (designated +1 and marked by the arrow). The Transactivation Response (TAR) element is 
encoded by the first 60 bp of R; it forms an RNA stem loop structure which binds Tat The U3 region can 
be subdivided into three functional regions: the core promoter; the basal enhancer and the 
modulatory region. Some of the key transcription factor binding sites in the U3 region are shown in 
the enlargement. Additional transcription factor binding sites exist in R, U5 and the Gag leader 
sequence. The proviral genome is packaged into chromatin. The position of the two nudeosomes 0 
and 1 on the HIV-1 LTR are shown. The acetylation status of these nudeosomes controls LTR gene 
expression.
COUP-TF is chicken ovalbumin upstream promoter transcription factor; RARE is retinoic acid response 
element; AP-1 is activator protein 1; Myb is Myb binding factor; NFAT is nuclear factor of activated T 
cells; GR is glucocorticoid receptor binding site; USF-1 is upstream stimulatory factor 1; Ets-1 is Ets-1 
binding factor; LEF-1 is Lymphoid enhancer-binding factor 1; C/EBP (NF IL-6) is CCAAT/enhancer 
binding protein; AP-2 is activator protein 2; NFkB is nuclear factor kappa B.
This diagram of the HIV-1 5'LTR was adapted from Hgure 1. in Stevens etal Aids 200612(3) 253-259.
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1.1.10.2.2. Tat-dependent transcription
As just discussed, some elongated transcript is transcribed from the HIV-1 LTR in 
the absence of Tat. The 101 amino acid Tat protein is encoded by a multiply 
spliced transcript of two exons. It contains a NLS, so is translocated to the 
nucleus after translation. Tat binds the TAR loop (Kao et al. 1987). This is an 
RNA element encoded by the first 60bp of the R region; it forms a highly stable 
secondary stem loop structure which is recognised by Tat. Tat recruits the 
positive-acting transcription elongation factor b (p-TEFb) to the HIV-1 promoter 
(Garcia-Martinez et al. 1997; Mancebo et al. 1997). The two most important 
components of p-TEFb are human cyclin T1 and CDK9 (Wei et al. 1998). CDK9 
phosphorylates the CTD of RNAPII on serine 2 and 5 (Zhou et al. 2000). CTD 
hyperphosphorylation greatly increases processivity of RNAPII and allows 
efficient elongation of transcripts. Tat also recruits additional HATs to the 
promoter, further improving DNA access.
1.1.11. 5 ’ and 3’ end processing
All proviral transcripts are capped at their 5’end, again using cellular capping 
machinery. HIV-1 Tat interacts with mRNA capping proteins, which stabilises 
nascent RNA transcripts. The poly(A) signal in both MLV and HIV-1 is found in 
the R region of the LTR. Transcription proceeds past this site; transcripts are 
then processed by nucleases and polyadenylated at the R/U5 boundary. 
Polyadenylation signals are thus present in the both the 5’ and 3’ LTRs. In HIV, 5’ 
poly(A) site usage is suppressed by U1 snRNP interaction with the major splice 
donor (MSD) (Ashe et al. 1997). In MLV, mutation of the downstream SD does 
not affect the activity of the 5’ polyadenylation signal (Furger et al. 2001). It is 
thought that the inability of MLV to actively suppress 5’ polyadenylation, 
necessitates the use of a weaker polyadenylation signal. In addition, upstream 
sequence elements in the U3 region enhance 3’ polyadenylation; these are found 
just downstream of the TATAA box in HIV-1 and dispersed throughout the U3 
region in MLV.
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1.1.12. Splicing and nuclear export
Cellular mRNAs that contain introns or splice sites are normally retained in the 
nucleus. Nuclear export of unspliced viral RNA is however required for the 
expression of Gag-pol proteins and for packaging of full length genomic RNA into 
new virions.
RNA transcripts of simple retroviruses come as unspliced full length transcripts 
and singly spliced envelope encoding transcripts. Simple retroviruses do not 
encode proteins that mediate splicing or RNA nuclear export. The ratio of 
unspliced to spliced transcripts is however important so that at a later stage 
proportionate quantities of viral proteins are made. Simple retroviruses are 
thought to contain RNA elements that allow transport of full length RNA from 
nucleus to cytoplasm, e.g. the constitutive transport element (CTE) in the Mason- 
Pfizer Monkey beta retrovirus. It was recently reported that the Mo-MLV 
packaging signal is involved in nuclear export of full length RNA (Smagulova et 
al. 2005).
Transcripts of complex retroviruses such as HIV-1 can undergo multiple 
alternative splicing events. HIV-1 Tat, Rev and Nef are encoded by multiply 
spliced transcripts; these are exported from the nucleus to the cytoplasm. 
Therefore, these proteins are expressed early after HIV-1 infection of the cell.
Nef has many roles in HIV-1 infection (Steffens and Hope 2001). It 
downregulates CD4 and other cell surface proteins such as MHC Class I. This 
probably has a role in superinfection resistance and the recognition of infected 
cells by cytotoxic T cells. Nef also enhances virion infectivity. The Rev protein is 
critically important in the nuclear export of full length and incompletely spliced 
HIV-1 transcripts, which encode HIV-1 structural proteins (Malim et al. 1989). 
Rev recognises the Rev-responsive element (RRE) present in these transcripts. 
The RRE is an RNA element in the env coding region that folds into a complex 
secondary structure in a manner analogous to the TAR loop. Rev interacts with 
cellular transport proteins to mediate nuclear export of RRE containing 
transcripts.
1.1.13. Late events in the retroviral life cycle: Translation, 
assembly, budding and maturation
Retroviral virions are assembled from three polyprotein precursors, namely Gag, 
Gag-pol and Env. The Gag polyprotein precursor is translated from unspliced 
viral RNA; it contains MA, CA and NC proteins. Gag and pol genes are separated 
either by a stop codon, or they may be in a different reading frame. Gag-pol 
fusion proteins are produced by either read through (termination suppression i.e. 
the stop codon is read as a coding codon) in the case of MLV or by ribosomal 
frameshifting in HIV-1. In this way, 5 to 10% of Gag polyproteins synthesised are 
Gag-pol fusion proteins (Shehu-Xhilaga etal. 2001).
Assembly of gammaretroviruses and lentiviruses occurs at the plasma 
membrane. Though HIV-1 assembly in CD4+ T cells occurs at this site (Palmer et 
al. 1985), controversy existed surrounding the site of HIV-1 assembly in 
macrophages. Some studies suggested this occurred in late endosomes in these 
cells (Pelchen-Matthews et al. 2003); more recently it was shown these were in 
fact invaginations of the plasma membrane (Deneka et al. 2007).
Membrane targeting (M) domains are contained within the matrix (MA) sequence 
of Gag. Gag and Gag-pol polyproteins localise to the plasma membrane following 
myristoylation of their N terminal glycine. The Env polyprotein is translated from a 
spliced transcript. The N terminus of Env contains a short hydrophobic signal 
peptide that docks it to the surface of the rough endoplasmic reticulum (RER) 
and mediates its translocation into the lumen of the RER. The C terminus of Env 
is anchored into the RER membrane. Env reaches the cell surface via the cell’s 
secretory pathway. On its way there it undergoes a number of modifications: it is 
glycosylated; it assembles into oligomers and it is cleaved by cellular proteases 
into its two subunits SU and TM.
Gag polyprotein is the driving force of retroviral assembly (Gottlinger 2001). In 
most retroviruses, Gag alone is sufficient to mediate budding. Virus like particles 
(VLPs) are efficiently generated in the absence of Env, but Env incorporation into 
virions is essential for them to be infectious. Gag polyprotein oligomerisation 
occurs through interaction (I) domains in NC. The NC portion of Gag also
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contains an RNA-binding domain that recognises the packaging signal and 
ensures genomic RNA packaging into virions. Gag polyproteins are spatially 
orientated during assembly. MA (at the N terminus) and NC (towards the C 
terminus) make up the outermost and innermost layers of the retroviral protein 
shell, respectively.
Late (L) domains in Gag mediate retroviral budding (Reviewed in (Martin-Serrano
2007)). The key protein involved in this process is ESCRT-III. ESCRT stands for 
Endosomal Sorting Complex Required for Transport. These complexes normally 
function in the sorting of ubiquitinated cell membrane proteins for degradation in 
multivesicular bodies. MLV and HIV-1 recruit ESCRT-III in different manners:
The MLV p12 domain of Gag, located between MA and CA, contains a PPXY 
motif. It becomes ubiquitinated and recruits an HECT ubiquitin ligase. HIV-1 p6 
contains a PTAPP domain which interacts with Tsg101, a subunit of the ESCRT-I 
complex. HECT ubiquitin ligase and ESCRT-I are thought to function as adaptor 
proteins that allow the L-domains of MLV and HIV-1, respectively, to interact with 
ESCRT-III, enabling retroviral budding. The virions that bud from the cell are 
immature and non infectious particles. Maturation to generate infectious virions 
occurs soon after budding and is dependent on viral protease (PR). PR cleaves 
Gag and Gag-pol polyproteins and gives rise to mature virions with distinct 
morphology. It was recently demonstrated that HIV-1 Vpu is required for the final 
release of mature HIV-1 virions from the plasma membrane. It counteracts a 
cellular factor that tethers these viral particles to the cell surface (Neil et al.
2008).
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1.2. Retroviral pathogenesis
This thesis examines whether vectors derived from MLV and HIV-1 can transform 
cells and the significance of this for the safety of gene therapy. This section shall 
therefore focus on the pathogenesis of MLV and HIV in mice and humans, 
respectively. There is a long standing association between retrovirus infection 
and cancer. However, retroviruses cause a number of other diseases.
The most well known today is HIV induced immunodeficiency in humans. 
Immunodeficiency is also seen in a range of other species including mice 
(Du5H), cats (Feline Immunodeficiency Virus (FIV) and Feline Leukaemia Virus 
(FeLV)) and monkeys (SIV). Retrovirus associated neurological disorders have 
been described. HIV-1 and Human T lymphotropic virus 1 (HTLV-1) can cause 
AIDS dementia and tropical spastic paraparesis, respectively. FeLV-C and 
Equine Infectious Anaemia Virus (EIAV) can cause anaemia in cats and horses, 
respectively. This list is by no means exhaustive.
1.2.1.Acutely transforming retroviruses
At the start of the 20th century, it was shown that leukaemia and sarcoma could 
be induced in chickens within days of infection with transmissible agents. 
(Ellerman and Bang 1908; Rous 1979). These were later shown to be the 
retroviruses Avian Leukosis Virus (ALV) and Rous Sarcoma Virus (RSV), 
respectively. More such acutely transforming retroviruses were discovered over 
the years. The use of temperature sensitive mutants of RSV demonstrated that 
the virus was required for both initiation and maintenance of the transformed 
state (Martin 1970). The genome of RSV was shown to contain RNA sequences 
that are not present in replication competent but transformation defective avian 
leucosis viruses (Duesberg and Vogt 1970). This “extra” RNA carries a viral 
oncogene (v-onc). In 1976, the v-onc of RSV was shown to have originated from 
a cellular oncogene (c-onc) (Stehelin etal. 1976). This was a milestone finding in 
cancer research and led to the discovery of many more oncogenes. Acutely 
transforming retroviruses at some point captured c-onc sequences by
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recombination. They transduce oncogenes into the cells they infect and can 
rapidly transform them in this way.
1.2.2.Chronically transforming retroviruses with special 
emphasis on Murine Leukaemia Viruses
Chronically transforming retroviruses do not transduce oncogenes. They too 
were found to induce cancer in susceptible hosts, albeit with a longer latency 
period. About a dozen different murine leukaemia virus (MLV) strains have been 
isolated over the years. Most cause haematopoietic tumours in mice; the type of 
tumour depends on the isolate (Reviewed in (Schiff and Oliff 1986)). Endogenous 
AKV, found in AKR inbred mice, was the first isolated strain of MLV. Serial 
passage of AKV through newborn mice resulted in the Gross Passage A strain of 
MLV. AKR mice succumb to T cell leukaemia/lymphoma within 10-12 weeks of 
birth; neonatal Gross A infection has the same effect. Neonatal Moloney MLV 
(Mo-MLV) infection causes T cell lymphoma. Mo-MLV infection causes acute pro- 
monocytic leukaemia (APML) in adult BALB/c mice undergoing a chronic 
inflammatory reaction in response to pristane treatment (Shen-Ong and Wolff 
1987). Friend MLV (Fr-MLV), the replication competent component of Friend 
virus, causes mostly erythroleukaemias. The viral determinants responsible for 
disease specificity by these different strains of MLV shall be discussed.
1.2.2.1. Mo-MLV leukaemogenesis
Neonatal Mo-MLV infection induces overt T cell lymphoma with a latency period 
of 3-4 months in C57BL and BALB/c mice. However, as soon as 4-6 weeks post­
infection pre-leukaemic abnormalities such as defects in bone marrow 
haematopoiesis, splenomegaly and thymic atrophy can already be observed 
(Davis et al. 1987; Li and Fan 1990; Bonzon and Fan 1999). These pre- 
leukaemic changes have been extensively studied but it is not clear what their 
role in leukaemogenesis is. It is thought these events are a result of chronic 
viraemia in infected mice.
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1.2.2.2. Generation of Mo-Mink Cell Focus inducing (Mo-MCF) viruses 
and their role in leukaemogenesis
Mo-MLV infection in mice is accompanied by the generation of Mo-MCF viruses 
(Hartley et al. 1977). Mo-MCF viruses result from env recombination between 
sequences of exogenous ecotropic MLV and endogenous polytropic MLV; the 
latter are present in the mouse genome. Mo-MCF viruses have a polytropic host 
range. Normally, cells that have already been infected by ecotropic MLV cannot 
become re-infected by this virus, a phenomenon known as superinfection 
resistance, usually caused by viral envelope proteins occupying the receptor. 
Polytropic Mo-MCF viruses can superinfect Mo-MLV infected cells because they 
use a different receptor for entry. There is weak interference with superinfection 
by polytropic MLV (Marin et al. 1999), so Mo-MCF viruses can superinfect Mo- 
MCF-virus infected cells too. This can result in the accumulation of numerous 
provirus copies in a single cell. Logically, clones will emerge in which several 
cooperating oncogenes have been activated by insertional mutagenesis. This is 
consistent with the idea that several oncogenes, regulating distinct pathways, are 
required for cell transformation (Reviewed in (Hahn and Weinberg 2002)).This 
would explain why MLV variants that generate MCF viruses, induce lymphoma 
more efficiently (Brightman et al. 1991). Mo-MLV leukaemogenesis is also more 
efficient in mice compared to rats. The rat genome does not encode endogenous 
polytropic MLV, preventing MCF virus generation. However, Mo-MLV infected 
rats do develop lymphoma, demonstrating that MCF viruses are not strictly 
required for this.
1.2.2.3. Viral determinants of pathogenesis outside the LTR
As discussed in section 1.2.2.4., retroviral enhancers are the main determinant of
MLV pathogenicity. However, determinants elsewhere in the virus exist. Mo-MLV, 
but not Fr-MLV, induces promonocytic leukaemia in adult pristane-treated mice. 
Unlike the differences in disease-type seen after neonatal infection with these 2 
viruses, the U3 region was shown not to be responsible for this (Wolff and Koller 
1990). Analysis of reciprocal chimeras of these viruses demonstrated that
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determinants in the ^-gag-PR and env regions of Mo-MLV were responsible for 
leukaemia induction in this model instead (Mukhopadhyaya et al. 1994).
1.2.2.4. Proviral insertional mutagenesis of cellular proto-oncogenes: 
Retroviral enhancers as determinants of disease-type and latency
As described in the introduction to this section on MLV pathogenesis, different
strains cause different types of haematological malignancies. The first clue as to 
what determines disease-specificity was given by the generation of chimeric 
viruses between Mo-MLV which causes T cell lymphoma and Fr-MLV which 
causes erythroleukaemia (Chatis et al. 1983). The LTRs of Mo-MLV were 
replaced by those of Fr-MLV, and this virus caused predominantly 
erythroleukaemias. The reverse chimera caused mainly T cell lymphoma. Later 
experiments showed that replacing just the enhancer elements (direct repeats) 
was sufficient to change disease-specificity (Li et al. 1987). In addition, the 
greater the number of direct repeats present in the enhancer, the shorter the 
latency period. This is consistent with the idea that enhancer activity is controlled 
by the presence of cell specific transcription factors. By implication, erythroid 
specific transcription factors bind the Friend enhancer, whereas T cell specific 
transcription factors bind the Moloney enhancer. The importance of individual 
transcription factor binding sites in the direct repeat was investigated next (Speck 
et al. 1990). The sites shown in Figure 1.5.a. were mutated one by one and their 
effect on Mo-MLV pathogenicity was tested. Mutations in at least 2 out of 3 
GREs, in both LVb (Ets-1) sites, in 2 out of 4 NF-1 sites or in both CBF sites 
delayed the latency period of disease induction. In addition, mutations in the 
CBF/LVb sites changed the disease-specificity in favour of erythroleukaemia. 
CBF is highly expressed in T cells; a later study showed that the higher the 
affinity of CBF for its binding site, the more rapid is disease induction (Lewis et al. 
1999). Mutations in both LVa, LVc or the promoter proximal GRE do not change 
disease specificity or latency. Deletion of the MCREF-1 site downstream of the 
direct repeats also relaxes disease specificity to erythroid and myeloid 
leukaemias (Manley et al. 1993).
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These studies have important implications for viral vectors: The choice of LTR 
will determine transgene expression levels, which will vary between cell types. In 
terms of safety, cell types that express transcription factors whose binding sites 
are present in the enhancer will be at greater risk of transformation by insertional 
mutagenesis.
1.2.2.5. Mechanisms of insertional mutagenesis
Several ways in which chronically transforming retroviruses such as MLV can 
activate expression of cellular genes near integration sites have been described 
and are shown in Figure 1.6. If the cellular genes concerned are proto­
oncogenes (c-onc), expression of which confers a survival and/or growth 
advantage onto the cell, this may be the initiating event in neoplastic 
transformation of this cell. In all mechanisms of insertional activation described 
below, the retroviral LTR is invariably involved. These cis-acting elements of the 
virus are retained in retroviral vectors, hence they have the potential to affect 
proto-oncogene expression in similar ways.
1.2.2.5.1. Promoter insertion
Promoter insertion (Figure 1.6.a) requires the provirus to integrate in the same 
transcriptional orientation as the gene. It was the first described mechanism 
whereby chronically transforming retroviruses could activate gene expression. In 
ALV-induced lymphomas in chickens, c-myc was activated by 3’LTR promoter 
insertion (Hayward et al. 1981). It was found that the 5’LTR of the provirus was 
deleted in most tumours. Usually the 3’LTR is inactive when the 5’LTR is 
transcriptionally active, because of promoter interference (Cullen et al. 1984). 
5’LTR promoter insertion is also possible and has been described for c-myb 
activation by Mo-MLV (Shen-Ong et al. 1986). It involves generation of a fusion 
transcript, enabled by read-through through the 3’LTR polyadenylation site 
(Figure 1.6.c). This transcript is then spliced from a splice donor (SD) present in 
the virus to a splice acceptor (SA) in the downstream cellular gene. As long as 
provirus insertion occurs upstream of the gene or the first coding exon, a wild 
type protein will be produced.
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1.2.2.5.2. Enhancer activation
Retroviral enhancers are able to activate cellular promoters over large distances. 
Evil activation by retroviral integration 90kb upstream was reported in a murine 
myeloid tumour (Bartholomew and Ihle 1991). C-myc activation by Mo-MLV 
integration 270kb downstream was demonstrated in a rat T cell lymphoma (Lazo 
et al. 1990). Enhancers can activate cellular promoters when the provirus has 
integrated both up- or downstream of the gene (Figure 1.6.b). Insertions can 
occur in any orientation with respect to gene transcription; however, in most 
cases upstream insertions occur in opposite transcriptional orientation, whereas 
downstream insertions occur in the same transcriptional orientation.
1.2.2.5.3. Disruption of mRNA destabilising elements
Figure 1.6.d shows proviral insertion into the 3’UTR of a gene. The 3’UTR of
certain genes contains AU-rich elements (ARE) that destabilise mRNA. Proviral 
insertion in this region can result in premature termination of the transcript by the 
use of either a sense viral polyadenylation signal in the 5’LTR or a cryptic 
antisense polyadenylation signal in the viral enhancer (Uren et al. 2005). mRNA 
is stabilised and its half-life in the cytoplasm prolonged, resulting in increased 
protein production. This mechanism of insertional activation has been described 
for N-myc (van Lohuizen et al. 1989) and Pim-1 (Selten et al. 1985).
1.2.2.5.4. Inappropriate transcriptional termination
Proviral integration within a transcription unit can result in coding sequence 
disruption or premature termination of the transcript. This can in turn lead to 
production of a truncated, inactive or unstable protein. Important negative 
regulatory domains may be missing, generating constitutively active 
oncoproteins. For example, MoMLV insertions in the last intron of the Tpl-2 gene 
in rat T cell lymphomas results in the expression of an oncogenic carboxy 
terminal truncated Tpl-2 kinase protein (Ceci etal. 1997).
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Proto-oncogene
Figure 1.6. Mechanism s o f insertional mutagenesis
A. Prom oter insertion -  provirus insertion has occurred in the same orientation as proto-oncogene  
transcrip tion . In this illustration, p ro to-oncogene transcription is initiated from the 3'LTR o f the  
provirus.
B. Enhancer activation -  in this illustration the provirus has inserted upstream in reverse orientation  
w ith  respect to  proto-oncogene transcription. Enhancer elements contained within the U3 region of 
th e  provirus activate gene expression from the endogenous promoter. This mechanism o f insertional 
m utagenesis  can occur w hen  th e  provirus has integrated upstream or dow nstream  o f a 
pro to -oncogene in either transcriptional orientation.
C. G eneration o f a readthrough transcript -  Provirus insertion needs to occur in the same orientation as 
pro to -oncogene transcription. A transcript is initiated from the 5'LTR o f the provirus and reads through  
into dow nstream  cellular sequences. Splicing generates a transcript in which the viral leader sequence 
is fused to  exons o f a cellular proto-oncogene.
D. Disruption o f th e  3'UTR -  Provirus insertion in 3'UTR AU-rich elem ents (AREs) that regulate the  
stability o f m RNA, can result in transcripts w ith a prolonged half-life.
(Reproduced from  C hapter 10 in Retroviruses, 1997, JM Coffin, SH Hughes, HE Varmus w ith  permission 
from  Cold Spring H arbor Laboratory Press).
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1.2.2.6. Identification of CIS in Mo-MLV induced haematopoietic 
malignancies
Analysis of retroviral integration sites (RIS) in tumours induced by chronically 
transforming retroviruses revealed many of these had occurred in the same loci. 
Loci that were found to be frequent targets of retroviral integration in independent 
tumours are so called common insertion sites (CIS). The genes near some CIS, 
were known proto-oncogenes, whose sequence was present as v-onc in acutely 
transforming retroviruses. For example, c-myc and c-myb (discussed below) are 
transduced by acutely transforming retroviruses of chickens. Analysis of genes 
near other CIS led to the identification of previously unknown proto-oncogenes, 
e.g. the serine threonine kinase Pim-1 (Cuypers etal. 1984).
The most commonly found RIS in T cell lymphomas following neonatal Mo-MLV 
infection of C57BL and BALB/c mice, were in c-myc (40%), N-myc (35%) and 
Pim-1 (45%) (Reviewed in (Jonkers and Berns 1996)). In a quarter of tumours 
insertions in both c-myc and Pim-1 were found. Most T cell lymphomas in these 
mice were oligoclonal with RIS in both c-myc and Pim-1 present in independent 
clones. The acquisition of new RIS during tumour progression was frequently 
observed after serial transplantation of tumours in syngeneic mice (Cuypers et al. 
1986). In these tumours, c-myc expression occurred mostly by enhancer 
activation; whereas N-myc and Pim-1 expression was activated by disruption of a 
3’UTR mRNA destabilising element. MLV infection of adult pristane treated 
BALB/c induces myeloid leukaemia (Shen-Ong and Wolff 1987). In all tumours, 
retroviral insertion sites in c-myb were found, resulting in expression of either an 
amino or carboxy terminal truncated c-myb protein.
In recent years, the use of retroviral insertional mutagenesis screens has 
widened beyond the identification of new oncogenes. Retroviral insertional 
mutagenesis can accelerate tumourigenesis in tumour prone mouse models 
(Berns et al. 1989). Analysis of CIS in these tumours allows identification of 
cooperating oncogenes. Tumour progression genes were recently identified by 
this approach in the CD2 myc/Runx2 model, that already expresses two 
oncogenes predisposing it to lymphoma (Stewart et al. 2007). Use of the Blm'7'
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model, which has a high rate of loss of heterozygosity, allowed the identification 
of tumour suppression genes by insertional mutagenesis (Suzuki et al. 2006). 
Inactivation of tumour suppressor genes by insertional mutagenesis is rare, as it 
requires either the production of a dominant negative protein from the disrupted 
allele, or inactivation of both alleles. Loss of both p53 alleles is a common 
occurrence in Fr-MLV induced erythroleukaemias (Johnson and Benchimol 
1992). SFFV insertions in one of these p53 alleles were detected in some 
tumours, and are thought to contribute to p53 loss in these cells (Ben-David et al. 
1990).
The Retrovirus Tagged Cancer Gene Database (RTCGD) currently holds some 
500 CIS from studies using 28 different mouse models (Akagi et al. 2004). This 
database was consulted to find out whether any RIS integration sites in my IL-3 
independent mutants of the BAF3/BCL15 cell line were known CIS. The BCL15 
cell line we used, already expressed the human Bcl2 oncogene. An interaction 
search of the RTCGD database was performed to identify genes found in the 
same tumours as Bcl-2. Nine such genes were identified from 4 different tumour 
models; they are: growth factor independent 1 (Gfi1), wingless-related MMTV 
integration site 6 (Wnt6), SET translocation (Set), RAR-related orphan receptor 
gamma (Rorc), Harvey rat sarcoma virus oncogene 1 (Hras), transcription factor 
12 (Tcf12), v-myc myelocytomatosis viral related oncogene (Mycn), Myc and 
Pim-1. c-myc was shown to collaborate with Bcl-2 in transforming BAF3 cells to 
IL-3 independence (Malde and Collins 1994).
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1.2.3.Lentiviruses with emphasis on HIV
1.2.3.1. Introduction
Acquired Immunodeficiency Syndrome (AIDS) as a clinical entity was first 
recognised in 1981. Pneumocystis carinii pneumonia (PCP), until then only seen 
in severely immunocompromised individuals, was diagnosed in 5 previously 
healthy homosexual males in Los Angeles. The virus that causes AIDS was 
isolated in 1983 (Barre-Sinoussi et al. 1983) and was subsequently named 
Human Immunodeficiency Virus (HIV). In 1985 it became clear that “slim 
disease” that had become increasingly prevalent in parts of Sub Saharan Africa 
was caused by the same virus (Serwadda et al. 1985). An estimated 25 million 
people worldwide have died of HIV/AIDS since 1981. This year marks the 25th 
anniversary of the discovery of HIV. The introduction of highly active anti­
retroviral therapy (HAART) in 1996, led to a dramatic decrease in mortality and 
morbidity of HIV-infected individuals in the developed world. However, as yet no 
permanent cure or effective vaccine for HIV/AIDS has been found.
1.2.3.2. Origins of HIV
The distribution of HIV-1 is global. In 1986 a related virus, HIV-2, was isolated, 
which is prevalent mostly in West Africa. HIV-2 also causes AIDS. However, the 
onset of disease is slower compared to HIV-1 and the disease is less severe. 
HIV-1 and HIV-2 are phylogenetically related to simian lentiviruses from 
chimpanzees (SIZcpz) and sooty mangabeys (SIZsm), respectively. At least 3 
cross species transmissions of SIZcpz from chimpanzees to humans are thought 
to have occurred in Western Central Africa (Cameroon/Gabon), resulting in the 
establishment of HIV-1 groups M, O and N (Reviewed in (Heeney et al. 2006)). 
SIZcpz and SIVsm are non-pathogenic in their natural hosts; although SIVmac, 
which is closely related to SIVsm, causes AIDS in macaques.
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1.2.3.3. Clinical course of HIV infection
The main route of HIV transmission is sexual. Upon HIV infection, people may 
experience a mononucleosis-like seroconversion illness. Opportunistic infections 
may occur at this time as a result of acute immunosuppression. HIV infection is 
then usually asymptomatic for many years. During this time there is a gradual 
decline in CD4+ T cell count. Symptomatic disease usually presents itself when a 
patient’s CD4+ T cell count is less than 500 per pi. At this time, patients become 
increasingly susceptible to opportunistic infections. AIDS is a clinical syndrome 
defined by 20 AIDS-defining illnesses: opportunistic infections such as PCP 
and/or AIDS defining malignancies such as Kaposi sarcoma (KS), Non-Hodgkin’s 
lymphoma (NHL) and anogenital cancers.
1.2.3.4. HIV immunopathogenesis
HIV infection causes a specific immunodeficiency of CD4+ helper T cells. A long 
held view was that this is the result of gradual virus mediated death of CD4+ T 
cells during the asymptomatic stage of infection. However, recent studies 
suggest most of the damage to the immune system is done during acute infection 
(Reviewed in: (Haase 2005) (Picker 2006) (Grossman et al. 2006)).
Establishment of HIV infection in most cases occurs in the mucosal immune 
system in the lamina propria beneath the mucosal epithelial cell surface of the 
urogenital tract. Relatively few activated CD4+ T cells, in which HIV replicates 
most efficiently, are present in the mucosal immune system. The most abundant 
cell type are CD4+ effector memory T cells, which express CCR5 making them 
readily infectable by transmitted M-tropic HIV-1 (Mattapallil et al. 2005). These 
cells are “resting” but do support HIV replication, and are crucial in the 
establishment of HIV infection because of their abundance. Dendritic cells (DC) 
are also found in mucosal epithelia and are thought to be an important target 
early in HIV-1 infection (Reviewed in: (Piguet and Steinman 2007)). DC are less 
readily infected than CD4+ T cells. However, they can capture HIV-1 virions via 
C-type lectins e.g. DC-SIGN on their cell surface, without necessarily becoming 
infected themselves. These virions are sequestered in intracellular compartments
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within DC without being degraded, so they remain infectious. After migration to 
the lymph nodes, DC very efficiently transfer these virions to CD4+ T cells via 
direct cell-to-cell contact (McDonald et al. 2003; Piguet and Sattentau 2004). This 
is thought to greatly facilitate transmission at this site.
Once infection is established in the draining lymph node, it rapidly disseminates 
to other lymphoid tissue compartments such as the peripheral lymph nodes, the 
spleen and gut-associated lymphoid tissue (GALT). 60% of total CD4+ T cells, 
mostly effector memory T cells, are found in the GALT and this cell population is 
almost completely destroyed early in infection by direct cytopathic effects of the 
virus (Li et al. 2005; Mattapallil et al. 2005).
The GALT is also instrumental in raising an immune response against HIV.
Neutralising antibodies and cytotoxic T cell response against HIV have been 
detected, but due to its high mutation rate HIV quickly evolves to evade both.
It is now believed that the reason why there is a drop in viraemia after acute 
infection is because the supply of CD4+ T cells in the gut is exhausted; not 
because a potent immune response is raised against the virus (Phillips 1996). 
This pool is somewhat replenished by naive and central memory T cells that 
have not been targeted in acute infection. This process of replenishment is 
stimulated by a generalised state of immune activation which exists at the time of 
clinical latency (Grossman et al. 2006). Immune activation also increases the 
number of activated T cells, providing a source for ongoing HIV replication. It is 
thought that the loss of this ability to regenerate effector memory T cells is 
responsible for the eventual drop in overall CD4+ T cell numbers. This is seen 
clinically by an increased susceptibility to opportunistic pathogens.
Activated CD4+ T cells survive for only a few days following infection. The
introduction of HAART allowed the study of HIV reservoirs in patients (Simon and 
Ho 2003). It became evident that latent reservoirs are established very early 
during infection. Long lived cell populations such as truly resting/quiescent 
memory CD4+ T cells and dendritic cells contain transcriptionally inactive 
proviruses. Upon reactivation from latency, virus is produced by these cells. This 
explains the need for life long antiretroviral therapy to suppress HIV replication.
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1.2.3.5. HIV associated malignancies
HIV-infected patients are more prone to a variety of cancers. The factors involved 
in this are thought to be chronic immune stimulation, impaired tumour 
surveillance and infection with oncogenic herpes- or papilloma viruses. The latter 
are associated with three AIDS defining malignancies: Kaposi sarcoma, Non 
Hodgkin’s lymphoma and anogenital cancer (Boshoff and Weiss 2002).
1.2.3.5.1. Kaposi sarcoma (KS)
This is the most common cancer in AIDS patients. KS is a malignancy of the 
lymphatic endothelial precursor cells caused by Human Herpes Virus 8 (HHV-8) 
also known as Kaposi sarcoma herpes virus (KSHV). Organs in which KS lesions 
are commonly found are the skin, mouth, gastrointestinal tract and lungs.
1.2.3.5.2. Non Hodgkin’s Lymphoma (NHL) (Killebrew and Shiramizu 2004)
AIDS-associated NHLs are almost uniquely B cell in origin. 80% of these are
systemic lymphomas. Of these, only a minority (20%) are confined to the lymph 
nodes. Half of them are associated with Epstein Barr Virus (EBV) infection. The 
other half is thought to result from oligoclonal B cell expansion in response to 
chronic antigen stimulation. In the absence of CD4+ T cell control over B cell 
proliferation, a population emerges that is at increased risk of transformation. 
Primary CNS lymphomas make up about 20% of NHL. They are always 
associated with EBV infection. KSHV also infects B cells and is able to transform 
these cells in a manner similar to EBV. KSHV is associated with rare NHL, 
namely primary effusion lymphoma (PEL) and plasmablastic lymphoma, a variant 
of Multicentric Castleman’s disease.
1.2.3.5.3. Anogenital and Cervical Cancers
HIV infected people are at increased risk of cancers caused by human papilloma 
viruses (HPV). These include cervical cancer in women and anorectal and genital 
cancer in both sexes.
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1.2.3.5.4. HIV-induced insertional mutagenesis in rare lymphomas
Most of the target cells for HIV infection in vivo are terminally differentiated cells.
In gene therapy, pseudotyping with heterologous envelope proteins confers a 
broader tropism to lentiviral vectors. The targets of lentiviral vector transduction 
are likely to be less mature progenitor cells such as CD34+ haematopoietic stem 
cells (HSC). These cells may be more susceptible to transformation. Although 
CD34+ cells can be infected by wild type HIV-1 ex vivo, this has rarely been 
detected in HIV infected patients (Moses et al. 1998). Has direct involvement of 
HIV in transformation of its targets cells ever been demonstrated in HIV infected 
patients? A case report exists that describes a rare CD4+ T cell lymphoma found 
in an AIDS patient (Herndier et al. 1992). This lymphoma contained a monoclonal 
HIV-1 provirus integration 1 kb upstream of the c-fes/fps proto-oncogene 
(Shiramizu et al. 1994). c-fes/fps expression was activated in tumour cells. 
Intriguingly, the same group found monoclonal HIV-1 integrated in the c-fes/fps 
locus in HIV infected macrophages in 3 more polyclonal lymphomas of mixed 
immunophenotype (Shiramizu etal. 1994).
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1.3. Vector construction
In the context of gene delivery, vectors are vehicles used to introduce genes into 
target cells. Both non-viral and viral vectors exist. Table 1.3. summarises the 
properties of the different viral vectors that are currently being developed for use 
in gene delivery. This section shall focus on the development of vectors from 
simple (MLV) and complex (HIV-1) retroviruses. Initially, features particular to 
these two types of vectors will be discussed separately. Common concepts such 
as insert configuration, self-inactivating vector design, production and 
pseudotyping will then be addressed.
1.3.1. Retroviral vectors
Retroviruses integrate into the genome of host cells they infect. This property 
allows stable gene expression, which is highly desirable in the context of gene 
therapy. It also allows a transgene introduced into a progenitor cells to be passed 
on to all its progeny. However, the introduction of foreign DNA into the cell 
genome per se is potentially mutagenic. The problem is confounded by the 
presence of potent gene regulatory elements in the LTRs. These elements are 
retained in retrovirus derived vectors.
Acutely transforming retroviruses are naturally occurring vectors that transduce 
oncogenes into cells. This observation led to the eventual exploitation of 
retroviruses as vectors for gene therapy. Acutely transforming retroviruses were 
mostly replication defective, due to extensive deletions in their viral coding 
regions, and relied on viral proteins provided by replication competent helper 
viruses to replicate. Two reviews on retroviral vector design were consulted: 
(Takeuchi and Pizzato 2000; Buchschacher 2001)
59.
Table 1.3. The main groups of viral vectors
Vector Genetic
Material
Packaging
Capacity
Tropism Inflam­
matory
potential
Vector
genome
forms
Main limitations Main advantages
Enveloped
Retrovirus RNA 8 kb Dividing cells 
only
Low Integrated Only transduces dividing 
cells; integration might 
induce oncogenesis in 
some applications
Persistent gene transfer 
in dividing cells
Lentivirus RNA 8 kb Broad Low Integrated Integration might induce 
oncogenesis in some 
applications
Persistent gene transfer 
in most tissues
Herpes 
Simplex 
Virus -1
dsDNA 40 kb * 
150 kb **
Strong for 
neurons
High Episomal Inflammatory; transient 
transgene expression in 
cells other than neurons
Large packaging 
capacity; strong tropism 
for neurons
Non-envelopad
AAV ssDNA < 5  kb Broad, with the 
possible 
exception of 
haematopoietic 
cells
Low Episomal 
(> 90%) 
Integrated 
(< 10%)
Small packaging capacity Non-inflammatory; non 
pathogenic
Adenovirus dsDNA 8 kb* 
30 kb§
Broad High Episomal Capsid mediates potent 
inflammatory response
Extremely efficient 
transduction of most 
tissues
* Replication defective ** Amplicon8 Helper dependent
Adapted with permission from Macmillan Publishers Ltd: Thomas et al Nature Review Genetics 4: 346 -  368, 2003.
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1.3.1.1. Retroviral transfer vectors
The basic principle behind the design of a replication defective retroviral transfer 
vector is to replace the viral coding regions (gag, pol, env) by the transgene that 
is to be delivered to target cells. This is facilitated by the fact that the viral coding 
regions are found in the centre of the genome separated from the so called cis- 
acting elements. The latter are retained in the transfer vector. They include the 
LTRs, necessary for transcription initiation, polyadenylation and reverse 
transcription; the packaging (T) signal, required for transfer vector incorporation 
into particles; and the PBS and PPT, necessary for, respectively, first and second 
strand synthesis during reverse transcription. Most retroviral transfer vectors 
currently in use were derived from the genomes of ecotropic MLVs, particularly 
Mo-MLV. These vectors can hold inserts up to 7kb in size.
1.3.1.2. Retroviral packaging constructs
To enable vector virus production, proteins encoded by the viral gag, pol and env 
genes must be provided in trans. They are provided by retroviral packaging 
constructs. Packaging constructs have undergone a number of modifications 
over the years. The simplest such constructs were retroviral genomes from which 
the 4^  signal was deleted, such as in the 1st generation K\)-2 packaging cell line 
(Mann et al. 1983). However, because the high degree of homology between 
transfer and packaging constructs, only one recombination event was required to 
generate replication competent retrovirus (RCR), which is of course highly 
undesirable. In 2nd generation constructs, in addition to the 4^  signal, the PPT and 
3’LTR were removed (Miller and Buttimore 1986). This left just the 5’LTR driving 
gag, pol and env expression. In 3rd generation “split” packaging constructs, such 
as those in 4^  CRE and 4^  CRIP (Danos and Mulligan 1988), the gag, pol genes 
were separated from the env gene. Three recombination events would now be 
needed to generate RCR. Env expression from a separate construct also allowed 
pseudotyping with heterologous env proteins (See Section 1.3.6.)
61.
1.3.2.Lentiviral vectors
Vectors derived from gammaretroviruses can only transduce dividing cells. In 
recent clinical gene therapy trials using these vectors, haematopoietic stem cells 
(HSC), which are mostly non-dividing, required stimulation with cytokines prior to 
transduction. This necessitated a 4 day ex vivo culture time of HSC (See Table
1.4. in the next section). This can be shortened when lentiviral vectors are used, 
because they efficiently transduce non-dividing as well as dividing cells. Non­
dividing target cells such as neurons, hepatocytes and myocytes can be 
transduced, widening the application of lentiviral vectors. Lentiviral vectors based 
on the genomes of a simian (SIV), feline (FIV) and equine (EIAV) lentiviruses 
have now been designed, but those based on HIV-1 are currently at the most 
advanced state of development. The following reviews on lentiviral vectors were 
consulted: (Woods et al. 2002; Delenda 2004)
1.3.2.1. Lentiviral transfer vectors
The transfer vector contains the only HIV-1 sequence transferred to the target 
cell. The “first generation” lentiviral transfer vector pHR’ contains all HIV-1 cis- 
acting sequences necessary for packaging (T), reverse transcription (PBS, PPT, 
LTRs) and integration (integrase attachment sites)(Naldini et al. 1996). The RRE, 
part of the env ORF, is also retained. Additional cis-acting sequences were later 
introduced into lentiviral transfer vectors. The cPPT, located in the central region 
of lentiviral genomes, enhances nuclear translocation of pre-integration 
complexes and increases transduction efficiency in both dividing and non­
dividing cells (Zennou et al. 2000). The post-transcriptional regulatory sequence 
of Woodchuck hepatitis B virus (WPRE) improves transgene expression levels 
when inserted downstream of the transgene (Zufferey et al. 1999).
1.3.2.2. Lentiviral packaging constructs
The lentiviral packaging systems described are optimised for transient 
transfection (See Section 1.3.5). The “first generation” lentiviral packaging 
construct (pCMVAR9) encodes all HIV-1 genes with the exception of env and the 
accessory gene Vpu (Naldini et al. 1996). The HIV-1 packaging signal is deleted
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in this construct; the HIV-1 5’ and 3’LTR are replaced by a heterologous CMV 
promoter and a polyadenylation signal from the human insulin gene, respectively. 
“Second generation” lentiviral packaging constructs e.g. pCMVA8.91 only 
express gag, pol and the regulatory genes tat and rev, but none of the HIV-1 
accessory genes (Zufferey et al. 1997). Tat is required during vector production 
for transcription from the HIV-1 5’LTR of the transfer vector genome; Rev is 
necessary during production for nuclear export of transfer vector genomic RNA 
and gag-pol mRNA. Gag-pol mRNAs are targeted for degradation in the absence 
of Rev, because their coding regions contain so called inhibitory sequences 
(INS). “Third generation” lentiviral packaging contructs such as pMDL g/p RRE 
encode only gag, pol and the RRE (Dull et al. 1998). Rev is expressed from a 
separate construct. Tat is dispensable in combination with lentiviral transfer 
vectors, in which the 5’LTR U3 region has been replaced by a heterologous 
promoter that drives transfer vector RNA production in producer cells. However, 
Rev continues to be an absolute requirement for transfer vector RNA nuclear 
export. Gag-pol codon optimisation inactivates gag-pol INS, making it Rev- 
independent.
1.3.3. Insert configuration for transgene expression
In the simplest retroviral vectors, the transgene is expressed from the 5’LTR. In
first generation “intronless” retroviral vectors, the transgene start codon is in 
place of the Gag ATG (Eglitis et al. 1985). In the MFG vector, the retroviral SD 
and SA are present; the transgene start codon is in the same position as that of 
the deleted env gene (Riviere et al. 1995). Increased levels of spliced RNA in 
transduced cells explains higher transgene expression by these vectors (Krall et 
al. 1996). As Tat is not present in target cells, in lentiviral vectors a heterologous 
promoter, which is active in the target cell, is always required for transgene 
expression. This is also the case with self-inactivating vectors (See section
1.3.4.). The choice of heterologous promoters can control transgene expression: 
Constitutively active promoters derived from retroviral LTRs (such as spleen 
focus forming virus (SFFV), myeloproliferative sarcoma virus (MPSV)); other 
promoters from other viruses such as cytomegalovirus (CMV) or cellular genes
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(Phospho glycerate kinase (PGK), elongation factor 1a (EF1a)) can express 
transgenes in a range of cell types. The use of tissue-specific promoters 
potentially improves vector safety and efficacy by limiting transgene expression 
to specific target cells only. For example, to avoid an immune response to Factor 
IX, a liver-specific albumin promoter was used in one study (Follenzi et al. 2004). 
Similarly, the incorporation of microRNA (miRNA) target sequences in the 
transgene transcript prevents transgene expression only in cell types in which the 
particular miRNA is expressed (Brown et al. 2007). In this way transgene 
expression in antigen presenting cells can be avoided. Regulation of transgene 
expression is sometimes desirable; this can be achieved by using inducible 
promoters e.g. those controlled by tetracycline (Paulus et al. 1996). More than 
one transgene can be expressed from a single vector. This can be done using 
biscistronic vectors, where a second transgene is expressed downstream of an 
internal ribosomal entry site (IRES) (Adam et al. 1991). More efficient expression 
of the second transgene can be achieved using dual promoter constructs.
1.3.4. Generation of self-inactivating (SIN) vectors
In SIN vectors, the enhancer and promoter elements contained within the U3
region are removed from the 3’LTR of the transfer vector construct. Following 
reverse transcription, these gene regulatory elements will have been deleted 
from both LTRs. SIN vectors are believed to be safer for the following reasons: 
the number of enhancer/promoter elements in these vectors is reduced to just the 
internal heterologous promoter driving transgene expression. The risk of 
insertional mutagenesis by SIN vectors is therefore theoretically lower. Secondly, 
transgene expression may be more efficient, due to lack of transcriptional 
interference between the LTRs and the internal promoter. Minimal packaging 
systems have been developed for the production of both retro- and lentiviral 
vectors; SIN vector design yet further reduces the chance of RCR generation. 
Lastly, SIN lentiviral vectors are safer in the clinical setting. In case patients 
treated with these vectors become infected with wild-type HIV-1, the risk of SIN 
vector mobilisation by HIV-1 is lower.
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Enhancer/promoter deleted retroviral SIN vectors were first described in the late 
1980s (Yu et al. 1986; Yee et al. 1987). In MLV, upstream sequence elements 
(USE) that enhances polyadenylation are dispersed throughout the U3 region. 
Extensive U3 deletion in SIN vectors leads to inefficient polyadenylation at the 
3’LTR, increasing the risk of read-through into downstream cellular genes. This 
can be overcome by introducing heterologous USE in the deleted U3 region in 
the 3’LTR of SIN vectors (Schambach et al. 2007) or by placing a WPRE 
downstream of the transgene (Higashimoto et al. 2007).
In the first lentiviral SIN vector pHR SIN, 400bp of the U3 region were removed 
from the HIV-1 3’LTR of the lentiviral transfer vector plasmid (Zufferey et al.
1998). In HIV-1, the USE that enhances polyadenylation is found downstream of 
the TATA box, just upstream of the R region (Valsamakis et al. 1991).This 
allowed more extensive deletion of U3 sequence for the purpose of SIN lentiviral 
vector generation. In pHR SIN, only the first 35bp of U3, containing the integrase 
attachment site, and the final 20bp of U3 containing the USE essential for 
polyadenylation at the 3’LTR, are left. The core promoter, basal enhancer and 
the bulk of the modulatory region have all been removed (See Figure 1.5.).
When analysed by Northern blot, no transcripts originating from the SIN LTR 
could be detected (Zufferey et al. 1998), whereas some transcripts from a wild 
type LTR could be detected in HeLa cells, even in the absence of Tat. However, 
SIN lentiviral vectors are not completely transcriptionally silent (Logan et al. 
2004). It was found that the DBF-1 and Sp1 transcription factor binding sites 
present in the leader region downstream of the transcription start site, could 
induce transcription from the U3/R junction, resulting in some residual promoter 
activity, about 15% that of a wild type LTR. Mutation of the DBF-1 and Sp1 sites 
could reduce this even further, though mutation of the latter site resulted in a 
dramatic drop in titre, because the downstream Sp1 site overlaps with the 
lentiviral packaging signal and led to reduced full length genomic transcript 
packaging (Logan et al. 2004).
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1.3.5. Production
High titre retro- and lentiviral vector particles can be produced by transient 
transfection (Soneoka et al. 1995; Naldini et al. 1996). This involves transfecting 
transfer vector, packaging and envelope coding plasmid constructs into highly 
transfectable cells, most commonly 293T cells. SIN lentiviral vectors can be 
produced by transient transfection to similar titres as non SIN vectors, whereas 
the titres of SIN retroviral vectors are usually several fold lower than that of their 
wild type counterparts.
For clinical applications, vector production using stable packaging cells is 
desirable. These cells can be extensively screened for RCR generation, allowing 
the production of large batches of quality controlled vector. In recent clinical trials, 
the retroviral packaging cell lines 4^  CRIP (Danos and Mulligan 1988), Gp+ AM12 
(Markowitz et al. 1988) and PG13 (Miller et al. 1991) were used (See Table 1.5.). 
The latter produces Gibbon Ape Leukaemia Virus (GALV) pseudotyped particles; 
the former two produce MLV-A pseudotyped particles. All three cell lines are 
derived from mouse cells; retroviral vectors produced from these cells were used 
for ex vivo transduction of HSC. They would not be suitable for human in vivo 
use, as they are rapidly inactivated by human serum (Takeuchi et al. 1996). For 
this reason, retroviral packaging cells derived from human cells were developed 
(Cosset et al. 1995). There is also a reduced risk of cross-packaging endogenous 
retroviral sequences when human cells are used (Patience et al. 1998).
Stable lentiviral packaging cell lines have also been created. In 293T/HT1080- 
based STAR cells, codon-optimised HIV-1 gag-pol (lacking RRE), Tat and Rev 
are each expressed from a separate MLV-based retroviral vector (Ikeda et al. 
2003). STAR cells produce lentiviral particles pseudotyped with either MLV-A, 
RD114 or GALV. Non-SIN lentiviral transfer vectors can be introduced into these 
cells by transduction; whereas SIN lentiviral transfer vectors can only be 
introduced by transfection.
66.
1.3.6. Pseudotyping
The following reviews on pseudotyping were consulted: (Sanders 2002; 
Verhoeyen and Cosset 2004). As was alluded to in Section the
introduction of packaging constructs in which the gag-pol coding regions are 
separated from those of env, allowed the incorporation of heterologous envelope 
glycoproteins into retroviral particles. Vector particles with an altered tropism from 
that of the retroviral vector genome could be generated in this way. Retroviral 
vectors based on the genome of ecotropic MLV (Mo-MLV) are commonly 
pseudotyped with MLV-A envelope, to broaden tropism to include human cells. 
The gamma retroviral envelope proteins from RD114 and GALV can be used to 
pseudotype retroviral but not lentiviral cores. Cytoplasmic tail modifications of the 
RD114 and GALV envelope glycoproteins, for example by replacing it with the tail 
of MLV-A which efficiently pseudotypes lentiviral cores, overcomes this limitation 
(Verhoeyen and Cosset 2004). Retroviral and lentiviral particles can also be 
pseudotyped with envelope proteins from other viruses such as influenza 
haemagglutinin (Hatziioannou et al. 1998), Ebola (Wool-Lewis and Bates 1998), 
hepatitis C virus (Bartosch et al. 2003). The vesicular stomatitis virus G protein 
(VSV-G) is commonly used (Burns et al. 1993; Naldini et al. 1996). VSV-G 
confers a broad tropism onto pseudotyped particles; it also allows concentration 
by ultracentrifugation enabling high titre vector preparation. However, VSV-G 
pseudotyped vector cannot be used in vivo, as it is rapidly inactivated by human 
serum. Pseudotransduction (the transfer of transgene protein product in the 
absence of stable integration) has also been documented. Production of VSV-G 
pseudotyped vector particles from stable cell lines is problematic as stable 
expression of VSV-G protein is toxic to cells. Inducible VSV-G expression has 
therefore been required (Sanders 2002). Generally, the titres produced by these 
stable lines are lower than those achieved by transient transfection.
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Envelope proteins have also been modified with the purpose of targeting vector 
particles to specific cell types. Viral envelope glycoproteins were engineered to 
contain ligands, peptides or single chain antibodies (scFc) (Hatziioannou et al.
1999). Though efficient binding to specific target cells could be demonstrated, 
this was not accompanied by efficient virus entry. It seems the fusogenic ability of 
the modified envelope glycoproteins had been compromised, resulting in low titre 
vector (Verhoeyen and Cosset 2004). In a recent paper, separate binding and 
fusogenic molecules were incorporated into the envelope of lentiviral particles 
(Yang et al. 2006). The binding molecule recognises a specific cell surface 
receptor; binding induces endocytosis of vector particle. The fusogenic molecules 
were chosen to induce fusion with the endosomal membrane at low pH. Lentiviral 
particles expressing an engineered glycoprotein from Sindbis virus could target 
dendritic cells in vivo by recognising DC-SIGN (Yang et al. 2008).
1.4. Gene Therapy
1.4.1. Introduction
Gene therapy can be defined as the introduction of genetic material (DNA or 
RNA) into cells for therapeutic effect. In recent years, gene therapy has been 
explored as a treatment for diseases with limited alternative therapeutic options. 
The potential applications for gene therapy are numerous. Worldwide, gene 
therapy clinical trials are most commonly performed for cancer (66.5%). This is 
followed by cardiovascular diseases (9.1%), monogenic inherited disorders 
(8.3%) and infectious diseases (6.5%) (Edelstein et al. 2007). In just under a 
quarter of clinical trials, retroviral vectors were used for gene delivery. This 
section shall focus on the use of retroviral vectors in gene therapy. The 
therapeutic benefit of gene therapy using these vectors was most demonstrable 
in the treatment of individuals suffering from primary immunodeficiencies. It was 
in two of these trials that insertional mutagenesis caused malignant cell 
transformation, which inspired investigation in this thesis.
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1.4.2.Retroviral and lentiviral vectors in human gene therapy
One of the earliest uses of retroviral vectors in man was in gene marking studies.
To evaluate the efficacy of tumour infiltrating lymphocyte (TIL) treatment in 
metastatic melanoma, cells were transduced with a retroviral vector so that they 
could be tracked (Rosenberg et al. 1990). Gene transfer to haematopoietic stem 
cells (HSC) was first performed in cancer patients who needed autologous HSC 
transplantation (HSCT) as part of their treatment; HSC were transduced with 
retroviral vectors encoding multidrug resistance (MDR) genes, allowing higher 
doses of chemotherapy to be administered (Hanania et al. 1996). Lymphocytes 
and HSC are convenient targets for retroviral vector transduction as they are 
accessible and techniques for ex vivo culture exist. This allows ex vivo 
transduction of these cells; followed by re-infusion into patients. HSC gene 
therapy shall be discussed in the next paragraph. Progress in T cell gene therapy 
has also been made. In an extension of the TIL approach just described, gene 
transfer was used to create these cells in the first place as opposed to simply 
marking them (Morgan et al. 2006). Autologous PBL were transduced with a 
retroviral vector encoding a T cell receptor that recognises a melanoma tumour- 
associated antigen. 15 patients were treated in this study; in 2, transduced TIL 
could still be detected at 1 year post-infusion. This was accompanied by marked 
regression of metastatic melanoma lesions. Recently, the first clinical gene 
therapy trial using a lentiviral vector was reported (Levine et al. 2006). 
Autologous CD4+ T cells of 5 subjects suffering from drug resistant HIV-1, were 
transduced with a lentiviral vector encoding an antisense gene against the HIV-1 
envelope. Transcription of the env antisense gene is from a non-SIN HIV-1 LTR 
in the vector. Its expression depends on infection of the cell with wild type HIV-1, 
which provides Tat. Production of progeny of wild-type HIV-1 virions from this cell 
should be abolished, if degradation of env transcripts by the antisense RNA is 
effective. Other RNA-based gene therapy approaches, involving transduction of 
PBL or HSC, to create an HIV-1 resistant pool of lymphocytes are currently being 
explored (Reviewed in (Rossi et al. 2007)).
69.
SCID-X1
patient
No conditioning
Harvest of bone 
marrow cells
CD34+ cells 
selection
Infusion of autologous 
transduced graft 
17-19 x 106 CD34+ cells/kg 
(-40% transduction)
u §
Transduction with 
gamma retroviral 
vectors encoding Yc.
#•  •
# «
3 x 24h
X-vivo 10
4% FCS
IL-3/SCF/
TPO/Flt3-L
Fibronectin
Figure 1.7. Principle of gene therapy to  the  haematopoietic system
This figure illustrates the gene therapy protocol for the treatm ent o f SCID-X1 used in the trial by 
Cavazzana-Calvo eta l. Bone marrow was harvested from affected boys;CD34+ cells were isolated from  
the bone m arrow; these cells were transduced ex vivo with an MFG vector carrying a correct copy of 
the gam m a c transgene; transduced cells were re-infused back into the patient. This resulted in 
successful reconstitution of the im m une system in 9 out of 10 patients treated in this trial.
(Reproduced from  Bueren etal, Archives o f Medical Research 34(6): 589-99,2003, with permission from  
the publisher Elsevier.)
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1.4.3.Haematopoietic system gene therapy
Haematological malignancies are the commonest indication for allogeneic HSCT. 
HSCT can also provide a permanent cure for inherited diseases such as sickle 
cell anaemia, thalassaemia major and aplastic anaemias. Primary 
immunodeficiencies are a group of inherited disorders in which the innate or 
adaptive immune systems are dysfunctional to varying degrees. They 
encompass severe combined immunodeficiency phenotypes (SCID) as well as T 
cell deficiencies, phagocytic disorders, haemophagocytic disoders and Wiskott- 
Aldrich syndrome (WAS). In the late 1960s, it was shown that primary 
immunodeficiencies could be cured by HSCT and for the next 30 years this 
remained the only treatment (Gatti et al. 1968). Outcome following HSCT for 
primary immunodeficiencies, particularly SCIDs, is best when an HLA identical 
sibling donor is used, but drops when an HLA mismatched donor is used (3 year 
survival 77% versus 54%) (Antoine et al. 2003).
It was for this reason that gene therapy was explored as an alternative 
therapeutic approach to HSCT in patients for whom no suitable bone marrow 
donor is available.
1.4.3.1. Transduction of HSC
The concept of gene therapy to the haematopoietic system is as follows (See 
Figure 1.7.): To begin with a patient’s own HSC are used -  these can be derived 
from bone marrow, cord blood or peripheral blood following G-CSF mobilisation. 
CD34+ cells are fractionated from total bone marrow or peripheral blood cells, 
these are a heterogenous population of haematopoietic progenitor cells and only 
as little as 0.2% are HSC (Bhatia et al. 1997). The hallmark properties of HSC 
are self-renewal and the potential to develop into mature blood cells of different 
lineages. In clinical gene therapy protocols so far, the therapeutic gene was 
introduced by means of a retroviral vector based on MLV. Since HSC are 
quiescent and retroviral vectors can only transduce dividing cells, it is necessary 
to pre-stimulate CD34+ cells ex vivo for 1-2 days in the presence of cytokines 
prior to vector transduction. (As pointed out previously, this ex vivo culture time
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can be shortened when lentiviral vectors are used.) To enhance vector 
transduction of HSC, they are grown in the presence of vector supernatant in 
vessels coated with recombinant fibronectin (Pollok and Williams 1999). Gene 
therapy corrected autologous HSC are then infused back into the patient, who 
depending on the underlying condition has or has not received pre-conditioning 
chemotherapy to allow better engraftment.
1.4.3.2. Clinical gene therapy trials to treat primary immuno­
deficiencies
Details of recent clinical gene therapy trials for primary immunodeficiencies are 
shown in Table 1.4.
In March 1999, what turned out to be the first successful human gene therapy 
trial was initiated in France for the treatment of X-linked SCID (X-SCID) 
(Cavazzana-Calvo et al. 2000). In this condition, the common y chain gene is 
faulty; the protein encoded by this gene is a component of the IL -  2/4/7/9/15/21 
receptors. In X-SCID patients, a failure of IL-7 and IL-15 signalling in HSC results 
in the complete absence of T cells and NK cells, respectively. Though, X-SCID 
patients have B cells, these are dysfunctional. Unless they are treated by HSCT, 
X-SCID affected boys succumb to infection within the first year of life. In the 
French SCID trial, 10 patients were treated. Autologous HSC were transduced ex 
vivo with an MLV-A pseudotyped MFG retroviral vector expressing yc. In 9 out of 
10 children, successful immune reconstitution, particularly of the T and NK cell, 
but less so of the B cell compartments, was achieved. Similarly favourable 
outcomes were obtained in a British SCID gene therapy trial (Gaspar et al. 2004), 
in which 10 children were treated. The protocols used in X-SCID trials were very 
similar, except for the following differences: In the UK trial, the vector was 
pseudotyped with GALV, CD34+ cells were transduced in serum-free medium 
containing slightly lower concentrations of IL-3 and lastly the vector used in this 
trial did not contain the B2 mutation in the PBS. (It was shown recently that 
TRIM28 binds the Mo-MLV PBS in embryonic carcinoma and stem cells, 
resulting in transcriptional silencing of the provirus (Wolf and Goff 2007). The B2 
mutation prevents TRIM28 binding.) The main difference observed between the
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French and UK X-SCID trials is that the rate of T cell reconstitution in the latter 
trial is slower. Patients did not receive pre-conditioning chemotherapy in either 
trial. The success of both X-SCID gene therapy trials was largely attributed to the 
huge selective advantage of gene corrected cells in vivo that followed the gene 
therapy mediated restoration of their ability to respond to proliferation signals. 
Subsequent developments in the X-SCID gene therapy trials will be discussed in 
section 1.4.4.1.
The adenosine deaminase (ADA) enzyme which is deficient in ADA-SCID, is 
involved in purine metabolism; its deficiency results in abnormal T, B and NK cell 
development. ADA-SCID can be cured by HSCT; in addition lifelong replacement 
therapy with polyethylene glycol ADA (PEG-ADA) is available to those for whom 
no suitable donor can be found. Though PEG-ADA prolongs survival, not all 
ADA-SCID patients respond equally well to it. ADA-SCID was the first inherited 
monogenic disorder treated by gene therapy (Blaese et al. 1995; Bordignon et al. 
1995; Kohn et al. 1995). However, immune reconstitution in these early gene 
therapy trials was poor. It is thought that due to the continued use of PEG-ADA in 
gene therapy treated patients, the potential selective advantage of gene modified 
cells was abolished. In 2002, the first successful gene therapy trial for ADA-SCID 
was reported (Aiuti et al. 2002). Initially, two children for whom PEG-ADA was 
unavailable, were treated. They received non-myeloablative conditioning with 
busulfan prior to re-infusion of gene corrected cells, to allow better engraftment 
and proliferation of these cells. Full immune reconstitution as well as metabolic 
correction was achieved in all 5 children treated according to this protocol (Aiuti 
et al. 2007). A similarly encouraging outcome was achieved in the UK using a 
comparable protocol of elective PEG-ADA discontinuation with mild pre­
conditioning (Gaspar et al. 2006).
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Table 1.4. Overview of recent clinical gene therapy trials for 1° immunodeficiencies
Trial SCID-X1 
France1'23 SCID-X1 UK 4
SCID-ADA Italy5 SCID-ADA UK 6 CGD 7
# of patients 10 10 5 1 3
Transgene yc YC ADA ADA gp91phox
Vector MFG (B2) 
(Mo-MLV)
MFG
(Mo-MLV)
GIADA-1
LXSN SFada WPRE SF71gp91
Pseudotype MLV-A GALV MLV-A GALV GALV
Packaging cell 
line qjcrip PG13 Gp+AM12 PG13 PG13
Target Cell 
(ex vivo culture 
time)
BM CD34+ 
(24+72)
BM CD34+ 
(40+56)
BM CD34+ 
(24+72)
BM CD34+ 
(40+56)
PB CD34+ 
(36+72)
Conditioning - - Busulfan L-Busulfan Melphalan
Leukaemias 4 1 - - -
1 (Cavazzana-Calvo et al. 2000), 2 (Hacein-Bey-Abina et al. 2002),3 (Hacein-Bey-Abina et al. 2003)
(Gaspar et al. 2004), 5 (Aiuti et al. 2002), 6 (Gaspar et al. 2006),7 (Ott et al. 2006)
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The successes achieved using gene therapy for the cure of X-linked and ADA- 
SCID, very convincingly demonstrated the effectiveness of this treatment for 
disorders of the lymphoid compartment. In both conditions gene modified HSC 
are thought to have a selective advantage in engraftment over unmodified cells. 
This would not be so in the case of chronic granulomatous disease (CGD). CGD 
is a disorder of the myeloid compartment; CGD macrophages lack anti-microbial 
activity, predisposing CGD patients to severe bacterial and fungal infections. In 
the X-linked form of CGD, the protein product of the gp91 phox gene is not 
expected to confer a selective advantage on gene-modified HSC in a gene 
therapy setting. Two CGD patients, who were in their thirties, received non- 
myeloablative conditioning prior to reinfusion of retroviral vector corrected PB- 
mobilised autologous HSC (Ott et al. 2006). Vector transduced cells were found 
predominantly in the myeloid compartment of both patients resulting in 
functionally corrected phagocytes and clinical improvement. Though 
myelopoiesis was initially polyclonal, by 5 months after gene therapy, this had 
become increasingly oligoclonal. Several progenitor cell clones were found to 
disproportionately contribute to myelopoiesis, a phenomenon known as clonal 
dominance. These clones were enriched in integration sites near MDS-Evi1, 
Prdm16 or Setbpl, which are known proto-oncogenes. Emergence of these 
dominant clones probably contributed to the therapeutic effect of gene therapy in 
these two patients. Unlike in the X-SCID trial, neither of these patients developed 
frank leukaemia. Unfortunately, one patient succumbed to fatal infection 2 years 
after gene therapy. In this patient’s phagocytes, gp91 phox expression was lost 
due to methylation of the SFFV promoter in the retroviral vector.
1.4.4. Gene Therapy and cancer
1.4.4.1. Leukaemia in clinical gene therapy trials
As was alluded to earlier, severe adverse events in the form of leukaemia 
occurred in 5 children treated by gene therapy for X-SCID. The first 2 and most 
well documented cases occurred in the French X-SCID trial, some 2 V* years 
after gene modified cells were administered (Hacein-Bey-Abina et al. 2003). In
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both children, malignant clonal expansion of mature T lymphocytes was observed 
(1 y5 T cell clone in Pt 4; 3 ap T cell clones in Pt 5). Malignant T cell clones each 
contained a single copy of the vector; in both cases the vector integration site 
was found to be near the promoter of the LIM-domain only 2 (LM02) gene (In the 
first intron in Pt 4; 3kb upstream in Pt 5). This gene encodes a transcription factor 
that is considered to be a central regulator of haematopoiesis, and is a known 
proto-oncogene. LM02 expression was activated by enhancer sequences within 
the LTRs of the MFG vector. LM02 activation is thought to have been the 
initiating event in leukaemogenesis, however other chromosomal abnormalities 
were also found in malignant T cell clones. Details of the other two leukaemia 
cases in the French X-SCID trial were recently presented at the ESGCT annual 
meeting in November 2007. These occurred in patients 7 and 10, at 68 and 33 
months after gene therapy, respectively. Pt 7 had a malignant clonal expansion 
of immature T cells. These contained one copy of the vector, which had 
integrated upstream of the cyclin D2 gene, a known proto-oncogene. A malignant 
cortical thymocyte clone was found in Pt 10. This clone contained two copies of 
the vector; one integration site was in intron 1-2 of LM02; the other was in intron 
4-5 of Bmi1. In December 2007, it was announced one patient in the British X- 
SCID gene therapy trial had also developed leukaemia. LM02 was 
overexpressed in this leukaemia; in addition mutations in NOTCH were found 
(A.J. Thrasher, BSGT annual meeting April 2008).
In all, 5 patients out of a total of 20 patients treated by gene therapy for X-SCID 
experienced adverse effects that can be ascribed to vector mediated insertional 
mutagenesis. No such adverse effects have so far been seen in the ADA-SCID 
trial. It is therefore believed there are specific risk factors associated with X-SCID 
gene therapy. Restoration of signalling by the interleukin receptors of which yc is 
a part, especially IL-7 signalling, creates a strong proliferative signal for gene 
corrected cells, that could contribute to transformation of cells that already 
contained one oncogenic hit due to vector insertion. This was supported by the 
finding that in a leukaemia induced by wild type MLV, RIS in both LM02 and yc 
were found (Dave et al. 2004). This provided evidence for cooperation between
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LM02 and yc genes in tumourigenesis. The role of the yc transgene has been 
the subject of even more intense debate, following a short report in Nature 
claiming that the yc transgene itself was potently oncogenic (Woods et al. 2006). 
In this study, yc'7' and normal HSC were transduced at high MOI with a lentiviral 
vector encoding yc. A third of mice developed T cell lymphoma within 18 months 
of infusion. As none of the animals that had received BM transduced with a 
control lentiviral vector developed leukaemia, it was concluded the yc transgene 
was the main cause of leukaemia development in these mice. However, in a 
number of other studies in which yc was expressed at more physiological levels, 
as had been the case in the X-SCID gene therapy trial, oncogenicity of the yc 
transgene could not be demonstrated (Thrasher et al. 2006). A mouse model of 
X-SCID gene therapy has now been developed to assess risk factors specific to 
this disease (See section 1.5.1.)
In a recent series of follow-up papers on the SCID trials, the integration site 
distribution in pre-transplant CD34+ cells was compared to that in peripheral 
blood cells of different lineages at varying times post-transplantation (Aiuti et al. 
2007; Deichmann et al. 2007; Schwarzwaelder et al. 2007). In all 3 trials, there 
was an increased frequency of RIS near promoters and CIS in post-transplant 
samples. This suggests that selective pressure after transplantation allows such 
clones to engraft better. Identical RIS were found in both lymphoid and myeloid 
cells of the same patients, indicating HSC were transduced, despite their sparsity 
in CD34+ populations. RIS near known proto-oncogenes including LM02 were 
recovered from healthy patients in whom no clonal imbalance was evident, this is 
consistent with the idea that several genetic changes are needed for malignant 
transformation to occur.
1.4.4.2. Leukaemia and clonal dominance in animal models of gene 
therapy
Several months prior to the report of leukaemias in the French X-SCID trial, the 
first case of leukaemia in an animal model of gene therapy using a retroviral 
vector was reported (Li et al. 2002). In a murine retroviral gene marking study, 
acute myeloid leukaemia (AML) was observed in secondary and tertiary
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recipients of pooled BM transduced with a retroviral vector expressing a modified 
Low Affinity Nerve Growth Factor Receptor (dLNGFR). All affected mice carried 
the same leukaemic clone in which a single copy of the vector had integrated in 
the first intron of the Evil gene in the same transcriptional orientation. Evil 
encodes a zinc finger transcription factor and was first identified as a CIS in 
myeloid tumours of AKXD23 mice (Mucenski et al. 1988). In leukaemic clones, 
Evil was expressed; transcripts were initiated from both LTRs.
In a subsequent study, it was shown leukaemia could also develop in primary 
recipients of bone marrow, transduced at high MOI with an MDR expressing 
retroviral vector (Modlich et al. 2005). Leukaemia development is thus a function 
of vector dose. Leukaemic clones contained multiple RIS, at least 3 of which 
were in putative proto-oncogenes.
In subsequent serial transplantation studies in C57BI6 mice of retroviral vector 
transduced bone marrow, no leukaemias developed (Kustikova et al. 2005). 
However, haematopoiesis in secondary recipients relied on just a few clones. RIS 
in these dominant clones were uniquely in known CIS, proto-oncogenes or other 
signalling genes, including two in Evil. Three independent hits in this locus were 
detected amongst the 22 RIS cloned from primary recipients, but surprisingly 
none of these Evil clones became dominant in secondary recipients.
The first report of malignancy in a large animal model of gene therapy emerged 
in 2006 (Seggewiss et al. 2006). A rhesus macaque developed AML 5 years after 
gene therapy. Autologous CD34+ cells were transduced with an MSCV vector 
encoding GFP and a drug resistant variant of the dihydrofolate reductase gene 
(L22Y). During the first year after transplantation, this animal experienced 80% 
myeloid marking; most marked cells derived from a single clone. This clone 
disappeared and for the next 3 years 1-4% of PB cells were GFP positive. In vivo 
selection for vector transduced cells was performed 2 years after gene therapy. 
This resulted in a transient increase in marked cells. One of the two vector 
integrations in the leukaemic clone was found to have occurred in the Bcl2-A1 
gene. Interestingly, this very same clone had been responsible for the transient 
clonal dominance seen in the first year after transplantation.
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Administration of SIN EIAV but not SIN HIV vectors into foetal and neonatal mice 
is associated with the development of liver tumours (Themis et al. 2005). 
Analysis of vector integration sites in these tumours did not reveal targeting of 
one specific locus, so it is still not known whether insertional mutagenesis played 
a role in tumour development. EIAV but not HIV vectors in this study contained a 
longer version of the WPRE element that encoded a truncated X protein. This 
protein is known to be involved in the development of hepatocellular carcinoma 
(HCC) in woodchucks. (The WPRE in most vectors, including those in use in our 
lab, contain mutations that prevent X protein expression.)
In a recent report, HCCs in mice were observed after in vivo neonatal gene 
therapy with an adeno-associated virus (AAV) vector (Donsante et al. 2007). 
These two studies taken together suggest administration of vectors to the foetal 
and neonatal liver might be particularly tumourigenic. As can be seen in Table 
1.3., AAV infrequently integrates into the genome. The vector used here encoded 
the p-glucuronidase gene, defective in mucopolysaccharidosis VII, which was 
expressed from a p-actin promoter and CMV enhancer. AAV vector integration 
sites were recovered from the tumours of 4 mice. All four were found to have 
occurred in a 6kb locus on mouse chromosome 12. It now seems that insertional 
mutagenesis is not restricted to gene therapy with retroviral vectors. Microarray 
analysis of neighbouring cellular gene expression revealed significant up- 
regulation of the Rian and Mirg genes, which encode multiple small nucleolar 
RNAs (snoRNAs) and miRNAs, respectively. Only miRNAs have thus far been 
implicated in cancer. Insertional activation of the mir-17-92 cluster, a known 
oncogenic miRNA cistron (primary transcript), was recently found in SL3-3 MLV- 
induced T cell lymphomas (Wang et al. 2006). Insertional activation of this same 
miRNA cluster was also implicated in some F-MLV induced erythroleukaemias 
(Cui et al. 2007).
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1.5. Assays to quantify insertional mutagenesis by 
retroviral and lentiviral vectors
Despite the large number of animal studies that had preceded the clinical gene 
therapy trials, the number of leukaemias encountered in the recipients of yc- 
transduced HSC was not anticipated. In hindsight, the duration of follow-up in 
these preclinical studies was arguably not long enough and also the levels of 
gene transfer were too low to observe adverse effects. For the benefit of future 
gene therapy clinical trials, it is now time for a thorough re-evaluation of the 
mutagenic potential of vectors. Toxicology studies of any pharmaceutical 
compound -gene therapy vectors can be classed as such- require suitable assay 
systems. Like any other assay, those that measure insertional mutagenesis by 
integrating vectors need to be sensitive, quantitative and reproducible. In 
general, this means there needs to be a measurable effect of the vector above 
the background spontaneous mutation frequency; this effect would be expected 
to be dependent on vector dose, i.e. the number of integrants being screened. 
Ideally, a direct comparison between vectors based on different parental viruses 
and vectors of different configuration could be made. Such assays would then 
allow us to design vectors with a reduced potential for insertional mutagenesis. 
Although in vivo studies usually follow in vitro studies, animal models developed 
to assess the potential for insertional mutagenesis by retro- and lentiviral vectors 
will be discussed first.
1.5.1. In vivo mutagenesis assays
Neonatal wild type Mo-MLV infection can accelerate tumour formation in the 
Cdkn2a'/' mouse model (Lund et al. 2002). This mouse is deficient in p16lnk4a and 
p19Arf, which regulate the Rb and p53 pathways, respectively. Bone marrow from 
the Cdkn2a"7" mouse was transduced with either a SIN lentiviral vector expressing 
GFP from an internal PGK promoter (LV) or a retroviral vector with intact LTRs 
(RV) (Montini et al. 2006). These cells were transplanted into lethally irradiated 
wild type FVB mice. Twice as many LV as RV integrants were screened, yet in 
the group that had received LV transduced cells, survival was comparable to that
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of control animals. Accelerated tumourigenesis was only observed in the group 
that had received the highest dose of RV vector. These mice had an increased 
risk of developing myeloid, but not lymphoid, tumours, which was explained by 
preferential retroviral LTR activity in myeloid cells. Tumours contained an 
average of 2-3 copies of the vector per genome.
An X-SCID disease-specific tumour prone mouse model was used to investigate 
any risk factors unique to X-SCID gene therapy (Shou et al. 2006).
In this study, Arf7' yc'7'double knockout mice were used as BM donors. Total BM 
cells were transduced with MSCV-yc-IRES-GFP or MSCV-GFP only vectors and 
then transplanted into lethally irradiated CD45.1 mice. 85% of mice that received 
yc-IRES-GFP transduced BM developed tumours by 55 weeks of follow-up 
versus 21% in the control group. The incidence of leukaemia in the yc-IRES-GFP 
group was much lower when Arf7* yc+/+ BM was used. The following hypotheses 
were proposed that could account for these differences: There are no NK cells 
present in yc'7" mice, which are involved in tumour surveillance; IL-7 signalling 
confers a strong proliferative signal to T cell precursors and thirdly there is an 
expanded pool of primitive (lymphoid) progenitors in X-SCID.
The following important observations were made in these two studies: In the first 
study a direct comparison between a non-SIN retroviral vector and a SIN 
lentiviral vector containing a cellular internal promoter was made. The latter 
combination was shown to have a reduced potential for insertional mutagenesis, 
suggesting it might be safer to use in future gene therapy clinical trials. The 
second study emphasised the importance of the disease background in gene 
therapy, with X-SCID being a potentially more risky setting than other conditions.
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1.5.2. In vitro mutagenesis assays
Prior to tests in animals, the mutagenicity of all potential new pharmaceutical 
compounds are first tested in in vitro mutagenesis assays. These are designed to 
be simple, quick and cheap. They will never supersede tests in animals, but 
provide a convenient first indication of the genotoxic potential of new compounds. 
In this section, firstly the principles of the simplest prokaryotic mutagenesis 
systems will be introduced. These measure gain of function following exposure to 
mutagens. Assays using cultured mammalian cell lines have been in existence 
for several decades. These measure inactivation of a defined allele following 
mutagen exposure. As we shall see, retroviruses and derived vectors were tested 
in these assays.
At present, one in vitro assay, which uses primary cells, has been developed to 
measure insertional mutagenesis by retro- and lentiviral vectors. The findings of 
this study will be discussed. Lastly, I will end this introduction by setting out the 
aims of this thesis.
1.5.2.1. Prokaryotic in vivo mutagenesis assays
The simplest assay to measure the mutagenicity of chemical compounds is the 
Ames Test (Reviewed in: (Mortelmans and Zeiger 2000)). It was developed in the 
1970s by Bruce Ames (Ames et al. 1972). The Ames test uses several strains of 
Salmonella typhimurium that are unable to synthesise histidine. Each strain 
carries different mutations in the His gene. The idea is that exposure to a 
mutagen can introduce mutations into the His gene that restores its function. 
Different mutagens cause different types of mutations, which are picked up by 
the particular strain in which most revertants are observed. In this way, the Ames 
test provides limited information about the mechanisms by which a particular 
compound induces mutations. The number of colonies seen on an agar plate 
containing minimal histidine is proportional to the mutagenicity of the compound 
tested. The Ames test has been modified over the years to improve its sensitivity. 
Indirect toxicity testing was enabled by the inclusion of a metabolic activation 
system in the test. This is most commonly rat liver homogenate, which provides
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enzymes e.g. cytochrome P450, which metabolise compounds to intermediates. 
This reaction occurs in the presence of the tester strains, so that mutagenicity of 
the metabolites is assayed. Furthermore, the lipopolysaccharide coat of the tester 
strain is engineered so it is more permeable to chemicals. Error prone DNA 
repair is encouraged in some strains, either by deletion of the gene enabling 
accurate excision repair or by introduction of a plasmid encoding this function. 
Despite its relative simplicity, the Ames test is still widely used as an initial screen 
to test the genotoxicity of new compounds.
1.5.2.2. In vivo mutagenesis assays using cultured mammalian cells
Instead of screening for gain of gene function, mutagenesis assays using
cultured mammalian cells select for loss of gene function following exposure to a 
mutagen. The principle is otherwise similar to that of the Ames test. Cells are 
incubated in the presence of a mutagen. The mutagen can disrupt expression of 
a defined allele, commonly Hprt or Tk (See below); the absence of the protein 
encoded by this gene is selected for. Following exposure to the mutagen, cells 
are firstly cultured for a few days in normal growth medium to allow phenotypic 
expression of potential mutants; mutants are then selected in the presence of a 
compound that kills only parental cells.
Just like chemical compounds and physical agents, the mutagenicity of 
retroviruses and later retroviral vectors were tested in these systems.
The first demonstration that a chronically transforming retrovirus, Mo-MLV, could 
inactivate a defined allele came in 1981 (Varmus et al. 1981). A rat fibroblast cell 
line that had been transformed with RSV, which was present as a single copy per 
genome, was superinfected with Mo-MLV. Morphological revertants, that had lost 
v-src expression, were selected for. In only approximately 10% of revertants, 
rearranged RSV proviruses could be found. In two revertants, Mo-MLV had 
integrated into the RSV provirus, upstream of v-src but downstream of the 5’LTR 
driving its expression.
Mo-MLV was subsequently tested in two well established mammalian 
mutagenesis systems. In a 1985 study, the mouse F9 embryonal carcinoma cell 
line was used (King et al. 1985). In this system, loss of hypoxanthine-guanine
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phosphoribosyltransferase (Hprt) following Mo-MLV infection was selected for. 
This enzyme is involved in purine salvage. It is encoded by an X-linked gene of 
~33kb. In male cells it is thus present as a haploid allele. Hprt ''' cells can be 
grown in medium containing the purine analogue 6-thioguanine (6TG). Hprt +/' 
cells incorporate this compound into DNA, where it leads to strand breaks and 
cell death. Following Mo-MLV infection, Hprt mutants were obtained at a cell 
frequency 12 fold over the background frequency of 3.5 x 10'8. The provirus 
frequency was 1-4 x 10'8. More mutants were obtained at higher virus copy 
numbers.
A more recent study measured Hprt loss after retroviral vector transduction of 
V79 Chinese hamster cells (Themis et al. 2003). The spontaneous frequency to 
Hprt in these cells is 2.9 xIO-6. MLV vector transduction at low MOI of 1-2, did 
not increase the mutation frequency over background; transduction at high MOI 
(~6), did increase the mutation frequency 2.3 fold over background. It is not clear 
how many vector integrants were screened in this study. 63% of Hprt''' clones 
analysed had rearranged the Hprt allele.
MLV based vectors were also used to measure thymidine kinase (TK) 
inactivation in the TK6 human B cell lymphoma cell line (Grosovsky et al. 1993). 
Selection of TK mutants was performed in the presence of trifluorothymidine 
(TFT), a pyrimidine analogue, that is incorporated into DNA of T K +/' cells. Vector 
transduction at low MOI of 1-2, resulted in a 5 fold increase in the cell frequency 
at which mutants were obtained. Again, in only a minority of mutants could an 
integrated provirus in the TK locus be detected.
As was demonstrated in section 1.2.2.4., mutagenicity associated with 
retroviruses and vectors derived from them, is not just confined to the disruption 
and inactivation of single copy genes. The types of mammalian cell culture 
assays described above did therefore underestimate the mutagenicity of 
retroviruses and retroviral vectors. As shall become clear in the introduction to 
Chapter 3, the assay we are proposing to develop has more in common with the 
Ames test in the sense that it selects for gain of function mutations. Gain of
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function of a range of different target genes by retroviral vector insertion is 
selected for.
1.5.2.3. Immortalisation of primary bone marrow by retroviral vectors
It was demonstrated that immortalised cell lines could be obtained after serial
passage of primary BM cells that had been transduced with a murine stem cell 
virus (MSCV) - based vector (Du et al. 2005). These cell lines were immature 
myeloid cells in phenotype; they remained dependent on growth factors and were 
unable to induce leukaemia when transplanted back into mice. Vector integration 
sites in immortalised clones were identified. Half contained RIS in Evil or 
Prdm16, resulting in upregulated expression of these genes.
The Baum lab adapted this approach to develop an in vitro assay for insertional 
mutagenesis (Modlich et al. 2006). Lineage negative primary BM cells from 
C57BI6 were transduced; then grown as a bulk culture for 2 weeks, before being 
plated out into 96 well plates. The number of wells containing clones that had 
acquired serial replating ability was scored. Two different vectors were initially 
compared: a retroviral vector containing wild type 5’ and 3’ SFFV LTRs (WT 
SFFV) and a SIN retroviral vector containing an internal SFFV U3 promoter (SIN 
SFFV). The replating frequency per vector copy number was 12 fold lower for the 
SIN compared to the wild type retroviral vector (1 in 362 versus 1 in 4347 
transducing events). In a follow-up study, a SIN vector containing an internal 
Elongation Factor 1a (EF1a) promoter (SIN EFS) was tested (Zychlinski et al. 
2008). No clones were detected with this vector; the replating frequency of this 
vector was estimated to be at least 10 fold lower than that of SIN SFFV. A SIN 
vector containing a 250bp chicken cHS4 insulator (SIN SFFV cHS4) in the U3 
region was also tested. The replication frequency per vector copy of SIN SFFV 
cHS4 was 2.5 fold lower than that of SIN SFFV. The insulator element thus 
somewhat reduces insertional mutagenesis, but unlike the SIN EFS vector there 
is still detectable transforming activity.
Clones obtained with the wild type vector shared many RIS. In 8 clones analysed 
in detail, 6 contained independent RIS near Evil; all 8 had upregulated Evil 
expression. 2 out of 3 SIN-SFFV clones analysed, also had activating insertions
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in Evil. This cell culture assay suggests that an internal EF1a promoter is unable 
to transactivate Evil expression. This gives some indication that SIN vectors 
containing cellular promoters might be safer to use in gene therapy.
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1.6. Thesis Aims
This thesis describes the development of a cell line assay that allows us to 
quantify insertional mutagenesis by retroviral and lentiviral vectors and to analyse 
the mechanisms by which this occurs.
The interleukin-3 (IL-3) dependent cell line BCL15 is derived from the mouse 
bone marrow cell line BAF3 and over-expresses human Bcl2. The frequency at 
which IL-3 independent mutants are obtained following vector transduction was 
measured.
I aimed to compare the mutagenic potential initially of lentiviral versus retroviral 
vectors and subsequently of different vector configurations. As will be shown in 
chapter 3, insertional activation of one of several cellular genes can transform 
BAF3 cells to IL-3 independence. Which of these genes had been targeted by 
vector insertion in transformed cells was investigated. The mechanisms whereby 
vector insertion activates expression of transforming genes was analysed.
This in vitro assay may inform us which viral vectors and vector configurations 
are safest. This will allow the design of vectors with a reduced mutagenic 
potential for use in future gene therapy pre-clinical and clinical trials.
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Chapter 2
2. Materials and methods
All buffers and solutions named in the text are listed in Table 2.1.
2.1. Tissue culture materials and methods
2.1.1. Tissue culture adapted cell lines
The following human and mouse derived cell lines were used: 293T, TE671, 
BAF3 (Ba/F3), BCL15 and WEHI3B.
The 293T cell line is a highly transfectable derivative of the 293 human 
embryonic kidney cell line, that expresses the SV40 large T antigen. The TE671 
cell line is derived from a human rhabdomyosarcoma. They were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco), supplemented with 10% 
Foetal Calf Serum (FCS), 2mM L-Glutamine, 100 units/ml Penicillin and 100 
pg/ml Streptomycin (all from Gibco). This medium will be referred to as complete 
medium. The 293T and TE671 cell lines are both adherent; cells were 
subcultured using trypsin/EDTA (Gibco). 293T cells were passaged 1:4 or 1:6 
every 2-3 days; TE671 were passaged 1:10 or 1:20 every 3-4 days.
WEHI3B is a BALB/c mouse myelomonocytic leukaemia cell line that produces 
IL-3 as a result of insertional activation of the mouse IL-3 gene by an 
intracisternal A particle (IAP) (Ymer et al. 1985). Conditioned medium was 
harvested from WEHI3B cells when the cells reached confluence (cell density of 
106 cells/ml). WEHI3B supernatant was filtered through a 0.45 pm filter and 
stored in aliquots at -20°C. The optimal concentration of WEHI3B supernatant 
needed to grow BAF3 cells was determined by tritium [3H] thymidine proliferation 
assay.
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The BAF3 cell line is an IL-3-dependent mouse pro-B lymphocyte cell line 
(Palacios and Steinmetz 1985). The BCL15 cell line, which is also dependent on 
IL-3, is derived from BAF3, but already over-expresses human Bcl2 (Collins et al. 
1992). BAF3 and BCL15 cells grow in suspension; both cell lines were grown in 
complete medium supplemented with 2-10% WEHI3B cell conditioned medium 
as a source of IL-3. BAF3/BCL15 cells were passaged 1:20 every 2 days or 1:50 
every 3 days, to maintain cell density between 5 x 104 and 106 cells/ml. All cell 
lines were grown in a 10% CO2 incubator at 37°C.
2.1.2. Production of VSV-G pseudotyped retroviral and lentiviral 
vectors
2.1.2.1. Transfer vector plasmids
The HIV-1-derived lentiviral vectors used were pHV (Ikeda et al. 2003) and 
pHRSIN-CSGW (Demaison et al. 2002) (Figure 2.1.a.). pHV has a wild-type 3’ 
long terminal repeat (LTR) from HIV-1 subtype B isolate HXB2. pHV’s 3’ and 
5’LTRs were derived from pH7G (Oxford Biomedica). Its self-inactivating 
derivative pHRSIN-CSGW, has a 400 bp deletion in the 3’LTR U3 region. These 
vectors are otherwise identical and contain an internal spleen focus-forming virus 
(SFFV) LTR promoter driving eGFP expression and a woodchuck hepatitis virus 
post-transcriptional regulatory element (WPRE). pHRSIN-CSGW was kindly 
provided by A. Thrasher (Institute of Child Health, UCL).
The retroviral vector pCNCG (Soneoka et al. 1995) contains wild type Mo-MLV 
LTRs and an internal CMV promoter driving GFP expression. The MPSV LTR- 
driven retroviral vector pMFG.S eGFP (Riviere et al. 1995) was kindly provided 
by J.S. Lee (Harvard Gene Therapy Initiative) (Figure 2.1.b.).
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A. Lentiviral transfer vector plasmids: 
pHV
CMV _____  ipGA RRE cPPT SFFV GFP WPRE
C>RU5
SD
pHRSIN CSGW
l|JGA RRE cPPT SFFV GFP WPRE
U3 R U5
j U3 R U5
[F
I
R ue
SD
B. Lentiviral packaging construct plasmid: 
pCMVAR8.91
CMV
GAG I —X P0L
RRE polyA
-4--------
1
REV
C. VSV-G envelope coding plasmid: 
pMDG
CMV VSV-G polyA 
[ = >  1 1
Figure 2.1 .a. Constructs used in transient three plasmid transfection of 293T cells for the production of 
high titre lentiviral vector.
A. The HIV-1 derived lentiviral transfer vectors pHV (Ikeda et al, 2003) and pHRSIN CSGW (Demaison et al, 
2002) are shown. pHV was a wild type HIV-1 3'LTR, whereas pHRSIN CSGW contains a 400bp deletion (A) in 
the U3 region of the HIV-1 3'LTR, resulting in the generation of a self-inactivating lentiviral vector.The vector 
backbones of pHV and pHRSIN CSGW are otherwise identical.
Lentiviral transfer vector plasmids were co-transfected into 293T cells with pCMVAR8.91 (B) and pMDG (C).
B. pCMVAR8.91 (Zufferey et al, 1997) is a second generation lentiviral packaging construct expressing HIV-1 
Gag, Pol,Tat and Rev.
C.The envelope coding plasmid pMDG (Naldini et al, 1996) is used to pseudotype lentiviral vector particles 
with the vesicular stomatitis virus G (VSV-G) protein.
CMV is the human cytomegalovirus im m ediate early promoter; Y is lentiviral packaging signal; SD is HIV-1 
major splice donor; GA is truncated Gag 5'UTR; RRE is Rev-responsive element; cPPT is central polypurine 
tract; SFFV is spleen focus forming virus LTR promoter/enhancer; GFP is green fluorescent protein reporter 
gene; WPRE is woodchuck post-transcriptional regulatory element.
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A. Retroviral transfer vector plasmids: 
pCNCG
CMV _______ W NEO CMV GFP
 3 =R U5
SD
pMFG.S eGFP
U3 R I I £
SD SA
GFP
U3 R U5
U3 R U5
B. Retroviral packaging construct plasmid: 
pCMVintron
CMV
> = > -c
polyA
MoMLV GAG-POL |—T   I
C. VSV-G envelope coding plasmid: 
pMDG
CMV VSV-G polyA
l = >  I I
Figure 2.1.b. Constructs used in transient three plasmid transfection of 293T cells for the 
production of high titre retroviral vector.
A. The retroviral transfer vectors pCNCG (Soneoka et al, 1995) and pMFG.S eGFP (Riviere et al, 1995) are 
shown. These constructs contain w ild-type Moloney Murine Leukaemia Virus (Mo-MLV) and 
myeloproliferative sarcoma virus (MPSV) 3'LTRs, respectively.
Retroviral transfer vector plasmids were co-transfected into 293T cells with pCMVintron (B) and pMDG
(C).
B. pCM V intron encodes Mo-MLV Gag-Pol.
C. pM DG was used to produce VSV-G pseudotyped retroviral vector particles.
CMV is the  hum an cytomegalovirus immediate early promoter; is retroviral packaging signal; SD is 
splice donor; SA is splice acceptor; NEO is the neomycin resistance gene; GFP is the green fluorescent 
protein reporter gene.
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2.1.2.2. Three plasmid transfection of 293T cells
Vector virus was produced by transient three-plasmid transfection (Soneoka et al. 
1995; Besnier et al. 2002). On the day prior to transfection, 107 293T cells were 
plated per 15cm dish (Nunc). Plasmids used in transfection were prepared 
commercially by the Plasmid Factory. pMFG.S eGFP was prepared by Maxiprep. 
On the day of transfection, a mix containing the following quantities of plasmid 
was prepared in a total volume of 37.5 pi of TE buffer: 2.5 pg gag-pol expression 
plasmid (pCMVintron for retroviral vectors (Collins, MKL., Weiss, RA., Takeuchi, 
Y., Cosset, F-L. 1995, Patent GB9517263.1); pCMVAR8.91 for lentiviral vectors 
(Zufferey et al. 1997)), 2.5 pg VSV-G envelope expression plasmid (pMD-G 
(Naldini et al. 1996)) and 3.75 pg transfer vector plasmid. 45 pi Fugene6 
transfection reagent (Roche) was diluted in 500 pi Optimem serum-free medium 
(Gibco). The plasmid mix was added to the Fugene/Optimem mixture and 
incubated at room temperature for 15 minutes. In the meantime, the medium on 
the 293T cells was changed. The plasmid/Fugene complexes were then added 
to the cells. The following day the medium on the transfected cells was changed. 
Virus containing supernatants (18ml per 15cm plate) were harvested at 48h, 72h 
and 96h post-transfection, filtered through 0.45pm filters and either concentrated 
immediately or stored at - 80°C. Vector virus was 100 fold volume concentrated 
by ultracentrifugation for 2h at 19.000 rpm at 4°C in a Sorvall ultracentrifuge 
using the Surespin (6 x 36ml) swinging bucket rotor. Virus was resuspended in 
cold complete medium and left on ice for 2h before aliquoting and storage at - 
80°C.
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2.1.2.3. Titration of retroviral and lentiviral vector stocks on 293T and 
BAF3/BCL15 cells
Each batch of vector virus was titered on TE671 and BAF3/BCL15 cells. TE671 
cells were plated onto six-well culture dishes at a density of 105 cells/well one 
day prior to transduction. The number of cells in one well was counted just before 
transduction and this cell number was used in titre calculations. Serial dilutions of 
vector virus were prepared in DMEM supplemented with 5 pg/ml Polybrene (PB, 
hexadimethrine bromide, Sigma). 1 ml of each dilution was then added to each 
well of TE671 cells. The medium on the cells was changed the following day. For 
titrations on BAF3/BCL15 cells, serial dilutions of vector virus were once again 
prepared. 5 x 105 Baf3 cells were infected in a total volume of 500 pi medium in 
the presence of 5pg/ml PB. BAF3/BCL15 cells were incubated in the presence of 
virus for 4h. After 4h, the culture was expanded to a total volume of 10ml. Both 
TE671 and BAF3/BCL15 cells were assayed for GFP expression by flow 
cytometry at 72h post-transduction. Virus input was plotted against the 
percentage of GFP positive cells (See Figure 2.2. for a typical titration curve). 
The titre in infectious units (i.u.) per ml was calculated from data points where 
approximately 10% of the cells were GFP positive (Table 2.2.). Lentiviral and 
retroviral vector titers were in the range of 1 - 5 x 107 and 5 - 10 x 106 BCL15 
(GFP) infectious units/ml, respectively. Some vector batches were also titered by 
Q-PCR for integrated GFP copies. 106 cells were harvested at 72 hours post­
transduction and DNA was extracted using a DNAeasy kit (Qiagen).
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Figure 2 .2 .Titrations of neat and 100 fo ld  volum e concentrated HV vector supernatant on TE671 
and BAF3 cells
HV vector containing supernatant was collected at 48, 72 and 96 hours post-transfection. Four fold 
serial dilutions of neat supernatant (open symbols) or supernatant 100 fold volum e concentrated by 
ultracentrifugation  (filled symbols) w ere  added  to 4  x 10s TE671 cells (A) or 106 BAF3 cells (B, 
concen tra ted  supernatant only). Cells w ere  transduced in the presence o f 5 p g /m l Polybrene  
(hexad im ethrine brom ide).The percentage o f GFP positive cells was measured by flow  cytom etry at 48  
hours post-transduction. Vector titres w ere  calculated from data points at which 1 -  10% o f cells 
express GFP and are shown in Table 2.2.
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Table 2.2. Comparison of HV lentiviral vector titres before and after 
concentration on TE671 and BAF3 cell lines
Collection TE671 100X UC
TE671
Neat Yield (%)
BAF3 
100X UC
BAF3/ 
TE671 ratio
48 hours 2.50 x 108 8.32 x106 30.0 2.73 x107 9.1
72 hours 6.88 x 108 1.72 x107 40.1 6.45 x107 10.7
96 hours 6.59 x10s 1.54 x107 42.7 8.03 x107 8.2
Using the titration data shown in Figure 2.2., vector titres in infectious units per 
millilitre (i.u./ml) were calculated from data points at which 1 - 10% of cells are 
GFP positive. The number of infectious units in a given volume of supernatant 
was calculated by firstly dividing the percentage of GFP positive cells obtained at 
this data point by 100 and then multiplying this number by the number of target 
cells on the day of transduction. The titre on TE671 cells was calculated for each 
collection before (Neat) and after concentration (100X UC). The yield is a 
measure of the efficiency of concentration. It was calculated by dividing the 
vector titre obtained after concentration by the neat vector titre times 100 and is 
expressed as a percentage. The titre of concentrated vector supernatant on 
BAF3 was calculated and compared to that on TE671. The fold difference in titre 
between these two cell lines is shown in the last column of the table.
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2.1.3. Irradiation experiments
5 x 106 parental BAF3 and HV A2 cells were washed thrice in complete medium 
without IL-3. Cells were then irradiated using a Pantac X-ray machine with an 
output of 240 KeV at a dose rate of 0.7 Gy/min. Immediately following irradiation, 
cells were pelleted and resuspended in the appropriate volume of medium with or 
without IL-3. BAF3 cells were cultured at 2 x 105 cells/ml (with IL-3) or 106 
cells/ml (without IL-3). HV A2 cells were cultured at 2 x 105 cells/ml (with or 
without IL-3).
2.1.4. Spiking experiments
BAF3 and HV A2 cells were washed thrice in complete medium without IL-3. 
Cells were counted and 10 fold serial dilutions of HV A2 cells were prepared. The 
required number of HV A2 cells (in 500pl) was added to 50ml culture containing 5 
x 107 BAF3 cells. In the experiment shown in Figure 6.3., spiked cultures were 
irradiated at 2 Gy using the Pantac X-ray machine as above.
2.1.5. Cell viability measurements
2.1.5.1. Trypan blue exclusion
One volume of cell culture was incubated for 5 minutes with an equal volume of 
trypan blue. The number of viable, trypan blue excluding, cells was counted in a 
haemocytometer under a light microscope.
2.1.5.2. Propidium iodide exclusion
Cell viability was measured by propidium iodide (PI) exclusion as described 
(Thomas et al. 2004). 105 BAF3 cells were pelleted and then incubated for 5 
minutes with HBBS containing 5 pg/ml PI. Uptake of the dye was measured by 
flow cytometry using a BD LSR and Cell Quest software. A FSC/SSC gate was 
used to exclude debris. 10.000 cells were analysed on a FSC/FL-2 dot plot. Live 
cells were FL-2 negative and FSC high; apoptotic cells were FL-2 dull, FSC 
intermediate and dead cells were FL-2 bright, FSC low. To differentiate between 
live parental BAF3 cells (GFP negative) and mutants (GFP positive), cells were 
analysed on a FL-1/FL-2 dot plot in the spiking and mutagenesis experiments.
96.
DAY 1:
Transduce 5 x 107 cells with 
vector virus for 4 hours 
in 50ml complete medium with IL-3
Expand culture volume 12 -15 times 
Culture cells in complete medium with IL-3
DAY 3/4:
Wash 5 x 107 cells (per selection method) 
free of IL-3; 
freeze any excess culture/  v
STANDARD SELECTION MODIFIED SELECTION
Plate cells in 24 well plates at 5 x 105 cells 
per well in 2ml complete medium 
without IL-3
Plate cells in 24 well plates at 5 x 105 cells 
per well in 2ml complete medium 
supplemented with 1 pg/ml bGH
DAY 10/11:
Rescue cells by adding IL-3 back 
to the medium
DAY 14/15:
Wash any growing cells free of IL-3; 
select cells in 10ml complete medium 
without IL-3 in T25 flasks
DAY 10/11 and once a week thereafter: 
Replace 1ml medium in each well by 
1ml fresh medium containing bGH
Monitor flasks for media colour changes 
indicating outgrowth of 
IL-3 independent clones
Monitor wells for media colour changes 
indicating outgrowth of 
IL-3 independent clones
Assay IL-3 independent clones for 
long-term IL-3 independence 
Characterise mutants on 
DNA/RNA/protein level
Figure 2.3. Selection protocols used in insertional mutagenesis experiments
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2.1.6. Insertions! mutagenesis experiments
The flowchart in Figure 2.3. summarises the selection protocols used in 
insertional mutagenesis experiments.
On day 1, 5 x 107 to 108 BAF3 or BCL15 cells were transduced with vector virus 
for 4 hours. Target cells were transduced at a multiplicity of infection (MOI) of 4- 
12 in experiments LV2-5; and 0.1-1.1 in experiments RV1-3 (determined by Q- 
PCR). Target cells were transduced at a cell density of 106 cells/ml and were 
grown in complete medium containing IL-3. After 4 hours, the culture volume was 
expanded 12-15 fold. Following transduction, target cells were cultured for 48-72 
hours in complete medium containing IL-3 to allow vector integration and the 
possible modification of neighbouring gene expression to occur. On day 3-4, 
cells were washed free of IL-3 and plated in 24 well plates at a cell density of 5 x 
105 cells per well in 2ml culture volume in complete medium without IL-3. The 
original target cell number of 5 x 107 to 108 was washed and plated out; any 
spare culture was frozen down and stored at -80°C for future reference. A small 
fraction of mock and vector transduced cells was analysed for GFP expression 
by flow cytometry and the average number of integrants per cell was determined 
by Q-PCR (experiments LV2-5 and RV1-3 only).
Cells selected according to the standard selection protocol were starved of IL-3 
for 7 days. Cultures were rescued by adding IL-3 back to the medium on day 
10/11. In each well, 1ml medium was replaced with 1ml fresh medium containing 
2x IL-3. Following rescue with IL-3, cells in the wells reached confluence after 2-3 
days. On day 14-15, a second selection round for IL-3 independence was 
initiated. Cells from each well were washed thrice in complete medium without IL- 
3 and were then grown in 10ml complete medium without IL-3 in T25 tissue 
culture flasks. These cultures were monitored for the presence of outgrowing 
cells. IL-3 independent clones (“mutants”) usually appeared 7 - 1 0  days following 
the start of the second selection round for IL-3 independence.
An alternative selection protocol, used in experiments LV3-5 and RV3, 
specifically selected for Ghr-insertional mutants by growing the cells from day 4 
onwards in complete medium without IL-3, but supplemented with 1pg/ml
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recombinant bovine growth hormone, bGH (A kind gift from G. Bogosian, 
Research Director in Agricultural Biotechnology, Monsanto, St. Louis, MO, USA). 
Cells were washed thrice in complete medium, and then resuspended in 
complete medium containing bGH. Cells were plated at 5 x 105 cells per well in 
2ml medium. Plates were regularly inspected for media colour changes in the 
wells, which indicated the outgrowth of a mutant. Mutants usually appeared 2 
weeks after the start of selection in serum plus growth hormone.
Mutants were tested for long-term IL-3 independence and further characterised 
on DNA/RNA/protein level. “Sibling” clones were eliminated after Southern blot, if 
their band patterns were similar. Once established, any long term IL-3 
independent mutants of the BAF3/BCL15 cell line were routinely cultured in 
complete medium without IL-3.
2.1.7. Statistical analysis
The Chi Square statistical method was used to determine how much the 
observed cell frequencies differed from the theoretically expected cell 
frequencies in the mock and vector transduced arms of each experiment.
X2 values were calculated using Smith’s Statistical Package (version 2.80, 
September 26, 2005, copyright 1995-2005, Gary Smith). In these comparisons, a 
X2 value greater than 11 is equivalent to p<0.001, which was considered 
significant.
2.1.8. Phenotypical studies on IL-3 independent mutants
2.1.8.1. Culturing cells in serum free medium or in the presence of 
recombinant cytokines
Cells were washed thrice in serum free medium. After the final wash, cells were 
resuspended in complete medium, complete medium containing IL-3, serum free 
medium or serum free medium containing recombinant cytokines. Recombinant 
cytokines used were: mouse interleukin 3 (403-ML/CF, R&D systems), mouse 
insulin-like growth factor 1 (791-MG, R&D systems) and bovine growth hormone 
(Monsanto).
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2.1.8.2. [3H] thymidine proliferation assay
On day 1, cells were washed thrice in serum-free medium and then cultured in 
serum free medium for 6 hours to synchronise cells and to remove any remaining 
IL-3 bound to them. Cells were then plated in 96 well flat bottom plates at a 
density of 2 x 104 cells per well in the presence of different concentrations of 
recombinant cytokines in 200pl total culture volume. On day 2, cells were pulsed 
with 1pCi [3H]-thymidine per well (ICN Biomedical, High Wycombe, UK). On day 
3, DNA from cells was harvested on a filtermat using a Tomtec Harvester Model 
96. [3H] incorporation into DNA was measured by liquid scintillation counting 
(Microbeta Systems). Control wells contained BAF3/BCL15 cells in serum free 
medium only, and these yielded <100 counts per minute [3H]-thymidine 
incorporation.
2.1.9. Flow cytometry cell surface staining
5 x 105 cells per stain were washed twice in HBSS 2% FCS. Cells were then 
incubated on ice for 1 hour with 5pg/ml biotinylated goat anti-mouse GHR 
antibody (BAF1360, R&D systems) which was diluted in blocking buffer (1X PBS, 
2% FCS, 0.01% Na Azide). Biotinylated normal goat IgG (BAF108, R&D 
systems) was used as isotype control; biotinylated goat anti-mouse IL-3 Rp 
antibody (BAF549, R&D systems) was used as positive control. Cells were 
washed twice in blocking buffer. Cells were then incubated with 1 pg/ml 
Allophycocyanin (APC)-conjugated streptavidin (17-4317, eBioscience) for 30 
minutes on ice in the dark. Finally, the samples were washed twice in blocking 
buffer before being resuspended in 500 pi HBSS. The samples were analysed by 
flow cytometry using a BD LSR and Cell Quest software.
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2.2. Molecular biology techniques
2.2.1. Plasmid preparation and manipulation
2.2.1.1. Preparation of heat shock competent E.coli
XL1-Blue competent cells (Invitrogen) were streaked onto an LB agar plate
containing 10 pg/ml tetracycline and grown overnight at 37°C. A colony was 
picked and inoculated into 2ml LB broth containing 10 pg/ml tetracycline. This 
culture was grown overnight in a shaking incubator at 37°C. The following 
morning, 1ml of overnight culture was inoculated into 100ml LB broth without 
antibiotics. This was grown in a shaking incubator at 37 °C until the OD600 was 
0.3-0.6. The culture was cooled on ice for 5 minutes; then the bacteria were 
pelleted and re-suspended in 50ml ice-cold TFB-I buffer. After a 5 minute 
incubation on ice, bacteria were pelleted again and re-suspended in 5 ml ice-cold 
TFB-I I buffer. Bacteria were aliquoted after a 15 minute incubation on ice and 
stored at -80°C.
2.2.1.2. Introduction of plasmid DNA into E.coli
Competent cells were thawed on ice and added to 2 pi ligation reaction. This 
mixture was left on ice for 20 minutes. Bacteria were heat shocked for 45 
seconds at 42°C and immediately put back on ice for 2 minutes. 950 pi of SOC 
medium (Invitrogen) was added, and bacteria were grown in a shaking incubator 
at 37°C for 1.5 hours. 100 pi of transformation mixture was then plated on LB 
agar plates containing the appropriate antibiotics. Blue white screening for 
colonies containing insert carrying plasmids was performed by precoating LB 
agar plates with Blue White screening reagent (X-gal/ IPTG) (Sigma). White 
colonies were further screened by PCR to confirm presence of the insert.
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2.2.1.3. Plasmid DNA mini-/midi-/maxi- preparations
Plasmids were extracted using Qiagen plasmid purification kits (QIAprep Spin
Miniprep kit; Plasmid Midi kit; Plasmid Maxi kit). A single colony was inoculated 
into 2-3 ml LB broth containing lOOpg/ml ampicillin (Miniprep). The culture was 
grown overnight in a shaking incubator (250 rpm/min). For midi and maxi 
preparations a 2 ml overnight starter culture was diluted into 25 or 100 ml 
selective LB broth and grown overnight in a shaking incubator. Bacteria were 
pelleted and re-suspended in 250 pi, 4 ml or 10 ml buffer P1. The cells were then 
lysed by addition of 250 pi, 4 ml or 10 ml buffer P2 and left at room temperature 
for 4-5 minutes. The mixture was neutralised by addition of 250 pi, 4 ml or 10 ml 
buffer N3. The resulting precipitate was then pelleted by centrifugation. The 
supernatant containing plasmid DNA was applied to an anion-exchange resin 
column provided by QIAprep Mini, Midi or Maxi kits. Purified plasmid DNA was 
eluted in water or EB buffer. The plasmid DNA concentration was determined by 
Nanodrop. The quality of the plasmid preparation was determined by running a 
fraction out on an agarose gel.
2.2.2. Restriction enzyme digests
Restriction enzymes used were obtained from Promega or New England Biolabs 
(NEB) and were performed according to the manufacturer’s instructions. Digests 
on plasmid DNA were performed for 2 hours. Genomic DNA was digested 
overnight; to ensure complete digestion extra enzyme was added to overnight 
digests the following morning.
2.2.3. Isolation o f DNA fragments from agarose gels (gel- 
purification)
1-2% agarose gels were used to separate DNA fragments according to size. Gels 
were made by dissolving 1-2 grams agarose in 1X TAE buffer (Tris-acetate- 
EDTA). 0.2pg/ml ethidium bromide was added to visualise DNA on a UV 
transluminator. 6X DNA loading buffer was added to DNA fragments (and PCR 
products). 10pl of 100bp or 1kb GeneRuler DNA ladder (Fermentas) was 
included on each gel to allow quantification and size determination of DNA
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fragments. DNA fragments were cut out of agarose gels and purified using a 
QIAquick gel extraction kit (Qiagen). Agarose gel slices were solubilised; applied 
to a column carrying a silica membrane; washed and eluted in water or EB buffer.
2.2.4.Subdoning of DNA fragments
PCR products were cloned into pGEM T Easy vector (Promega). 3 pi PCR 
product was ligated with 50 ng pGEM T Easy vector for 1 hour at room 
temperature or overnight at 4°C. 2 pi ligation reaction was used to transform 
competent XL1-Blue E.coli. M13 forward or reverse primers were used to 
sequence plasmids carrying inserts.
2.2.5.Genomic DNA extraction
Cells were harvested and washed twice with HBSS. Cell pellets were either 
stored at -80°C for DNA extraction at a later date or used immediately. Genomic 
DNA for use in quantitative PCR and integration site PCR was extracted from 106 
cells per sample using a DNeasy Blood and Tissue kit (Qiagen). Cells were lysed 
for 10 minutes at 56°C using Proteinase K. RNA was digested by adding RNAse 
A. The samples were loaded onto a DNeasy spin column, washed twice with PE 
buffer and finally eluted in 200 pi buffer AE.
DNA for use in Southern blotting was prepared from 2 x 107 cells. Cells were re­
suspended in 500 pi lysis buffer and lysed overnight in a 60°C water bath. To 
precipitate DNA, 1250 pi of precipitation buffer was added per sample. This was 
left at room temperature for 30 minutes. The DNA was then pelleted by 
centrifugation at 13.000 rpm for 15 minutes at 4°C. This was followed by 3 
washes of the DNA pellet in 70% ethanol, with 30 minutes shaking time and a 15 
minute spin at 13.000rpm per wash. The DNA pellet was air dried for -10-15 
minutes. The pellet was finally resuspended in 200 pi TE pH 8 buffer and left to 
dissolve at 4°C overnight.
Genomic DNA samples were stored in aliquots at 4°C or -20°C. DNA 
concentration was measured by NanoDrop spectrophotometer; a small fraction 
was also analysed by gel electrophoresis to assess genomic DNA quality.
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2.2.6.Southern blotting
15 pg genomic DNA was digested overnight at 37°C with 60 units of a restriction 
enzyme in a total volume of 200 pi. Digested DNA was concentrated by ethanol 
precipitation and dissolved in 20 pi TE buffer. DNA fragments were separated by 
overnight gel electrophoresis on a 0.7% agarose gel at 20V. A picture was taken 
of the gel, and the transfer and hybridisation protocol was started immediately. 
Prior to blotting the DNA from the gel onto a membrane, the gel was sequentially 
submerged in depurination solution for 10 minutes, denaturation solution for 30 
minutes and neutralisation solution of 30 minutes. Each of these incubations was 
done on a revolving platform at room temperature. The gel was rinsed with 
distilled water in between incubations with the different solutions. DNA fragments 
were blotted overnight by neutral transfer, using 20X SSC, onto a positively 
charged nylon membrane (HybondTM-XL, Amersham Bioscience). DNA 
fragments were crosslinked onto the membrane using a Stratalinker UV
Crosslinker (Stratagene). The membrane was then washed in 2X SSC. The 
membrane was pre-hybridised in Rapid-HybTM Buffer (GE Healthcare)
supplemented with 10 pg/ml Salmon Testis DNA (Sigma) overnight at 65°C. 
Digested genomic DNA was probed with a 32P labelled GFP probe (A 720bp 
PCR product generated using primers GFP-F and GFP-R; see Table 2.3.1.). The 
probe was made using the Rediprime II Random Prime Labelling System (GE 
Healthcare). Each probe was labelled with 50 pCi (=1.85 MBq) of Redivue [a- 
32P] dCTP (GE Healthcare). Unincorporated nucleotides were removed using 
the QIAquick Nucleotide Removal kit (Qiagen). Prior to addition to the
hybridisation buffer, the probe was denatured by heating it to 100°C for 5
minutes. The membrane was hybridised in the presence of the probe overnight at 
65°C. The following day, the membrane was washed thrice in wash solution 1 (1 
x for 10 min and 2 x for 15 min) and once in wash solution 2 for 15 min at 65°C. 
The membrane was exposed to a phosphorscreen for several days. The 
phosphorscreen was visualised using a Storm Phosphorlmager (GE Healthcare). 
The image was analysed using ImageQuant software (GE Healthcare). Following 
exposure to phosphorscreen, blots were exposed to Kodak BioMax film (Kodak).
104.
2.2.7.Polymerase chain reaction (PCR)
All polymerase chain reactions were performed using HotStarTaq DNA 
polymerase (Qiagen). This enzyme has no polymerase activity at room 
temperature and requires a 15 minute activation step at 95°C. PCR reactions 
were performed in a total reaction volume of 25 to 100 pi. PCR reaction 
components and amplification parameters are shown below. PCR reactions were 
performed using a Peltier thermal cycler (Dyad) equipped with a heated lid. 
Primers were obtained from Invitrogen and are listed separately in Table 2.3.
PCR reaction components
Component Final concentration
10X PCR Buffer 1X
dNTPs 200 pM of each dNTP
Forward Primer 0.5 pM
Reverse Primer 0.5 pM
HotStar Taq DNA 
polymerase
2.5 units/100 pi reaction
MgCb 1.5 mM
DNA template
Distilled Water
dNTPs deoxynucleotide triphosphates (Promega)
Amplification Parameters
Step Time Temperature °C
1. Initial Activation 15 min 95
Three step cycling
2. Denaturation 45 sec 94
3. Primer Annealing 30 sec ~5°C below Tm of 
primers
4. Extension 1 min 72
Number of cycles: 25-30
5. | Final extension 10 min | 72
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2.2.8. Quantitative PCR
100ng gDNA was used per reaction. Taqman quantitative PCR for integrated 
GFP copies was performed on duplicate samples. For each sample, Taqman 
quantification of 18S rRNA copies was performed in parallel to control for input. 
The QuantiTect Probe PCR Master Mix (Qiagen) was used in Q-PCR reactions; 
the reaction components are shown in the table below. The sequences of GFP 
and 18S primers and sequence-specific probes are shown in Table 2.3.2. 
Quantitative PCR reactions were performed in a 25 pi volume in 96 well plates 
using the ABI PRISM 7000 or Eppendorf Masterplex real time thermal cyclers. In 
the reactions in which GFP copies were quantified, 0.02 pg/ pi Salmon Testis 
DNA (Sigma) was present. Absolute quantification of both GFP and 18S copies 
was performed using plasmid DNA standards. For GFP quantification, lentiviral or 
retroviral transfer vector plasmid was used. For 18S quantification, a 600bp 
fragment of the 18S rRNA gene was amplified using the primers 18S rRNA-F and 
18S rRNA-R. A 10 fold serial dilution series of plasmid DNA, starting at 105 
copies and going down to 101 copies, was amplified and used to generate a 
standard curve. The number of cells in each sample was calculated by dividing 
the amount of DNA in the sample in pg by 13.2 (13.2 pg is the DNA content of a 
tetraploid BAF3 cell). The cell number was normalised to the number of 18S 
copies measured in the sample, assuming the number of 18S copies per cell is a 
constant. To calculate the average number of GFP copies per cell, the number of 
GFP copies measured by Q-PCR was divided by the normalised cell number. For 
each sample the average number of GFP copies per cell was further normalised 
to that obtained for mutant HV A2. This mutant contains a single copy of the 
vector per genome and was included as a control in each Q-PCR run.
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Q-PCR reaction components
GFP 18S
Genomic DNA 2 pi (-100 ng) 2 pi (-100 ng)
Salmon Testis DNA 0.5 pg -
Sequence-specific probe 0.3 pM 0.4 pM
Forward primer 0.3 pM 0.4 pM
Reverse primer 0.15 pM 0.2 pM
QuantiTect Probe PCR 
Master Mix
12.5 pi 12.5 pi
ddH20 Up to 25 pi total volume Up to 25 pi total volume
Amplification parameters
Step Time Temperature °C
1. Initial Activation 15 min 95
Two step cycling
2. Denaturation 15 sec 94
3. Annealing/ Extension 
Data Acquisition 60 sec 60
Number of cycles: 40
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2.2.9.Integration site PCR
2.2.9.1. Inverse PCR
Wild-type HIV-1 and MLV vector integration sites were cloned out by inverse 
PCR (IPCR) using a protocol modified from that described by (Carteau et al. 
1998). 2pg gDNA was digested overnight with Nlalll (HV only) or Mspl 
(HV/CNCG/MFG). To remove enzymes and salts, reactions were cleaned up 
using the QIAquick PCR Purification kit (Qiagen). Digested DNA was eluted in 
EB buffer in a final volume of 50 pi and DNA concentration was measured by 
NanoDrop spectrophotometer. To obtain intramolecular ligation of individual 
fragments, 200 ng digested genomic DNA was ligated in 500 pi volume using T4 
DNA ligase (Promega). The ligation was performed in a Peltier thermal cycler 
(Dyad) for 600 cycles of 30 sec at 12°C and 30 sec at 19°C. The ligation samples 
were cleaned using Microcon YM-30 columns (Amicon) and eluted in a final 
volume of 10 pi. 5 pi of this sample was amplified using 1st round PCR primers, 
shown in table 2.3.3. In nested amplification, 1 pi of first round product was used.
2.2.9.2. Linker mediated PCR
SIN lentiviral vector integration sites were cloned using LM-PCR, as described by 
(Wu et al. 2003). 1pg gDNA was digested overnight with Nlalll, Taql or Mspl 
restriction enzymes. A second digest, to destroy the internal band generated from 
the 5’LTR, was carried out for 2 hours with either EcoRI (for Nlalll or Mspl initial 
digest) or Sacl (for Taql initial digest). Digested DNA was column purified using a 
PCR Purification Kit (Qiagen). To generate the linker cassette, a positive linker 
oligonucleotide was annealed to a negative linker oligonucleotide. 100pmol of 
each linker oligonucleotide was heated to 95°C for 5 minutes and then slowly 
cooled to room temperature. 0.5pmol of linker cassette was ligated overnight at 
room temperature to digested DNA in a total volume of 35pl. This reaction was 
again column purified using a PCR Purification Kit. One third of the eluate was 
used in the first round of PCR. PCR reactions were performed using the 
HotStarTaq DNA Polymerase (Qiagen). In nested PCR, 1 pi of a 1:2 dilution of
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first round product was used per 50pl PCR reaction. Sequences of linker 
oligonucleotides and primers used in LM-PCR are shown in the table 2.3.4.
PCR products were separated by gel electrophoresis on 2% agarose gels. 
Individual bands were cut out of the gel and purified using a gel extraction kit 
(Qiagen). Each PCR fragment was eluted in a final volume of 30 pi. 3 pi of this 
eluate was cloned into the pGEM T Easy Vector (Promega). Commercial 
sequencing of plasmids containing host-virus junctions was carried out by Lark 
Technologies.
2.2.10. Integration site mapping
Sequence from a genuine HV vector integration site obtained by inverse PCR 
had to contain: at one end, 26bp (Nlalll) or 41 bp (Mspl) of HIV-1 U3 region 
sequence from the HUC forward primer to the restriction site; and at the other 
end, 34bp of U3 sequence from the IP3 reverse primer to the beginning of the 
5’LTR. Sequence from a genuine retroviral vector integration site obtained by 
inverse PCR had to contain: at one end, 73bp of MLV U3 region sequence from 
the Nested 5F forward primer to the Mspl restriction site; and at the other end, 
30bp of U3 sequence from the Nested 5R reverse primer to the beginning of the 
5’LTR.
Genuine LM-PCR product sequences had to contain 3’LTR sequence from the 
nested primer to the end of the 3’LTR and also the linker sequence.
Vector flanking DNA sequence was blasted against the mouse genome, released 
August 2007 (www.ensembl.org/Mus musculus). The same criteria as used by 
Wu et al were used to map vector-genome junction sequences onto the mouse 
genome (Wu et al. 2003). The sequence had to match a genomic location 
starting within 3bp after the beginning of the 5’LTR (inverse PCR) or the end of 
the 3’LTR (LM-PCR). The sequence had to show >95% identity to the genomic 
sequence and could only match one genomic locus with >95% sequence identity. 
Important integration sites were confirmed by locus-specific PCR. To amplify the 
5’LTR junction, a locus specific forward primer was designed and used in 
combination with a U3 region specific reverse primer. To amplify the 3’LTR
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junction, a locus specific reverse primer was designed and used in combination 
with a U5 region specific forward primer. Primer sequences are shown in Table 
2.3.5. Some of these locus-specific PCR products were sequenced. It was 
checked whether 5bp (HIV) or 4bp (MLV) duplications of host DNA flanked the 5’ 
and 3’ LTRs.
2.2.11. Multiplex PCR
In experiment LV3, multiplex PCR was used to identify additional HV vector 
integration sites in the Ghr locus. Seven different forward primers were designed 
every 2kb in the 15kb region immediately upstream of Ghr exon 2. A 10x primer 
mix was prepared containing 2pM of each locus-specific forward primer and 4pM 
of the HV vector-specific IP3 reverse primer. Multiplex PCR was performed on 
150ng gDNA using a Multiplex PCR Kit (Qiagen). Cycling conditions were as 
follows: 95°C 15’; 30x (94°C 30”, 55°C 90”, 72°C 2’); 72°C 10’. Sequences of 
locus-specific forward primers are shown in Table 2.3.6.
2.2.12. RNA extraction
Cells were grown in T75 flasks to a density of 5 x 105 cells/ml. 2 x 107 cells were 
pelleted in a 50 ml Falcon and washed twice in HBSS. Cells were lysed by 
repeatedly pipetting them in 1ml of RNAzol B reagent (Biogenics). The lysate 
was either frozen at -80°C for RNA extraction at a later date; or extraction was 
proceeded with immediately. To separate the aqueous from the organic phase of 
the lysate, 200pl Chloroform was added per sample, vortexed and kept on ice for 
15min. The homogenate was then centrifuged at 4°C for 15 minutes at 13.000 
rpm. Next, RNA was precipitated from the upper aqueous phase by adding an 
equal volume of isopropanol. This was left on ice for 15 minutes and then 
centrifuged at 4°C for 30 minutes at 13.000 rpm. The RNA pellet was washed 
twice with 200pl 70% EtOH (in DEPC-treated water). The RNA pellet was 
dissolved in 40pl RNase-free water, RNA concentration was measured and RNA 
was stored in aliquots at -80°C.
RNA for use in Q-RT-PCR was extracted from 5 x 106 cells using an RNeasy kit 
(Qiagen). Cells were washed twice in HBSS. After the final wash, cells were re­
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suspended in a denaturing guanidine-thiocyanate-containing buffer (buffer RLT) 
containing p-mercaptoethanol. The lysate was frozen at -80°C for at least one 
hour. The lysate was thawed on ice and ethanol was then added. This sample 
was then applied to an RNeasy column and washed twice. RNA was eluted in 50 
pi RNase-free water.
2.2.13. Reverse-transcriptase PCR
The reverse transcription reaction was performed using a Protoscript First Strand 
cDNA synthesis kit (New England Biolabs). First strand cDNA from Ghr, Igf1 or 
II3 mRNAs was synthesised using 2 pg total RNA as a template. The RT reaction 
was primed using random primers (Promega) or a gene specific reverse primer 
(Shown in Table 2.3.7). Firstly, RNA, 20pmol gene-specific primer/30pmol 
random primer and dNTPs in a total volume of 16 pi were heated for 5 minutes at 
70°C; next 2 pi 10X RT Buffer, 1 pi Mo-MLV reverse transcriptase (RT) and 1 pi 
RNase inhibitor were added per reaction. Reactions without RT were also 
performed on every sample. The samples were then incubated for 1 hour at 
42°C. The enzyme was inactivated for 5 minutes at 95°C. The reaction was 
diluted to a total volume of 50 pi. 2 pi of this reaction was used as template in the 
subsequent PCR reaction. Primer sequences are shown in Table 2.3.7. RNA 
from mouse liver was used as a positive control in the Ghr and Igf1 RT PCR 
reactions; WEHI3B RNA was used as a positive control in II3 RT PCR.
2.2.14. Quantitative RT-PCR
cDNA was generated from 1pg RNA using the QuantiTect Reverse Transcription 
kit (Qiagen). This kit contains a genomic DNA wipe-out reaction and uses 
random primers and oligo d(T) to prime the RT reaction. One eighth of this 
reaction (2.5pl) was used in Taqman quantitative PCR using the QuantiTect 
Probe PCR Master Mix (Qiagen). Reaction components are shown in the table 
below; amplification parameters were as described previously. The IL-3 primers 
and probe were designed using PrimerExpress software. The sequences are 
shown in Table 2.3.2. The dual labelled IL-3 probe spans the junction of exons 4 
and 5. pGEM T Easy vector containing the complete IL-3 cDNA as an insert was
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used for absolute quantification of IL-3 copies. A 10 fold serial dilution series of 
this plasmid, starting at 105 copies and going down to 101 copies, was amplified 
and used to generate an IL-3 standard curve. Taqman quantification of 18S 
rRNA copies was performed in parallel, as described previously. A 10 fold serial 
dilution series of the 18S plasmid, starting at 1010 copies and going down to 106 
copies, was amplified and used to generate an 18S standard curve. The ratio of 
IL-3 copies per 18S copies was calculated from duplicate samples.
Q-RT-PCR reaction components
IL-3 18S
RT reaction 2.5 pi 2.5 pi
Sequence-specific probe 0.3 pM 0.4 pM
Forward primer 0.3 pM 0.4 pM
Reverse primer 0.15 pM 0.2 pM
QuantiTect Probe PCR 
Master Mix
12.5 pi 12.5 pi
ddH20 Up to 25 pi Up to 25 pi
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2.3. Appendix
Table 2.1. Buffers and solutions
1X PBS (Phosphate- 
buffered saline)
1.9mM NaH2P04; 8.1mM Na2HP04; 154mM NaCI; 
pH 7.4
1X HBSS (Hanks 
balanced salt solution)
5.4mM KCI; 0.3mM Na2HP04-7H20; 0.4mM KH2P04; 
4.2mM NaHC03; 1.3mM CaCI2; 0.5mM MgCI2-6H20; 
0.6mM MgS04-7H20; 137mM NaCI; 5.6mM D-glucose; 
pH 7.4
1XTAE buffer 40mM Tris (pH 7.8), 20mM sodium acetate and 1mM EDTA
Elution buffers
TE 10 mM Tris.CI, 1mM EDTA, pH 8.0
EB 10 mM Tris-CI, pH 8.5
AE 10 mM Tris-CI, 0.5 mM EDTA, pH 9.0
Bacterial media and solutions
LB (Luria-Bertani) 
agar
1% bacto typtone, 0.5% bacto yeast, 0.5% NaCI (pH 
7.0) with 15g/L bactoagar
LB (Luria-Bertani) 
broth
1% bacto typtone, 0.5% bacto yeast and 0.5% NaCI 
(pH 7.0)
SOC medium
2% tryptone; 0.5% yeast extract;
10 mM NaCI; 2.5 mM KCI; 10 mM MgCI2; 
10 mM MgS04; 20 mM glucose
TFB-I
30 mM potassium acetate; 100 mM rubidium chloride. 
10 mM calcium chloride; 50 mM magnesium chloride. 
15% glycerol; pH 5.5 with acetic acid
TFB-II
10 mM MOPS; 75 mM calcium chloride; 
10 mM rubidium chloride; 15% glycerol; 
pH 6.5 with KOH
Genomic DNA extraction buffers
Lysis buffer 10mM Tris.CI (pH 7.4); 10mM EDTA; 10mM NaCI; 0.5 % SLS; 1 mg/ml Proteinase K
Precipitation buffer 18.75pl of 5M NaCI/1250|jl Ethanol 75mM
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Southern Blotting solutions
Depurination Solution 0.25M HCI
Denaturation Solution 0.5 M NaOH 1.5 M NaCI
Neutralisation Solution 1 MTrisCI 1.5 M NaCI pH 7.4
20X SSC 3.0M NaCI 0.3M sodium citrate pH 7.0
Wash Solution 1 2X SSC 0.1XSDS
Wash Solution 2 0.1XSSC 0.1XSDS
Table 2.3. Prim er Sequences
Table 2.3.1. Primers used to generate Southern Blot probe
GFP-F ATG GTG AGC AAG GGC GAG GA
GFP-R TTA CTT GTA CAG CTC GTC CAT GCC
Table 2.3.2. Quantitative (RT) PCR Primer and Probe Sequences
GFP
GFP-TQ-F CAA CAG CCA CAA CGT CTA TAT CAT
GFP-TQ-R ATG TTG TGG CGG ATC TTG AAG
GFP-TQ-P 5-FAM-CCG ACA AGC AGA AGA ACG GCA TCA A-3TAMRA
18S
18S-TQ-F TCG AGG CCC TGT AAT TGG AA
18S-TQ-R CCC TCC AAT GGA TCC TCG TT
18S-TQ-P 5’-FAM-AGT CCA CTT TAA ATC CTT-3TAMRA
IL-3
IL-3-TQ-F AAC TTA ACT GTT GCC TGC CTA CAT C
IL-3-TQ-R AAG TCA TCC AGA TCT CGA ATG AAG AC
IL-3-TQ-P 5’-FAM-C GAA TGA CTC TGC GCT GCC AGG G-3TAMRA
Primers used to generate 18S and IL-3 inserts for plasmid DNA standards
18S-F TAC CTG GTT GAT CCT GCC AGT A
18S-R TTA CGA CTT TTA CTT CCT CTA GAT AG
IL-3-F ATG GTT CTT GCC AGC TCT ACC
IL-3-R TAG ATA AAT TGA TAA GAC ATT TGA TGG C
F = forward primer; R = reverse primer; P = probe
All primers were synthesised by Invitrogen; 5’-FAM/3’-TAMRA dual labelled 
probes were synthesised by Sigma.
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Table 2.3.3. Inverse PCR primer sequences and cycling conditions
Lentiviral inverse PCR (1st round)
95°C 15’; 35x (94°C 45”, 53°C 30”, 72°C 1'); 72°C 10’
HUE AGC CAA TGA AGG AGA GAA CAC CC
HUB GAT CAA GGA TAT CTT GTC TTC GT
Lentiviral inverse PCR (Nested)
95°C 15’; 30x (94°C 45”, 54°C 30”, 72°C 1’); 72°C 10’
HUC CTT GTT ACA CCC TGT GAG CCT
IP3 TCT TGT CTT CGT TGG GAG TGA
Retroviral inverse PCR (1st round)
95°C 15’; 35x (94°C 45”, 51 °C 30”, 72°C 1’); 72°C 10’
Mspl-5F GAG AAG TTC AGA TCA AGG TC
Mspl-5R TCC ATG CCT TGC AAA ATG GC
Retroviral inverse PCR (Nested)
95°C 15'; 30x (94°C 45”, 53°C 30”, 72°C 1’); 72°C 10’
Nested-5F CAA GGT CAG GAA CAG ATG GA
Nested-5R GCT TGC CAA ACC TAC AGG TG
Table 2.3.4. Linker mediated PCR primer sequences and cycling conditions 
I LM PCR Linker Plus
Nlalll Plus GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA 
AGG GAC TAC ATG
Taql/Mspl Plus GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA 
AGG GAC
LM PCR Linker Minus
Nlalll Minus P04-TA GTC CCT TAA GCG GAG
Taql/Mspl Minus PO4-GC GTC CCT TAA GCG GAG
CSGW LM PCR (1st round)
95°C 5’; 30x (94°C 45”, 55°C 30”, 72°C 1’); 72°C 10’
Linker 1 GTA ATA CGA CTC ACT ATA GGG C
HIV-1 3’LTR 1 AGT GCT TCA AGT AGT GTG TGC C
CSGW LM PCR (Nested)
95°C 5’; 30x (94°C 45”, 55°C 30”, 72°C 1’); 72°C 10’
Linker Nested AGG GCT CCG CTT AAG GGA C
HIV-1 3’LTR Nested GTC TGT TGT GTG ACT CTG GTA AC
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Table 2.3.5.a.Sequences of site-specific PCR primers for confirmation of
lentiviral vector integration sites
Experiment 
Mutant Name
Confirmation of 5’LTR 
junction:
Locus-specific forward primer 
(Used in combination with 
HIV-1 U3 primer IP3 
TCT TGT CTT CGT TGG 
GAG TGA)
Confirmation of 3’LTR 
junction
Locus-specific reverse primer 
(Used in combination with 
HIV-1 U5 primer GT250 
GAC CCT TTT AGT CAG 
TGT GGA A)
LV1 HV A2 HV A2-F:
GAG CTA CAA GGT CAT 
ACA CTC
HV A2-R:
GAG CAC AGA GGA AGG 
TGG AAA
LV2 HV3 HV3-F:
GGA TTC AGT ATC TGG 
AAC TTC
HV3-R:
AAT GCA TCA ATA CAT 
AGA CTG
LV2 HV14 HV14-F:
GGG ATC AGA GCT AAA 
CAA AGA
HV14-R:
CCA AGT CCT AGC CAA 
CAT TCT
LV3 HV32/HV49 HV32/HV49-F:
CAG TAA CAT CCC ACT 
TCC TGA
HV32/HV49-R:
GCT CAG CAC AGG GCT 
TTG AAT
LV3 HV41 HV41-F:
CGC TGC TTC AGT CCT 
GTT CTA CCT
HV41-R:
TTT CCA CAC TCC AAG 
TCT GAG GCA
LV3 HV43 HV43-F:
GTT CAG TGT TTG AGA 
GGA CCT CTG
HV43-R:
GTG TCG GAG TTG ACT 
GAA GTT ACC
LV4 GH 
CSGW1-1
Zfp407-F:
GAG CAGA AGA CCA ACA 
AAG CA
ND
LV4 GH 
CSGW1-1 and 
GH CSGW2-4
Cnot4-F:
GAA TGG TGA TAT CCC 
TGC CTT
ND
Gmeb-2-F:
GCA AGT GAT TAC CTC 
TGC TCA
ND
Wipi2-F:
TTA GGT GTG GGC ACA 
GGT TGT
Wipi2-R:
CTA AAC TGA AAC CTC 
AGC CCT
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Table 2.3.5.b. Sequences of site-specific PCR primers for confirmation of
retroviral vector integration sites
Mutant Confirmation of 5’LTR 
junction:
Locus-specific forward primer 
(Used in combination with 
MLV U3 primer Mspl5R 
TCC ATG CCT TGC AAA 
ATG GC)
Confirmation of 3’LTR 
junction
Locus-specific reverse primer 
(Used in combination with 
MLV U5 primer Mspl3F 
CCT CTG AGT GAT TGA 
CTA CC)
C40 C40-F:
CAC TAG TCA GGT GGG 
ATG AAG T
C40-R:
TAA GCA GAC CCT TAC 
CTC CGT C
C57AA(Chr 11) C57 AA-F:
ACT CTT GGA CTT CCT 
ACT CAG G
C57 AA-R:
TGT AGG CAG CCA GTG 
TCA AGA G
C57 AB (Chr 7) C57 AB-F:
CGC ATC ACT TCC TGC 
TAG GTT G
C57 AB-R2:
CTC AGG ACT CTC CAT 
ATC TGC T
C57 CA (Chr 9) C57 CA-F:
CAG GGA CTA CAC AGT 
GAG ATC C
C57 CA-R:
AGG GCC TCA CAA ATG 
TGT TCC T
C57 DA (Chr X) C57 DA-F2:
CAG TCT GCA GAC ACA 
AGT GAA G
C57 DA-R2:
ACC TGT GGA ATC TGA 
TGG TGA G
C96 BC (Chr 7) C96 BC-F:
ATA GGG AGT TGA GGT 
GGG GGA A 
C96 BC-F2:
TGG CTG GGT GAC ATG 
ATG AGC T
C96-BC-R:
CCC TTT GTG TGG TTC
CCA CCA T
C96-BC-R2:
GAA AGA CCA GCT CTC 
ACT CAC A
G 18AA(Chr 11) G18AA-F:
ATC TGG AGA CAG TGC 
TAA CCT C
G18AA-R:
AAA GCC CTG TCA TGG 
GTC ATC T
G18 AD (Chr 9) G18 AD-F:
T GT CAGT GGCCCT GGTAG 
GATA
G18AD-R:
GCTT GCT CAGCCAACTTT C 
TCA
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Table 2.3.6. Sequences of Multiplex PCR primers
Name Locus-specific forward primer
(Used in combination with HIV-1 U3 primer IP3)
108-HV-F TGC TCA GGT TGT CTC AGA GTA
110-HV-F GGA GGC AAA GCC TCT TGA TAA
112-HV-F GCT AAG CTT GGA TTT ATG CGC T
114-HV-F GGC CAA CGT TTG ATG GAG TAA T
116-HV-F GGT AGA CTT TAG AGG TAC TGA G
118-HV-F GTT CAT GCT AAG GTG AGT GAA G
120-HV-F AGC CTT AGT ATA CAG TGG GCT A
Table 2.3.7. Reverse -  transcriptase PCR primers
Name Application Sequence Product
size
Growth Hormone Receptor
GHR
A1
F-primer 
Exon 4
TGG ACA GAA GGA GAT AAT CCT GAT
552GHR
RT3
R-primer 
Exon 8
GAA CTC GCT GTA CTT TTC AAA GCT C
Interleukin 3
IL3FW F-primer 
Exon 1
ATG GTT CTT GCC AGC TCT ACC
602IL3RW R-primer 
Exon 5
TAG ATA AAT TGA TAA GAC ATT TGA 
TGG C
Insulin-like growth factor 1
Igf1-F F-primer 
Exon 2
TCG TCT TCA CAC CTC TTC TAC CTG
321Igf1-R R-primer 
Exon 3
CTT CTG AGT CTT GGG CAT GT
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Chapter 3
3. Optimisation of mutagenesis assay conditions
3.1. Introduction
In the mutagenesis assay I tried to establish, IL-3 independent mutants of an IL-3 
dependent cell line, BAF3, were selected. The BAF3 cell line was established in 
the early 1980s from mouse bone marrow of BALB/c mice. It is pro-B cell in 
phenotype and its growth is dependent on IL-3 (Palacios et al. 1984). The BAF3 
cell line was chosen instead of other cytokine-dependent cell lines for the 
purpose of setting up an insertional mutagenesis assay for several reasons. 
Firstly, BAF3 cell biology is well characterised. The signalling pathways activated 
in this cell line downstream of the IL-3 receptor are known. Other cytokines and 
their receptors, as well as oncogenic proteins, that can cause IL-3 independent 
survival and proliferation of BAF3 cells have been described. This knowledge 
should be helpful in identifying vector induced transforming events in any BAF3 
cell mutants.
Secondly, BAF3 cells were reported to undergo apoptosis reliably upon IL-3 
withdrawal. This is a pre-requisite for a cell line in which factor independent 
mutants are selected following vector transduction. Lastly, retroviral vectors had 
previously been used as insertional mutagens of the BAF3 cell line in our lab with 
the purpose of identifying anti-apoptotic genes. These studies, though not 
quantitative, offered a proof of principle that retroviral vectors could transform 
these cells and a single transforming event was sufficient to do so.
The above points will be discussed in greater detail in the sections that follow. I 
will start with a review of the signalling pathways activated by IL-3 in BAF3 cells. 
Next, the mechanisms by which BAF3 can be transformed to IL-3 independence 
will be discussed. Loosely based on the conditions of the earlier retroviral 
insertional mutagenesis studies in BAF3 cells, one pilot lentiviral vector 
mutagenesis experiment had already been performed before I joined the lab. The 
results section of this chapter will describe optimisation of these assay 
conditions.
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3.1.1. IL-3 signalling
The following reviews on IL-3 signalling were consulted during the writing of this 
section: (Reddy et al. 2000; Baker et al. 2007; Robb 2007)
3.1.1.1. IL-3 and the IL-3 receptor
The haematopoietic cytokines IL-3, IL-5 and GM-CSF are encoded by mouse 
chromosome 11. IL-3 promotes survival and proliferation of haematopoietic 
progenitor cells. In vivo IL-3 is produced under conditions of stress, mainly by 
activated T cells to stimulate haematopoiesis and recruit more differentiated 
immune cells to the periphery. The targets of IL-3 are progenitor cells of both the 
lymphoid and myeloid lineages; the IL-3 receptor is expressed on the cell surface 
of these cells (Robb 2007). The IL-3 receptor belongs to the gp140 family of 
class I cytokine receptors (Reddy et al. 2000). It is a heterodimeric receptor 
consisting of a unique IL-3 specific a chain and a common p chain (pc/ gp140/ 
CD131). pc is shared by the IL-5 and GM-CSF receptors; it is responsible for 
intracellular signal transduction by these receptors. Mice also encode an IL-3 
specific p chain (piL-3) in addition to pc. IL-3 receptor dimerisation only occurs 
once IL-3 has bound to the a chain; the pc is then recruited to the a chain and the 
two receptor subunits become linked through disulphide bonds, causing 
intracellular signalling to be initiated.
3.1.1.2. IL-3 receptor intracellular signalling pathways
IL-3 mediates the survival and proliferation of haematopoietic progenitor cells
through the activation of three known signalling cascades that eventually result in 
activation of gene expression in these cells. The way in which aberrations in 
signalling by these pathways can result in transformation of IL-3 dependent BAF3 
cells will be discussed in the next section.
The IL-3 receptor does not itself have any catalytic activity. Janus kinases (JAKs) 
are at the heart of all three signalling pathways activated by IL-3 (Baker et al. 
2007). Upon IL-3 receptor dimerisation, JAK2 becomes activated by 
autophosphorylation. Activated JAK2 then goes on to phosphorylate the 
intracellular domain of pc on 6 critical tyrosine residues (Y577, Y612, Y695,
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Y750, Y806 and Y866 (Martinez-Moczygemba and Huston 2003)). These 
phosphotyrosines serve as docking sites for many different signalling molecules 
that bind via their SH2-domains, including Signal Transducers and Activators of 
Transcription (STATs), Src family kinases, protein phosphatases (needed for 
signal termination) and adaptor molecules such as She, Grb2 and
Phosphatidylinositol 3 kinase (PI3K)(Baker et al. 2007). Src-family kinases fyn,
hek and lyn also play an important role in IL-3 signal transduction. These three 
kinases where shown to become activated upon IL-3 receptor dimerisation, 
however it is not clear whether this happens at the same time as JAK2
phosphorylation or as a downstream event of JAK2 activation (Corey and
Anderson 1999).
3.1.1.2.1. Signal Transducers and Activators of Transcription (STAT) 
signalling pathway
The STAT signalling pathway is activated by most cytokine receptors. STAT 
family members STAT3, 5a and 5b are activated by the IL-3 receptor. STATs are 
a group of transcription factors that are found in an inactive state in the 
cytoplasm. Three phosphotyrosines (Y612, Y695 and Y750) in the membrane 
proximal region of pc serve as docking sites for STATs. pc bound STATs become 
tyrosine phosphorylated on their carboxy termini, which is mediated by JAK2 or 
Src family kinases. Phosphorylated STATs dimerise and translocate to the 
nucleus where they function as active transcription factors. STAT5 target genes 
include Bcl-XL, Bcl-2, c-myc, cyclin D1/D2/D3/E and pim-1 (Baker et al. 2007). 
STAT5 is a mediator of IL-3 induced cell survival and proliferation. BAF3 
expressing dominant negative STAT5 are partially resistant to IL-3 induced cell 
proliferation. They are also more sensitive to apoptosis, because they express 
lower levels of Bcl-XL (Mui et al. 1996; Dumon et al. 1999). STAT5 was also 
shown to mediate NF-kappaB activation by IL-3 in BAF3 cells (Nakamura et al. 
2002). NF-kappaB was shown to be necessary for IL-3 mediated cell survival 
(Besancon etal. 1998).
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3.1.1.2.2. Ras - Mitogen Activated Kinase Pathway
The adaptor molecule She is another molecule recruited to a phosphotyrosine 
(Y577) on (3C. It becomes phosphorylated and associates with another adaptor 
molecule Grb2. This complex of adaptor molecules subsequently associates with 
the guanine nucleotide exchange factor (GNEF) mSos which exchanges GDP for 
GTP on Ras. This leads to activation of the Raf-1/ MEK/ ERK pathway. This 
MAPK cascade eventually results in the activation of c-fos and c-jun; two 
transcription factors that heterodimerise with each other and bind to AP-1 sites 
that are present in the promoters of genes that promote cell proliferation.
ERK phosphorylates the pro-apoptotic protein BAD on serine 112 (Scheid et al. 
1999). (Akt phosphorylates BAD on serine 136, see next section). Dually 
phosphorylated BAD is sequestered in the cytosol by 14-3-3 and hence is 
inactive. Unphosphorylated BAD promotes cell death by binding and inhibiting 
the activity of Bcl-XL and Bcl-2 (del Peso et al. 1997), so that the pro-apoptotic 
protein Bax is displaced. Bax dimers induce apoptosis by associating with the 
mitochondrial membrane, leading to cytochrome c release and caspase 
activation (Low et al. 2001).
3.1.1.2.3. Phosphatidylinositol 3 kinase (PI3K) Pathway
Upon IL-3 signalling, serine 585 on pc is phosphorylated by protein kinase A. 14-
3-4 docks here and in turn binds PI3K. PI3K, by phosphatidylinositol triphosphate 
(PIP3) generation, recruits and activates Akt serine/ threonine kinase. Akt itself 
inactivates a number of pro-apoptotic proteins by phosphorylation. These include 
BAD (on serine 136 (del Peso et al. 1997), see previous paragraph), caspase 9 
and FKHRL1 (Brunet et al. 1999). This latter protein is a transcription factor 
involved in the transcription of pro-apoptotic genes such as Fas ligand. It 
localises in the cytoplasm after phosphorylation. PI3K also stimulates glycolysis; 
maintenance of ATP levels is essential to cell survival (Mathieu et al. 2001).
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3.1.1.3. Why do BAF3 cells undergo apoptosis upon IL-3 withdrawal?
Upon IL-3 withdrawal there is expected to be much reduced IL-3 receptor
signalling. In BAF3 cells down regulation of Bcl-XL) but not Bcl-2, mRNA and 
protein occurs upon IL-3 withdrawal (Leverrier et al. 1997). Existing Bcl-XL 
protein is sequestered by BAD, releasing its pro-apoptotic counterpart Bax (Low 
etal. 2001).
3.1.2.BAF3 transformation to IL-3 independence
3.1.2.1. Over-expression of anti-apoptotic proteins
Insertional activation by retroviral vectors of the Bcl-X gene in BAF3, resulted in a
mutant that survives but does not proliferate in the absence of IL-3 (Thomas et al. 
1998). Over-expression of another anti-apoptotic protein Bcl-2 in BAF3 gave a 
similar phenotype (Collins et al. 1992). In order for this type of mutant to 
proliferate in the absence of IL-3, c-myc expression is also required. It was 
shown that both Bcl-2 and Bcl-XL in cooperation with c-myc could induce cytokine 
independent growth of BAF3 (Malde and Collins 1994; Miyazaki et al. 1995; 
Nosaka et al. 1999).
3.1.2.2. Aberrant expression of growth factors or their receptors
BAF3 cells are dependent on IL-3. One obvious way in which BAF3 can become
IL-3 independent is by autocrine production of this cytokine. Cytokines and 
growth factors other than IL-3 could also provide survival and proliferation signals 
substituting those of IL-3 if these factors are produced in an autocrine fashion. 
Asides from IL-3, BAF3 were shown to be responsive to IL-4 and IGF-1, but only 
IGF-1 could sustain long term survival (Leverrier et al. 1997).
Alternatively, expression of growth factor receptors not normally expressed by 
BAF3 cells could confer IL-3 independence provided their ligands are present in 
the selection medium. BAF3 constitutively express the receptors for IL-3, IL-4 
and IGF-1. The IL-3 and IL-4 receptors are made up of several subunits. 
Complementation of the f3c (of IL-3/IL-5/GM-CSF) and yc (of IL-2/4/7/9/15/21) 
with other a chains could make BAF3 responsive to other cytokines. This has
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been demonstrated when the complete cDNAs of the receptors for IL-2 (Collins 
et al. 1990), IL-5 (Pless etal. 1997), GM-CSF (Rosas et al. 2007), IL-9 (Demoulin 
et al. 1996), IL-15 (Bulanova et al. 2003) and IL-21 (Ozaki et al. 2000) were 
introduced into BAF3. We are planning to select in serum only without additional 
cytokines, so this type of mutant would not be picked up.
Receptors for cytokines of the growth hormone family such as erythropoietin 
(EPO), thrombopoietin (TPO), G-CSF, prolactin (PRL) and growth hormone (GH) 
consist of a single subunit that homodimerises upon ligand binding. BAF3 
transfected with the EPO-R (Jones et al. 1990), MPL (Alexander et al. 1995), 
G-CSF-R (Li and Sartorelli 1995), PRL-R (Sasaki et al. 1996) and GHR (Jeay et 
al. 2000) are still cytokine-dependent, but whereas they could previously only 
survive and proliferate in response to IL-3, they can now also do so in response 
to EPO, TPO, G-CSF, PRL and GH, respectively. Only constitutively active 
mutants of these receptors confer complete cytokine-independence to BAF3. For 
example, an MPL mutant with a single amino acid substitution in the 
transmembrane domain that results in constitutive receptor dimerisation has 
been described. BAF3 cells expressing this mutant MPL are independent of any 
cytokine and even serum for their growth (Alexander et al. 1995; Onishi et al. 
1996). Epidermal growth factor (EGF), fibroblast growth factor (FGF) and platelet 
derived growth factor (PDGF) and growth hormone (GH) are present in serum. 
EGF can support short term proliferation of EGFR expressing BAF3 cells (Collins 
et al. 1988). Expression of FGFR1 can confer FGF-dependent growth onto BAF3 
cells (Wang et al. 1994) and expression of PDGFRp can confer PDGF- 
dependent growth onto BAF3 cells (Irusta and DiMaio 1998).
3.1.2.3. Aberrant expression or activity of intracellular signalling 
proteins
BAF3 cells are potently transformed by constitutively active protein kinases as 
described below. However, over-expression of these proteins per se for example 
by insertional activation, may not be sufficient to transform these cells.
The three main signal transduction pathways activated by IL-3 are the STAT, 
Ras-MAPK and PI3K/Akt pathways.
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3.1.2.3.1. JAK2
The JH2 domain of JAK negatively regulates the activity of this protein. JH2- 
deficient JAK2 is itself hyperphosphorylated and leads to increased STAT5 
phosphorylation. JH2-deficient JAK2 leads to IL-3 independent proliferation of 
BAF3 cells (Malinge etal. 2007).
3.1.2.3.2. STAT
It was shown that the introduction of a constitutively active STAT5 mutant into 
BAF3 cells conferred cytokine-independent proliferation to these cells and also 
protected against DNA-damage induced apoptosis (Onishi et al. 1998; Hoover et 
al. 2001). Onishi et al used a STAT5 double point mutant that was hypertyrosine 
phosphorylated. BAF3 expressing this mutant proliferated independently of IL-3 
but were still dependent on serum. Introduction of this STAT5 mutant in 
combination with a constitutively active Raf-1 mutant resulted in an IL-3 and 
serum-independent mutant. Of note, introduction of wild type STAT5 into BAF3 
never gave rise to IL-3 independent growth. Constitutively active STAT5 was 
shown to increase expression of Bcl-XL, pim-1 and c-myc.
3.1.2.3.3. Ras-MAPK
BAF3 cells expressing constitutively active Ras were able to proliferate 
independently of IL-3 (Hoover et al. 2001).
3.1.2.3.4. PI3K/Akt
BAF3 cells expressing myristoylated Akt showed increased viability but did not 
proliferate in the absence of IL-3. Mathieu et al describe a BAF3 mutant obtained 
by retroviral insertional mutagenesis in which Akt was found to be constitutively 
active. However, the retroviral vector integration site in this mutant was not 
specified. This mutant survived as well as proliferated in the absence of IL-3 
(Mathieu etal. 2001).
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3.1.2.4. Transformation by viral oncoproteins
Viral oncogenes (v-onc) are transduced by acutely transforming retroviruses; 
most subtly differ from their cellular proto-oncogene counterparts (c-onc) in that 
they carry mutations that confer constitutive enzymatic activity to viral 
oncoproteins (Also see section 1.2.1. of the introduction), v-abl, the oncogene 
carried by the Abelson murine leukaemia virus (A-MLV), was one of the first 
genes shown to transform BAF3 cells to IL-3 independence (Mathey-Prevot et al. 
1986). v-src and v-/ps, the v-onc of the Rous and Fujinami sarcoma viruses 
respectively, were also tested but they caused partial and no IL-3 independence 
of BAF3, though they did do so in other IL-3 dependent cell lines (reviewed in 
(Blalock et al. 1999)). Most of the v-onc found to cause factor-independence in 
IL-3 dependent cell lines are tyrosine kinase proteins that act upstream of the 
Ras/MAPK pathway.
3.1.2.5. Which type of mutant are we most likely to select for?
Essentially four types of potential BAF3 mutants have been described in this
section. The first type of mutant has enhanced cell viability due to over­
expression of anti-apoptotic proteins, but will not proliferate in the absence of IL- 
3. Whether this type of mutant is detected depends on the duration of IL-3 
starvation. Cell viability is maintained for a few days, but eventually cells die 
anyway. IL-3 would have to be added back to the culture before this decrease in 
cell viability sets in, to allow this type of mutant to grow out. A second type of 
mutant is self-sufficient in cytokine production. These autocrine mutants should 
be able to grow out. Bystander cells may be rescued along the way via a 
paracrine effect if the cytokine is secreted to high enough levels. In a third type of 
mutant, IL-3 dependence has been substituted by dependence on another 
cytokine or growth factor whose receptor is not normally expressed on the cell 
surface of BAF3 cells. Detection of these mutants would dependent on the 
presence of the cytokines at sufficient concentrations in the selection medium. 
Lastly, mutants that are completely independent of any cytokines or even serum 
could be obtained. So far these mutants were seen only when constitutively
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active protein kinases were introduced into BAF3 cells. Simple over-expression 
of key protein kinases alone would probably not be sufficient to transform BAF3 
cells and additional mutations in these proteins are likely to be required. 
However, truncated proteins missing negative regulatory domains caused by 
vector insertion could potentially transform BAF3 cells.
3.1.3. Retroviral insertional mutagenesis in factor-dependent cell 
lines
Wild type retroviruses and retroviral vectors have been used to generate factor- 
independent mutants in cytokine dependent haematopoietic cell lines other than 
BAF3 (Table 3.1). The objective of these studies was to identify genes involved in 
the acquisition of growth factor independence and transformation of 
haematopoietic cells in leukaemia.
Factor independent mutants of the promyelocytic D35 cell line, that is normally 
dependent on IL-3 or GM-CSF for its growth, were described (Stocking et al. 
1988). Long term marrow cultures of C3H/HeJ mice were immortalised with wild 
type Friend SFFV and Rauscher MLV retrovirus to establish the D35 cell line 
(Greenberger et al. 1980). The D35 cell line contains multiple (-10) copies of 
these viruses, which are also released from the cell. Factor-independent D35 
mutants were obtained at a cell frequency of 2.4 x 10'7. The mechanisms 
whereby these mutants had become growth factor independent were analysed 
(Stocking et al. 1988). 9 out of 11 mutants were found to secrete a growth factor 
that could support growth of parental D35 cells to a greater or lesser extent. 
GM-CSF was produced by 6 mutants, and IL-3 by another 3 mutants. Provirus 
insertions were found 250-750bp upstream of the GM-CSF cap site in 3 out of 6 
GM-CSF producing mutants. All three insertions were in reverse orientation to 
GM-CSF gene transcription. An intracisternal A particle (IAP) insertion in the 
3’UTR was found in a fourth GM-CSF producing clone. In a follow-up study, an 
IAP insertion upstream of IL-3 was found in 1-2 IL-3 producing mutants 
(Heberlein et al. 1990). The two D35 mutants that did not produce a growth factor 
were found to express a common p chain of which the extracellular domain was 
truncated (Hannemann et al. 1995). No provirus/lAP insertions in this locus were
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found. In both mutants, a large portion of mouse chromosome 15 was found to 
be deleted which encoded for both pn_-3 and the extracellular portion of Pc. These 
mutants are most likely spontaneous mutants that have arisen through 
chromosomal rearrangement. In addition, introduction of truncated pc alone was 
not sufficient to transform D35 parental cells and secondary mutations were 
shown to be required (Prassolov et al. 2001).
Factor independent mutants of two IL-3 dependent cell lines, FDC Pmix and 
FDC-P1(M), were analysed. Both these cell lines had been immortalised by 
retroviral infection, but contained fewer proviral copies than D35. This explains 
the lower cell frequency at which IL-3 independent mutants were obtained. A 
number of IL-3 producing mutants were shown to have IAP insertions upstream 
of IL-3.
Insertional mutagenesis using retroviral vectors was performed in the human 
erythroleukaemia cell line TF-1, which is dependent on GM-CSF (Stocking et al. 
1993). This study is interesting because it provides numbers at which factor- 
independent mutants were obtained. In total 1.58 x 108 TF-1 cells were 
transduced with a MPSV retroviral vector. Cells contained an average of 6.5 
provirus copies, determined by quantitative Southern blot. 241 mutants were 
obtained at an integrant frequency of 2.3 x 10"7. Unlike the study in D35 cells, 
only a minority of these mutants (13%) secreted a growth factor. No vector 
integration sites were analysed in this study. In a follow-up study, the 
phosphorylation status of signalling proteins in 14 mutants that did not produce 
growth factors was analysed. 11 out of 14 mutants were found to express 
constitutively phosphorylated p60cSrc, but a possible relationship to retroviral 
vector integration site was never established (Horn et at. 2003).
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The same MPSV retroviral vector was used in another study to obtain GM-CSF 
dependent mutants of the IL-3 dependent cell line FDC-P1(M)(Laker et al. 2000). 
This cell line only expresses the IL-3 receptor. Following vector transduction, 
cells were selected in serum plus GM-CSF to select for mutants that had 
insertionally activated the GM-CSF a chain. Over 100 mutants were obtained at 
an integrant frequency of 1.4 x 10'7. 18 mutants were analysed and all expressed 
the GM-CSF a chain. In 40% gross rearrangements of the GM-CSF a chain locus 
were found, but neither provirus, LTR nor IAP insertions were present in these 
rearranged loci. Thus the role of the vector in generating these mutants could not 
be demonstrated.
In a follow-up study using the same vector and cell line, vector transduced FDC- 
P1(M) cells were subjected to an unbiased selection in medium containing serum 
only, without additional cytokines (Meyer et al. 2002). Mutants were obtained at 
an integrant frequency of 1.5 x 10'7. -10%  of mutants secreted a cytokine. In one 
mutant, a vector integration site 1kb upstream of Pdgfrbeta was found. This 
mutant expressed the PDGF receptor. Although, no activating mutations in the 
receptor itself could be detected, over-expression of this gene in parental FDC- 
P1(M) was not sufficient to confer IL-3 independence to these cells. It was 
therefore postulated that secondary mutations had contributed to IL-3 
independence in the Pdgfrbeta insertional mutant.
The last three studies described here all demonstrate that the rate at which 
factor-independent mutants of a factor-dependent cell line are obtained can be 
increased over background by using retroviral vectors as insertional mutagens. 
The cell frequency at which factor-independent mutants were obtained was 
proportional to the number of vector integrants screened and one mutant was 
generated for every 107 integrants. The phenotype of factor-independent mutants 
differed between cell lines; with autocrine secretion of growth factors being a 
common mechanism in some cell lines but not in others. A detailed analysis of 
integration sites was not possible at the time many of these studies were 
performed, and only rarely could it be demonstrated that virus/vector integration 
was directly responsible for transformation.
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Table 3.1. Summary of selected retroviral insertional mutagenesis studies in fact 
cell lines
Cell ling Description Mutagen Phenotype Insertions Frequency
D35 Mouse promyelocytic 
IL-3/GM-CSF dependent
WT Friend SFFV 
WT Rauscher MLV 
IAP
9/11 mutants produce 
autocrine factor 
(6/9 GM-CSF; 3/9 IL-3)
GM-CSF producing 
mutants:
MLV/SFFV insertions 5’ 
of GM-CSF gene in 3 
mutants
IAP insertion in GM-CSF 
3’UTR in one mutant 
IL-3 producing mutants: 
IAP insertions 5’ of IL-3 in 
1-2 mutants
2.4 x 107 cells
2/11 mutants have 
truncation of (3C 
extracellular domain plus 
deletion of fk -3
No vector insertion, but 
large chromosomal 
deletion. (Probably 
spontaneous mutants)
FDC-Pmix Mouse multipotent 
IL-3 dependent
IAP 3/7 IL-3 secretion IAP Insertions 5’ of IL-3 Mock (IAP): 
3.6 x 10"* cells
4/7 No growth factor 
secretion
FDC-P1(M) Mouse promyelocytic 
IL-3 dependent
IAP 12/14 GM-CSF secretion 
2/14 No growth factor 
secretion
Mock (IAP): 
1.7x1 O'* cells
TF-1 Human erythroleukaemia 
cell line
GM-CSF dependent
MPSV RV vector 13% autocrine 
mechanism
No insertion sites 
analysed
Mock:
6.7 x 10'* cells 
Vector:
85% other mechanisms No insertion sites 
analysed
11/14 mutants analysed
pvnrese mnstitiitiuAlu
1.5 x Iff* cells 
2.3 x 107 integran
Table 3.1. Summary of selected retroviral insertional mutagenesis studies in factor-dependent 
cell lines ___
Cell line Description Mutagen Phenotype Insertions Frequency References
FDC-P1(M) Mouse promyelocytic 
IL-3 dependent
MPSV RV vector Selection for GM-CSF a 
chain expressing 
mutants
No insertion sites 
analysed;
rearrangements in GM- 
CSF a chain locus in 40% 
of mutants analysed; 
probably a lot are 
spontaneous mutants
Mock (IAP);
5.4 x 10"* cells 
Vector:
3.0x1 O'7 cells
1.4 x 107 integrants
(Laker, Friel et al. 2000)
FDC-P1(M) Mouse promyelocytic 
IL-3 dependent
MPSV RV vector 4/45 secreted IL-3 
3/45 secreted GM-CSF 
38/45 unknown other 
mechanisms
1 mutant contained RV 
insertion 997bp upstream 
of PdgfrfJ in reverse 
orientation
Mock (IAP);
4.6 x 10* cells 
Vector;
2.7 x 107 cells
1.5 x 10'7 integrants
(Meyer, Laker et al. 
2002)
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3.1.4. Retroviral vector insertional mutagenesis in the BAF3 cell 
line to identify anti-apoptotic genes
As mentioned, retroviral vectors derived from myeloproliferative sarcoma virus 
(MPSV) had previously been used to obtain IL-3 independent insertional mutants 
of the BAF3 cell line (Thomas et al. 1998; Mathieu et al. 2001). The main aim of 
these early studies was to identify genes involved in the regulation of apoptosis, 
therefore mutants that remained viable but did not proliferate in the absence of 
IL-3 were specifically selected for. Retroviral vector integration sites in IL-3 
independent mutants were used as tags to identify these anti-apoptotic genes. 
Insertional activation of anti-apoptotic genes confers short-term resistance to IL-3 
deprivation to these BAF3 mutants. BAF3 cells that overexpress B c I-X l survive 
but do not proliferate in the absence of IL-3 (Collins et al. 1992; Thomas et al. 
1998). Upon IL-3 withdrawal they enter Gi arrest, but lose viability after several 
days.
The selection protocol for apoptosis-resistant BAF3 mutants in these early 
studies was as follows (Thomas et al. 1998): BAF3 target cells were transduced 
on Day 1 and then cultured in the presence of IL-3 for the next 48 hours. IL-3 
withdrawal was initiated on Day 3 for a total of approximately 60 hours. Firstly the 
cells were cultured in complete medium without IL-3 for 30 hours by which time 
~95% of the cells had died. Dead cells were then eliminated by Ficoll density 
gradient; the remaining live cells were cloned in 1.5% Methocel MC semi-solid 
medium for another 30 hours in the absence of IL-3. IL-3 was then added back to 
these cultures. After 10 days individual clones were expanded in liquid medium 
containing IL-3 before characterisation for their ability to resist apoptosis upon IL- 
3 withdrawal. In these experiments, IL-3 independent mutants were obtained at a 
cell frequency of 1.4 x 10'7 and integrant frequency of 1.2 x 1CT6. Out of the 19 IL- 
3 independent mutants that were analysed, 4 (21%) were resistant to multiple 
apoptosis inducing pathways. These 4 mutants were found to have up-regulated 
B c I -X l expression due to retroviral vector / solo LTR insertion between 928 and 
200bp upstream of the Bcl-X gene locus.
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3.1.5. Pi lot insertional mutagenesis experiment in the BAF3 cell 
line
It was recognised that the duration of IL-3 starvation impacts on the type of 
insertional mutant that is eventually selected for. As was discussed in section
3.1.2. on BAF3 transformation, insertional activation of 3 types of genes could 
result in IL-3 independence of BAF3 cells. These are genes encoding growth 
factors or their receptors, genes encoding intracellular signalling proteins and 
genes encoding (or regulating) anti-apoptotic proteins.
Mutants in which anti-apoptotic genes are activated by insertional mutagenesis 
can only be identified when IL-3 is added back to the medium. This might not 
however be necessary to identify mutants that have insertional activation of the 2 
other types of genes.
In a pilot experiment (Pilot, Table 4.1.) performed before I joined the lab, it was 
attempted at first to select for mutants without adding IL-3 back to the medium. In 
this experiment 108 BAF3 cells were transduced with HV lentiviral vector 
(depicted in Figure 2.1 .a.) at a MOI of 0.04. Selection for IL-3 independent clones 
was started on day 3 (48 hours post-transduction). 108 BAF3 cells were plated in 
24 well plates at a cell density of 106 cells/ml. Cells were starved of IL-3 for 5 
days, but no IL-3 independent clones grew out during this time. On day 8, cells in 
the mock and vector transduced arms of the experiment were rescued by adding 
IL-3 back to the medium, which surprisingly resulted in proliferating cells in all 
wells. On day 17, 8 randomly selected wells from each arm of the experiment 
were washed off IL-3. In the HV vector transduced cultures, all 8 wells contained 
GFP positive IL-3 independent clones. These clones were later shown to be one 
and the same mutant, named HV A2. Mutant HV A2 was able to proliferate long 
term in the absence of IL-3.
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3.1.5.1. Important observations made in the pilot experiment
Several important observations towards the development of an insertional
mutagenesis assay were made in this pilot experiment. Firstly, one long term IL-3 
independent mutant (HV A2) was obtained at a relative low integrant frequency 
of 1 in 4 x 106, suggesting the HV lentiviral vector could transform BAF3 cells to 
IL-3 independence. Secondly, HV A2 was unable to expand at initial selection in 
complete medium without IL-3 and only grew out after rescue by adding IL-3 
back to the culture. Thirdly, it was found that upon re-addition of IL-3 to the 
cultures, many mock-transduced parental cells were also rescued. Therefore, 5 
day IL-3 starvation alone was clearly not sufficient to completely eliminate 
parental BAF3 cells.
3.1.6. Aims
To address these problems, there was firstly a need to explore treatments that in 
combination with IL-3 withdrawal could more effectively eliminate untransduced 
parental BAF3 cells without affecting the chance of obtaining IL-3 independent 
insertional mutants. X-ray irradiation in combination with IL-3 withdrawal was 
tested. The effect of this treatment on parental BAF3 and the, at the time 
uncharacterised, mutant HV A2 were investigated.
Secondly, there was a need to quantify how many rare mutants could grow out 
amidst an excess of dead or dying cells. For this reason, cultures in which 
parental BAF3 cells were spiked with HV A2 mutants at different ratios were set 
up and starved of IL-3. The outgrowth of HV A2 mutant cells in the cultures was 
monitored. The results of these experiments would enable us to revise our 
mutagenesis assay conditions.
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3.2. Results
3.2.1.X-irradiation after IL-3 withdrawal accelerates the rate at 
which parental BAF3 cells undergo apoptosis, but can still be 
used to select IL-3 independent mutants
Treatments were explored that, in combination with IL-3 withdrawal, would allow 
the selective elimination of parental BAF3 cells without affecting mutant HV A2 
cell viability. Serum starvation was tested first, but this treatment did not 
differentially affect BAF3 and mutant HV A2 cell viability with both cells dying at 
similar rates (Data not shown).
BAF3 cells cultured in the presence of IL-3 are largely resistant to the effects of 
X-irradiation induced DNA damage. However, the rate at which BAF3 cells lose 
viability can be increased if cells are X-irradiated shortly after IL-3 withdrawal 
(Collins et al. 1992). The ability of the HV A2 mutant to resist X-irradiation had 
not yet been tested. Consistent with what was reported previously, BAF3 cultured 
in the presence of IL-3 survived X-irradiation at the two doses tested (Figure
3.1.). A decrease in cell viability could be seen between 36 and 72 hours post- 
irradiation; this was most evident at the higher dose of 4 Gy. From 72 hours 
onwards, cell viability increased again indicating that those BAF3 cells that had 
survived X-irradiation resumed proliferation. In the absence of IL-3, X-irradiation 
at 2 and 4 Gy accelerates the rate at which parental BAF3 cells undergo 
apoptosis. The HV A2 mutant is somewhat protected from X-irradiation induced 
apoptosis. At 4 Gy, HV A2 cell viability decreased to less than 1% within 48 hours 
of irradiation, but unlike parental BAF3 irradiated at the same dose some viable 
cells still remain detectable by flow cytometry over the next 3 days. At 2 Gy, the 
rate at which HV A2 lose viability is markedly slower and after 72 hours the 
remaining viable cells resume proliferation.
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100
<DO
0.1
Time (hours)
Treatment t1/10 (hours)
•  BAF3 - IL-3 0 Gy 26
•  BAF3 - IL-3 2 Gy 16
BAF3 - IL-3 4 Gy 16
— O— BAF3 + IL-3 0 Gy —A— HV A2 - IL-3 0 Gy
— O -  BAF3 + IL-3 2 Gy —A— HV A2 - IL-3 2 Gy
BAF3 + IL-3 4 Gy —A— HV A2 - IL-3 4 Gy
Figure 3.1. X -irradiation a fter IL-3 w ithdraw al accelerates the  rate at which parental BAF3 
cells undergo apoptosis, but can still be used to  select IL-3 independent m utants
5 x 106 BAF3 (circles) and HV A2 (triangles) cells w ere washed thrice in com plete m edium  w ithout IL-3 
and th en  X-irradiated w ith  0, 2 or 4  Gy. Following irradiation, cells were cultured in the presence 
(dashed lines) or absence (full lines) of IL-3. Cell viability in these cultures was measured by propidium  
iod ide (PI) exclusion every day for 5 days.
BAF3 w ere cultured in the  presence o f IL-3 at a cell density o f 2 x 105 cells/ml. There is a transient 
decrease in cell viability betw een 36 and 72 hours post-irradiation which is most pronounced in 
cultures irradiated  w ith  4 Gy. Cell viability increases from 72 hours post-irradiation, indicating that 
some BAF3 survived irradiation in the presence o f IL-3 and resumed proliferation.
BAF3 w ere cultured in the absence o f IL-3 at a cell density o f 106 cells/ml. Exponential trendlines were  
fitted  to  th e  BAF3 0 Gy, BAF3 2 Gy and BAF3 4  Gy data series. R-squared values were 0 .9505 ,0 .9959  and 
0.9599, respectively. The tim e at which 10%  ( t1/10) of the original number o f cells are still viable after 
each tre a tm e n t is shown in the figure legend . It was calculated using the form ula y =  c *  e rx, w here c is 
th e  in te rcept (set at 100), e is the base o f th e  natural logarithm and r is the decay constant.The decay 
constants for the  BAF3 0 Gy, BAF3 2 Gy and  BAF3 4 Gy data series were -0.0879, -0.143 and -0.1442, 
respectively. The rate at which BAF3 cu ltu red  in the absence of IL-3 undergo apoptosis is accelerated  
after irrad iation.
HV A2 w ere  cultured in the absence o f IL-3 at a cell density of 2 x 105 cells/ml. X -irradiation w ith  2 Gy 
leads to  a 72  hours transient decrease in HV A2 cell viability. HV A2 irradiated at 4  Gy lose cell viability 
at a sim ilar rate to  parental BAF3. X -irrad iation  with 2 Gy therefore seems to  be a suitable treatm ent to 
more e ffective ly  eliminate parental BAF3 cells, w ithout affecting th e  ability to  select mutants.
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3.2.2.HV A2 mutants are able to expand from amidst dead 
parental cells when spiked at ratios as low as 1.0 x 10)6
To determine the minimum cell density required for HV A2 mutants to expand
amidst an excess of dead or dying parental cells, IL-3 starved cultures of parental 
BAF3 cells were spiked with GFP expressing HV A2 mutants at different ratios. I 
had earlier established that the HV A2 mutant doubling time was approximately 
24 hours. HV A2 mutants spiked at 1.0 x 10"4 and 3.0 x 10"6 were able to grow 
out and could be detected by day 6 and 11, respectively (Figure 3.2.a). This was 
consistent with a mutant doubling time of 24 hours. HV A2 mutants spiked at 1.0 
x 10'7 could not be detected growing out during 11 day follow-up. By day 11, HV 
A2 mutants spiked at this ratio would be expected to make up ~0.03% of the 
population, which is on the limit of detection by flow cytometry. Follow-up of this 
culture should have been continued for longer. No spontaneous IL-3 independent 
mutants that do not express GFP, could be detected growing out in any of the 
spiked cultures, or cultures containing parental BAF3 only.
To investigate whether incomplete parental BAF3 elimination by IL-3 starvation 
alone was indeed a problem, as experienced in the pilot experiment, fractions of 
each culture were rescued by IL-3 addition on days 7, 9, 11 and 15 after IL-3 
withdrawal. In all cultures, including the one containing BAF3 only, cells could be 
effectively rescued by IL-3 at all time points. The percentage of GFP positive HV 
A2 mutants in the rescued cultures was measured (Figure 3.2.b). In cultures 
spiked at 1.0 x 10'4 and 3.0 x 10'6 and rescued on day 7 and 9, HV A2 mutants 
could be fully selected, as indicated by the high (>90%) percentage of GFP 
positive cells in these cultures. HV A2 spiked at 1.0 x 10'7 could not be fully 
selected upon rescue with IL-3.
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% GFP positive live cells in cultures rescued with IL-3 on days 7, 9, 11 and 15
Rescue 1.0x10^ 3.0x1 O’6 1.0x10'7 BAF3 only
Day 7 97.60 93.52 0.00 0.00
Day 9 89.52 94.20 0.62 0.00
Day 11 ND ND 0.56 0.00
Day 15 ND ND 0.09 0.00
Figure 3 .2. IL-3 independent HV A2 m utants are able to grow out in the presence of dead
parental BAF3 cells w hen spiked at ratios of 1.0 x 10'4 and 3.0 x 10"6.
5 x 107 parental BAF3 cells were washed thrice in com plete medium without IL-3 and spiked w ith HV 
A2 m utants a t ratios o f 1.0 x 10-4, 3.0 x 10"6 and 1.0 x 10'7. The negative control contained parental 
BAF3 cells only. Cells were cultured in the absence o f IL-3 at a density o f 106 cells/ml.
a. Cell viability in these cultures was measured by propidium iodide (PI) exclusion on days 6 ,7 ,1 0  and 
11. A GFP positive live cell population could be detected in cultures spiked 1.0 x 10-4 and 3.0 x 10-6 
w ith  HV A2 cells by days 6 and 11, respectively. No HV A2 cells spiked at 1.0 x 10'7 grew  out during 11 
day fo llow -up . In the unspiked BAF3 culture no spontaneous IL-3 independent mutants em erged.
b. Fractions o f each of the four cultures w ere  rescued by IL-3 re-addition on days 7, 9, 11 and 15, as 
indicated b y"R "o n  the chart. Growing cells em erged in all four cultures rescued at each tim e  point, 
including in th e  unspiked cultures contain ing  only parental BAF3 cells.The percentage o f GFP positive 
live cells in these rescued cultures was m easured by flow cytometry tw o weeks after rescue and is 
shown in th e  table. In cultures spiked 1.0 x 10 -4 and 3.0 x KT6 rescued on days 7 and 9 ,9 0 %  or more of 
the cells w ere  GFP positive. In cultures spiked 1.0 x 10'7, HVA2 m utants could not be fully selected after 
rescue w ith  IL -3.(N D  =  not done)
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It was demonstrated in the experiment shown in Figure 3.1. that HV A2 mutants 
are relatively resistant to X-irradiation. Spiking experiments similar to those 
shown in Figure 3.2. were set up, but this time cultures were irradiated at 2 Gy 
shortly after IL-3 withdrawal. Expansion of HV A2 spiked at different ratios was 
monitored in these cultures (Figure 3.3.). HV A2 spiked at 1.0 x 10'5 and 1.0 x 
10"6 were able to grow out at a similar rate to the previous spiking experiment, 
suggesting irradiation with 2 Gy does not affect the ability of HV A2 to expand 
when spiked at these ratios. Follow-up of this experiment was 20 days, yet HV 
A2 mutants spiked at 1.0 x 10'7 could never convincingly be detected. Again, no 
spontaneous IL-3 independent mutants emerged in this experiment.
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Figure 3.3. Following irradiation w ith  2 Gy, HV A2 cells are able to grow out in the presence 
of dead parental BAF3 cells when spiked at ratios of 1.0 x 10~5 and 1.0 x 10 '6.
Similar to  th e  experim ent shown in Figure 3.2., 5 x 107 parental BAF3 cells were washed thrice in 
com plete  m edium  w ithout IL-3 and spiked w ith HV A2 m utants at ratios o f 1.0 x 10'5, 1.0 x 10-6 and 1.0 
x 10 '7. The negative control contained parental BAF3 cells only. Cells were then X-irradiated with 2 Gy 
and  cultured in the absence of IL-3 at a density of 106 cells/ml.
Cell v iab ility  in these cultures was measured by propidium iodide (PI) exclusion on days 8 ,1 4 ,1 7  and  
20. A GFP positive live cell population could be detected in cultures spiked with 1.0 x 10'5 and 1.0 x 
10-6 H V  A 2 cells after tw o  weeks. No HV A2 cells spiked at 1.0 x 10'7 grew out during 20 day follow-up. 
In th e  unspiked BAF3 cultures no spontaneous IL-3 independent mutants emerged.
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3.3. Discussion
The aim of these early experiments was to devise ways to select better, rare IL-3 
independent mutants from amidst a large excess of dead or dying parental BAF3 
cells. The existing, but at the time uncharacterised, mutant HV A2 from the pilot 
experiment was used to test various assay conditions. Before I go on to describe 
how these can be modified in the light of the experiments presented in this 
chapter, I shall first described how these experiments have contributed to the 
better phenotypical characterisation of mutant HV A2.
3.3.1. Revelations about the HVA2 mutant phenotype
Firstly, the HV A2 mutant was shown not to be resistant to serum starvation. It
did not proliferate or maintain cell viability when cultured in serum-free medium. 
Mutants that produce IL-3 would be expected to survive and proliferate in serum- 
free medium, suggesting HV A2 did not acquire IL-3 independence by autocrine 
IL-3 stimulation. This could however only be formally excluded by identifying the 
vector integration site(s) in this mutant, and by looking for growth factors secreted 
in the culture medium by these cells. Serum independent growth was further 
reported of BAF3 transformed with the oncogenic human tyrosine kinase Brk 
(Kasprzycka et al. 2006). Serum-independence is a very robust phenotype only a 
very limited number of mutants are likely to display, hence it is not a good 
method to selectively eliminate parental cells from mutants.
Secondly, HV A2 cells were shown to be resistant to X-irradiation with up to 2 Gy. 
Again, autocrine IL-3 producing mutants would expected to be resistant to X- 
irradiation, similar to BAF3 cells cultured in the presence of IL-3. It was shown 
that X-irradiation induces expression of the pro-apoptotic cell surface receptor 
Fas on BAF3 cells (Gutierrez del Arroyo et al. 2000). X-irradiation with 4 Gy leads 
to single stranded DNA breaks. This damage is detected by ATM and ATR 
kinases that phosphorylate and thereby activate p53. X-irradiation was found to 
increase p53 levels in BAF3 cells (Palacios et al. 2000). Fas is constitutively 
expressed at low levels on BAF3 cells; a p53-mediated increase in its cell surface 
expression sensitises BAF3 cells to extracellular death ligands, such as Fas
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ligand, and could account for the decrease in cell viability observed following X- 
irradiation. Fas cell surface expression is not induced by IL-3 withdrawal per se, 
but its up-regulation is accelerated in X-irradiated cells which are deprived of IL- 
3. IL-3 can rescue BAF3 cells from X-irradiation induced apoptosis by reducing 
Fas receptor levels on the cell surface. Resistance to X-irradiation induced 
apoptosis was also correlated with Bcl-XL expression in BAF3 cells (Mathieu et 
al. 2001). Therefore, the mechanism responsible for IL-3 independence of HV A2 
cells is likely to induce some degree of Bcl-XL expression, but maybe to lower 
levels than that induced by IL-3 in parental BAF3 cells, explaining the partial 
resistance to X-irradiation of HV A2.
3.3.2.More effective elimination of parental BAF3 cells after X- 
irradiation
Parental BAF3 cell death upon IL-3 withdrawal was confirmed to be 
asynchronous, as demonstrated by the very effective rescue of parental BAF3 
cells by IL-3 even after two weeks of IL-3 starvation. Asynchronous parental 
BAF3 cell death is not a problem if IL-3 independent clones were able to expand 
without the need for rescue with IL-3, unfortunately this is not the case. Irradiation 
can accelerate decay of parental cells upon IL-3 withdrawal. There is however a 
possibility that a very small but still significant number of cells may survive X- 
irradiation and can be recovered upon rescue with IL-3. Rescue with IL-3 of 
irradiated spiked cultures was not tested. If IL-3 rescue is required for mutants to 
grow out; irradiation might reduce background rescue of parental cells and 
mutants of a phenotype similar to HV A2 should be able to survive at low doses 
of irradiation. Upon rescue, IL-3 can then stimulate the proliferation of these 
residual viable mutants.
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3.3.3.HV A2 mutants can expand amidst dying parental BAF3 
cells when spiked at ratios as low as 1(X6
In the pilot experiment, outgrowth of IL-3 independent mutants was only possible 
after rescue with IL-3. The series of spiking experiments go some way in 
explaining the need for rescue with IL-3. Only mutants spiked at ratios of 10'6 or 
higher were able to grow out. The mutant from the pilot experiment was obtained 
at a cell frequency of 10'8, so not surprisingly this mutant only grew out after 
rescue.
To have some idea as to how many integrants would need to be screened in 
mutagenesis experiments in order for mutants to grow out, quantitative 
considerations should be made. The distance from the integration site at which 
retroviruses are able to interfere with neighbouring gene expression is generally 
considered to be 103-104 base pairs (Baum et al. 2003; Baum et al. 2004). This 
means that theoretically 105 to 106 hits in a mouse genome of 2.7 x 109 base 
pairs could result in a mutant at a single locus. Going by the lower integrant 
frequency of 10'6, 108 target cells would need to be transduced at MOI 1 to obtain 
100 mutants at a single locus.
A predicted integrant frequency of 10-6 is consistent with that reported in earlier 
retroviral mutagenesis experiments in the BAF3 target cell. IL-3 independent 
mutants were obtained with an MPSV retroviral vector at a cell frequency of 1.4 x 
10'7 and an integrant frequency of 1.2 x 10'6 (Thomas et al. 1998). However, in 
this paper selection in the absence of IL-3 was of much shorter duration than in 
our pilot experiment. An IL-3 independent clone was defined as “a clone where 
the percentage of viable cells after 20 hours of IL-3 starvation was at least 8 fold 
higher than the parental cells”. Most of these clones were probably not long term 
IL-3 independent and also it was not established whether they were all 
independent clones. Hence, the frequency figures quoted above are likely to be 
overestimates. The integrant frequency in particular seems to be very high; as in 
studies using other factor dependent cell lines this was in the order of 1.4 -  2.3 x 
10'7, 10 fold lower (Stocking et al. 1993; Laker et al. 2000; Meyer et al. 
2002)(See Table 3.1.). In the pilot experiment with the HV lentiviral vector in
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BAF3 cells, the HV A2 mutant was obtained at an integrant frequency of 2.5 x 
10' 7 .
From the spiking experiments we now know that to obtain IL-3 independent 
mutants without rescue we need at least 100 mutants per 108 target cells. If the 
HV integrant frequency is really 2.5 x 10‘7, that would mean 108 target cells would 
have to be transduced with the HV lentiviral vector at MOI 4 at least, for mutants 
to grow out without rescue. As a compromise between a predicted integrant 
frequency of 10'6 and an observed integrant frequency of 2.5 x 10'7 in the pilot 
experiment, it was decided to transduce 108 target cells at MOI 2 with the HV 
lentiviral vector in mutagenesis experiments that will be described in the next 
chapter.
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Chapter 4
4. Insertional mutagenesis by a lentiviral vector
4.1. Introduction
The pilot experiment described in section 3.1.5. demonstrated that the HV 
lentiviral vector could transform BAF3 cells to IL-3 independence. The HV 
lentiviral vector, depicted in Figure 2.1.a, has two wild-type HIV-1 LTRs and an 
internal SFFV LTR promoter driving GFP expression (Demaison et al. 2002; 
Iked a et al. 2003).
In this chapter, I used the HV vector to select for IL-3 independent insertional 
mutants of the BAF3 cell line. At first the modified assay conditions informed by 
the results in chapter 3 were tested. Target cells were irradiated prior to selection 
to reduce background survival of parental BAF3 cells. I aimed to screen a 
sufficient number of integrants to enable mutants to expand in the presence of an 
excess of dying cells without the need for rescue with IL-3. Assay conditions 
were further modified to allow more efficient and reproducible mutant detection. 
This involved switching to a BAF3 cell derivative which over-expresses human 
Bcl2. I aimed to establish a frequency at which IL-3 independent mutants of this 
cell line could be obtained after transduction with the HV lentiviral vector. Any 
IL-3 independent mutants obtained with this vector were characterised in detail. 
In the previous chapter about half a dozen potential target genes, such as IL-3, 
IGF-1, Ghr, Pdgfr, Fgfrl and Bcl-X, that could transform BAF3/BCL15 cells to 
IL-3 independence were identified. Vector integration site analysis of mutants 
revealed which of these genes was responsible for transformation. The 
mechanism whereby the vector affects expression of this target gene was 
investigated.
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4.2. Results
4.2.1.HV lentiviral vector mutagenesis experiments in the BAF3 
cell line
In mutagenesis experiments in the BAF3 cell line, the number of integrants 
analysed was determined by GFP expression. Almost 5 x 108 BAF3 cells were 
transduced with the HV lentiviral vector in 6 independent mutagenesis 
experiments (Table 4.1.). screening approximately 8 x 108 HV vector integrants in 
the process. 108 target cells each were transduced at MOI 1 and 0.7, respectively 
in experiments LV1 A and B, in a single round of transduction. According to the 
calculations described in the discussion to chapter 3, ideally this number of target 
cells would need to be transduced at MOI 2 to pick up ~100 mutants. In 
experiment LV1 B the vector preparation needed to achieve high MOI proved to 
be highly toxic to target cells with half of them dying. It was therefore decided in 
subsequent experiments (LV1 C to F) to subject target cells to serial rounds of 
transduction to achieve high MOI.
In experiments LV1 A and B, IL-3 was withdrawn from cultures on Day 3, at 48 
hours after transduction, and this was followed immediately by irradiation with 2 
Gy. 107 cells were cultured in 10 ml medium without IL-3 in T25 tissue culture 
flasks. Cultures were fed once a week with fresh medium. Samples of these 
cultures were analysed by flow cytometry on a biweekly basis to monitor 
outgrowth of GFP positive, PI excluding populations i.e. possible mutants. It was 
hoped mutants could be detected without the need for rescue with IL-3. However, 
in case this should be required, irradiation would be expected to have efficiently 
eliminated any parental BAF3 and mutants would be selectively rescued. Half of 
the culture in each T25 flask from LV1 A and B was rescued by adding IL-3 back 
to the medium on days 30 and 14 of the experiment, respectively. Neither mutant 
nor parental cells could be rescued at either time point. Unrescued cultures were 
followed up for 6 weeks, but no mutants could be detected growing out. 
Irradiation with 2 Gy may have been too harsh a treatment; it was therefore 
decided to abandon this approach in subsequent experiments.
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Table 4.1. HV lentiviral vector mutagenesis frequencies
Experiment Target Celld
Mock Mutants HV Vector Transduced Mutants
Mutant
Number
Cell 
Frequencye
Mutant
Number
Cell
Frequency®
Integrant 
Frequencyf
Pilot BAF3 0 < 1.0 x 10"® 1 1.0x10-® 2.5 x 10"®
LV1 A ab BAF3 0 < 1.1 x 10-® 0 < 1.2 x 10"® < 1.2 x 10®
LV1 B ab BAF3 0 < 1.3 x 10"® 0 <2.1 x 10"® < 3.1 x 10-®
LV1 C b BAF3 0 < 1.4 x 10"® 0 < 1.2x10-® < 3.4 x 10"9
LV1 D b BAF3 0 <1.2x10-® 0 < 1.3 x 10-® < 5.0 x 10 9
LV1 E b VI34 0 < 1.1 x lO-8 0 < 1.1 x lO-® < 4 8 x 10"9
LV1 F BAF3 0 < 1.2 x 10-® 0 < 1.3 x 10-® < 5.1 x 10"9
LV2 9 BCL15 0 < 1.0 x 10"7 2 2.0 x 10"7
5.0x10-®
1.7x10®
LV3 9 BCL15 2 4.0 x 10 ® 13 2.6 x10‘7
1 8x 10' 
6.8x10®
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Table 4.1. HV lentiviral vector mutagenesis frequencies
1-10 x 107 IL-3 dependent target cells were transduced with the HV lentiviral 
vector. The cell and integrant frequencies at which IL-3 independent mutants 
were obtained following transduction with this vector are shown in the table.
a Target cells in experiments LV1 A and B were irradiated with 2Gy immediately 
after IL-3 withdrawal on day 3 of the experiment.
b Selection for IL-3 independent mutants in experiments LV1 A to E was 
performed in T25 tissue culture flasks in which cells were cultured at a density of 
106 cells/ml in 10ml volume. In all other experiments, including the pilot 
experiment, selection for IL-3 independent mutants was performed in 24 well 
plates at cell densities ranging from 2.5-10 x 105 cells/ml. 
c Selection for IL-3 independent mutants in experiments LV2 and 3 was 
performed according to the “standard selection protocol”. Cells were washed of 
IL-3 on day 3/4 and plated in 24 well plates at 5 x 105 cells per well in 2ml 
complete medium without IL-3. IL-3 was added back to the cultures on day 10/11 
by replacing 1ml medium with complete medium containing IL-3. Cultures 
reached confluence after 2-3 days and cells were again washed of IL-3. They 
were then cultured in T25 flasks in 10ml medium without IL-3. 
d BAF3 derivative cell lines VI34 and BCL15 over-express Bcl-XL and Bcl-2, 
respectively.
e The cell frequency was calculated by dividing the number of mutants by the 
total number of target cells in each experiment. Vector associated toxicity to cells 
was seen in some of the LV1 experiments. The number of target cells was 
therefore adjusted for the number of live cells analysed in each arm (mock or HV- 
transduced) of these experiments.
f The integrant frequency was calculated by dividing the number of mutants by 
the total number of integrants in each experiment. The number of “GFP” 
integrants was calculated by multiplying the number of live target cells by the 
MOI. The MOI was determined by flow cytometry for GFP expression at 48h to 
72h post-transduction. The GFP integrant frequency is shown in green. In 
experiments LV2 and LV3, the average number of vector copies per cell was also 
determined by Q-PCR. This number was multiplied by the number of target cells 
to obtain the number of “Q-PCR” integrants. The Q-PCR integrant frequency is 
shown in black.
9 The average cell frequencies at which IL-3 independent mutants were obtained 
in experiments LV2 and LV3 combined were calculated. The average mock cell 
frequency was 2 x 10'8; the average HV cell frequency was 2.3 x 10 (p < 0.001; 
X2 = 176.4). The average integrant frequencies were: 1.2 x 10'7 (GFP) and 4.3 x 
10'8 (Q-PCR).
148.
In experiment LV1 C and D, higher MOIs of 3.5 and 2.5, respectively, were 
achieved after 3 to 4 rounds of transduction of 4 hours each. After IL-3 
withdrawal, 107 cells were again cultured in T25 flasks in 10ml volume. Half the 
culture in each flask in experiments LV1 C and D were rescued with IL-3 on days 
20 and 14, respectively. Again, neither mutants nor parental cells could be 
rescued at either time point. This was surprising as cells cultured under similar 
conditions in the experiment shown in Figure 3.3. were effectively rescued by IL- 
3 after having been grown in the absence of IL-3 for up to two weeks. Cells in this 
experiment were cultured at the same cell density as those in LV1 C and D. 
BAF3 cells in the pilot experiment were also effectively rescued by IL-3, but were 
grown at a lower cell density of 2.5 x 105 cells per ml in 24 well plates.
In experiment LV1 F, I investigated whether cell density played a role in both the 
ability of mutants to grow out and the effectiveness of rescue with IL-3. Target 
cells were transduced at MOI 2.5 in a single round of transduction using a high 
titre HV vector preparation (5 x 107 BAF3 i.u./ml (by GFP expression), a titration 
curve of this vector batch is shown in Figure 2.2.). At the start of IL-3 withdrawal 
on day 3, a third each of the cells were cultured at 2.5 x 105, 5 x 105 and 106 
cells/ml in 24 well plates. One week later on day 10, half of the wells in each of 
the three groups were rescued with IL-3. Cells in ~80% of these wells were 
rescued, both in the mock and HV transduced arms of the experiment. Upon 
reaching confluence, the cells in these wells were washed and starved of IL-3 
again. In the neither the unrescued nor the rescued-re-starved cultures did any 
IL-3 independent mutants emerge.
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Figure 4.1. Survival of BAF3 cell line derivatives a fter IL-3 w ithdraw al.
Two BAF3-derivative cell lines V I34 (Thom as et al 1998) and BCL15 (Collins et al 1992), that 
over-express the anti-apoptotic proteins Bd-XL and Bd-2 respectively, were tested for their ability to  
resist apoptosis upon IL-3 w ithdrawal in comparison to  parental BAF3 cells.
Cells w ere washed thrice in com plete m edium  w ith o u t IL-3. Cell viability in these cultures was 
measured by propidium  iodide (PI) exclusion on days 1 ,2 ,3 ,4 ,7  and 11.
B d-XL over-expressing VI34 cells lose cell viability at a similar rate to BAF3 cells. Exponential trendlines 
were fitted  to  the BAF3 and V I34 data series. R-squared values were 0.9876 and 0.9511, respectively.The 
* 1/10 f ° r both 15 approxim ately 80 hours, calculated as described in Figure 3.1. Bcl-2 over-expressing 
BCL15 cells m aintain cell viability for up to 4 days following IL-3 withdrawal. Thereafter they lose cell 
viability but a t a much slower rate than BAF3/VI34 cells.
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4.2.2.A BAF3 derivative cell line over-expressing Bcl-2 may be a 
more suitable target cell in mutagenesis experiments
Approximately 8 x 108 HV vector integrants were screened in the BAF3 cell line,
yet this did not result in any IL-3 independent mutants. It was hypothesised that 
the BAF3 cell line might not be robust enough during selection in these 
mutagenesis experiments. For this reason, two BAF3 derivative cell lines VI34 
(Thomas et al. 1998) and BCL15 (Collins et al. 1992) that over-express the anti- 
apoptotic proteins Bcl-XL and Bcl-2, respectively, were tested as candidate target 
cells. Both these cell lines are still dependent on IL-3 for proliferation and long 
term survival. VI34 have a retroviral vector insertion into the Bcl-X locus. When 
cultured in the presence of IL-3, they express 2 fold more B c I-X l protein. Upon 
IL-3 withdrawal, normal Bcl-XL levels are maintained and cells remain viable for 
up to 32 hours (Low et al. 2001). BCL15 cells are engineered to express human 
Bcl-2. Upon IL-3 withdrawal, BCL15 cells arrest in the G1 phase of the cell cycle 
but eventually lose viability after ~100 hours (Collins et al. 1992). For BCL15 
cells, these earlier observations were confirmed in Figure 4.1. However, the 
phenotype of VI34 cells upon IL-3 withdrawal proved to be less robust than 
reported. VI34 cells die at a similar rate to parental BAF3. VI34 were the target 
cell in experiment LV1 E. However, no mutants were obtained screening 2 x 108 
integrants.
4.2.3.HV lentiviral vector mutagenesis in the Bcl-2 over­
expressing BCL15 cell line.
5 x 107 BCL15 cells were transduced with HV lentiviral vector in experiment LV2 
(Table 4.1). The number of vector integrants in all experiments with BCL15 cells 
was determined by quantitative PCR (Q-PCR) as well as by measuring GFP 
expression at 72 hours post-transduction. The number of Q-PCR integrants was 
usually 3-5 fold higher than the number of GFP integrants. The integrant 
frequencies quoted in the ensuing text were calculated using the number of Q- 
PCR integrants.
Cells in LV2 were selected from day 4 in 24 well plates at 5 x 105 cells per well in 
2ml medium. One fifth of the wells were rescued with IL-3 on day 11, after one
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week of IL-3 starvation. According to figure 4.1., 90% of BCL15 cells will have 
died at this time. However, in all wells in the mock and HV-transduced cultures to 
which IL-3 was added back, cells were effectively rescued. These cells were 
washed of IL-3 a second time round and cultured in T25 flasks in 8ml volume. 
Two weeks later, two IL-3 independent clones HV3 and HV14 (Figure 4.2.) grew 
out at a cell frequency of 2.0 x 10'7 and integrant frequency of 1.7 x 10'8 (Table
4.1.). This method of selection would become known as the standard selection 
protocol. No mutants emerged in wells not rescued by IL-3.
In experiment LV3, an additional 13 IL-3 independent mutants (HV10 /24 /25 /26 
/32 /41 /42 /43 /48 /49 /72 111 182, Figure 4.2.) were obtained using the standard 
selection protocol, at a similar cell frequency to LV2 of 2.6 x 10'7 and an integrant 
frequency of 6.8 x 10'8 (Table 4.1). In this experiment, two mock mutants (M8 
and M53) were also obtained at a cell frequency of 4.0 x 10'8.
4.2.4. Characterisation of HV lentiviral vector insertional mutants
4.2.4.1. Clonality and vector copy number determination in IL-3 
independent mutants
To determine how many unique IL-3 independent mutants were picked up in 
each experiment, Southern blots were performed (Figure 4.2.). Mutants’ genomic 
DNA was digested with a restriction enzyme that cuts only once inside the vector. 
Blots were hybridised with the cDNA for GFP. Examination of the band pattern 
revealed no similarities between different mutants, suggesting they are all unique 
clones. The presence of different intensity bands within a lane would suggest the 
cell population is not entirely clonal and bystander cells may be present. Again, 
this was not observed. (It is common for smaller bands to show up with greater 
intensity, because these DNA fragments are more efficiently transferred from gel 
to membrane). HV vector copy number could also be determined in each of the 
mutants. The pilot experiment was performed at low MOI of 0.04 (GFP); mutant 
HV A2 contains just a single copy of the vector. Experiment LV2 was carried out 
at MOI 12 (Q-PCR); the vector copy number in mutants HV3 and HV14 is 12 and 
7, respectively. Experiment LV3 was performed at MOI 3.8 (Q-PCR); LV3 
mutants have 1 -  4 copies of the vector per genome.
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Figure 4.2. Southern blots o f IL-3 independent mutants obtained in experiments LV1 -  3.
a. 15pg genom ic DNA of each m utan t was digested with BamHI, which cuts only once inside the vector. 
Blots w ere probed with the cDNA for eGFP. Band patterns were examined to determ ine clonality o f the  
mutants and HV vector copy num ber per genome, b. A phosphorscreen image is shown o f blots from  
LV1 and 2. Blots from LV3 were exposed to  autoradiography film. Irrelevant lanes on blots were 
removed. The tables below each b lo t show  the number of bands seen on the Southern b lo t as well as 
the num ber o f integration sites for each m u tan t that were cloned out by inverse PCR. (M utant HV26 is 
missing from  this figure.)
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Figure 4.3. HV lentiviral vector integration sites in IL-3 independent mutants were cloned 
using the inverse PCR technique
The inverse PCR technique is applied to amplify DNA of unknown sequence that is adjacent to DNA of 
known sequence. Silver et al first described the application of this technique for the amplification of 
cellular DNA adjacent to integrated provirus. The inverse PCR protocol shown here was adapted from 
that described by Carteau et al.
a. Overview of the inverse PCR technique. The HV lentiviral vector is shown as a provirus, flanked by 
mouse genomic DNA of unknown sequence in blue (I). Genomic DNA was digested by 4bp-cutter Mspl 
(or Nlalll, not shown). Mspl cuts 237bp downstream of the start of the HIV-1 U3 region and at unknown 
distance upstream of the 5'LTR. In addition, there is an Mspl site upstream of the 3'LTR in the WPRE 
region. Two fragments are amplified from each provirus using the primers shown (in red and green). 
The fragment of interest is that amplified from the 5'LTR as this contains flanking mouse genomic DNA; 
the fragment amplified from the 3'LTR only contains vector sequence and shows up on gels as a strong 
"internal band! Genomic DNA is digested with Mspl (II) and then circularised by ligation under low 
DNA concentration condition (III). These circles serve as templates for amplification with divergently 
oriented primers complementary to the HIV-1 U3 region (IV).
b. Inverse PCR products were size separated on 2% agarose gels.Typical gels from experiment LV3 after 
one and two rounds of amplification are shown, as indicated.
2pg genomic DNA of each LV3 mutant was digested with Mspl. The first round of amplification was 
performed on 10Ong circularised DNA fragments. In the second round of amplification, one hundredth 
of the first round product was used. The size of the internal band (arrow) after one and two rounds of 
amplification is 380bp and 345bp, respectively. Inverse PCR products were gel extracted, cloned into a 
plasmid vector and then sequenced.
c. Sequence of an inverse PCR product obtained from mutant HV A2.The inverse PCR product is 95bp 
in size.The nested PCR primers HUC and IP3 are shown in black. 40bp of mouse genomic DNA flanking 
the 5'LTR is shown in blue. DNA was digested with Nlalll in this experiment; the CATG site is underlined 
in the sequence. Vector sequence is shown in green. The arrow indicates where the vector insertion 
occurred.
d. Mouse genomic DNA sequence shown in c. was blasted against the mouse genome using Ensembl 
Mouse BlastView. A basepair view of the alignment with mouse chromosome 15 is shown here. It can 
be seen that the vector integrated in the same orientation as Ghr gene transcription.
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4.2.4.2. Identification of HV lentiviral vector integration sites in IL-3 
independent mutants
To investigate why the mutants became IL-3 independent, the genomic locus/loci 
where the vector(s) had integrated needed to be identified. The Southern blots 
shown in Figure 4.2. gave a good estimate of how many vector integration sites 
would need to be cloned out in each of the mutants. Mouse genomic DNA 
flanking the 5’LTRs of HV vector proviruses in the mutants from LV1-3 was 
amplified by inverse PCR. The principle of this method is shown in Figure 4.3.a. 
Inverse PCR allows amplification of DNA of unknown sequence that is adjacent 
to DNA of known sequence. Mutant genomic DNA was digested with a 4bp-cutter 
restriction enzyme. Digested DNA is then ligated under low DNA concentration 
condition that favours intramolecular ligation i.e. circularisation. This is used as 
template in PCR reactions using divergently oriented primers, complementary to 
the HIV-1 U3 region. In mutants that contained several copies of the vector, 
inverse PCR was performed using at least two different restriction enzymes, so 
most vector integration sites could be obtained. In most experiments I was able 
to clone out about half the total number of vector integration sites by inverse 
PCR. Inverse PCR products were size separated on agarose gels (Figure 4.3.b), 
extracted, cloned into a plasmid vector and then sequenced. The integrity of any 
sequences was assessed by checking for the presence of both primers, the 
restriction site, the 5bp duplication upstream of U3 and the appropriate length of 
vector sequence (75bp when Mspl digested; 60bp when Nlalll digested)(Figure
4.3.c). Sequences determined to be genuine integration sites were then blasted 
against the mouse genome (Figure 4.3.d). The 25 HV vector integration sites 
recovered in mutants from LV1-3 are shown in Table 4.2. No integration sites 
were recovered from mutants HV10, HV25, HV26 and HV42. Strikingly, in 10 IL-3 
independent mutants integration sites into the Growth Hormone Receptor (Ghr) 
locus on mouse chromosome 15 were found. This locus was previously identified 
as a retroviral common insertion site, Evi124. It is listed 6 times in the Retrovirus 
Tagged Cancer Gene Database (Akagi et al. 2004). Mutants HV A2 and HV49 
each contain just a single copy of the vector. In both these mutants, the vector
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had integrated into the Ghr, suggesting activation of this gene alone is sufficient 
to transform BAF3/BCL15 cells. Integration into the Plekha5 gene on mouse 
chromosome 6 was also found in two different mutants, HV3 and HV48.
4.2.4.3. Locations of HV vector insertions into the Growth Hormone 
Receptor locus
The locations of the HV vector insertions into the Ghr locus in the 10 different IL- 
3 independent mutants are shown in Figure 4.4. All HV vector insertions occurred 
in intron 1-2 of the Ghr, in the same transcriptional orientation as Ghr 
transcription. Intron 1-2 of the Ghr is over 125 kilobases in length; the first coding 
exon is exon 2. The mouse Ghr uses at least three alternative promoters and 
associated first exons (Menon et al. 1995; Yu et al. 1999; Menon et al. 2001). 
The transcripts originating from these promoters differ only in their 5’ untranslated 
regions and are termed L1, L2 and L5. Ghr promoter usage is tissue-specific and 
also depends on the developmental stage of the organism. Most Ghr transcripts 
in all tissues originate from the L2 promoter, which is 125 kilobases upstream of 
exon 2 (Edens and Talamantes 1998). The L1 promoter is predominantly used in 
pregnant liver (Schwartzbauer et al. 1998). The L5 promoter and first exon are 
immediately upstream of exon 2. The L5 transcript is most abundant in foetal liver 
and placenta where it makes up 10-15% of Ghr transcripts (Menon et al. 2001). 
As can be seen in Figure 4.4., most HV vector insertions occur in a 15 kilobase 
region immediately upstream of exon 2. They are close to the L1 or L5 
promoters. Only the vector integration site in Mutant HV A2 is not near any of the 
three known alternative promoters.
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Table 4.2. HV lentiviral vector integration sites in IL-3 independent 
mutants (LV1-3)
Clone SB IPCR
In
Gene
(Y/N)
Gene
Name
Entrez
Gene
ID
Chr Distance to TSS Ori
Predicted Gene 
Function RTCGD
LV1
HVA2 1 1 Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
LV2
HV3 12 6
Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
Y Dock2 94176 11 323kb Intron 27-28 ♦
Cytoskeletal
organisation
Y Stagl 20842 9 149kb Intron 7-8 + Cell cycle; cell division
2
Evi99
Y Hcfc2 67933 10 5867bp Intron 3-4 -
Y Plekha5 109135 6 103kb Intron 5-6 -
Y 2610020 H08 Rik 434234 7
48kb
Intron 12-13 +
HV14 7 2
Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
Y Usp45 77593 4 34kb intron 9-10 + Ubiquitin cycle
LV3
HV24 3 2
Y Ghr* 14600 15 + Growth Hormone Receptor
6
Evil 24
N 14
HV32 2
Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
N 7
37kb down­
stream of 
Btbdl
HV41 4 2
Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
Y Suclg2 20917 6 26kb Intron 1-2 +
Metabolic process; GDP 
forming activity; 
tricarboxylic acid cycle
HV43 4 1 Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
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Clone SB IPCR
In
Gene
(Y/N)
Gene
Name
Entrez
Gene
ID
Chr Distance to TSS Ori
Predicted Gene 
Function RTCGD
HV48 2
Y Senpl 223870 15 7kb Intron 2-3 -
Multicellular organismal 
dev't; protein 
desumoylation
Y Plekha5 109135 6 3kb Intron 1-2 +
HV49 1 1 Y Ghr 14600 15 ♦ Growth Hormone Receptor
6
Evil 24
HV72 2 1 Y Ccdcl 11 408022 8 10kb Intron 4-5 - DNA replication
HV77 4 4
Y Ghr* 14600 15 Growth Hormone Receptor
6
Evil 24
Y Gmps 229363 3 1217bp Intron 1-2 +
Purine nucleotide 
biosynthetic process; 
glutamine metabolic 
process
N 16
39kb 
upstream of 
AJcam
Y Hitt a 15251 12 15kb Intron 8-9 +
Angiogenesis; cartilage 
dev't
HV82 1 Y Ghr 14600 15 + Growth Hormone Receptor
6
Evil 24
Table 4.2. HV lentiviral vector integration sites in IL-3 independent 
mutants (LV1-3)
Inverse PCR was performed on IL-3 independent mutants from LV1-3 using two 
different restriction enzymes, Mspl and Nlall. PCR products were gel extacted, 
cloned into a plasmid vector and then sequenced. Vector-genome junction 
sequences were blasted against the mouse genome, released August 2007 
(www.ensembl.org/Mus musculus).
Some vector integration sites were obtained in the majority of mutants, with the 
exception of LV3 mutants HV10, HV25, HV26 and HV42.
SB indicates vector copy number in the mutant determined by Southern blot. 
I PCR indicates the number of insertion site loci identified in the mutant by inverse 
PCR. The Ghr insertion sites in mutants HV24 and HV77 (asterisks) were cloned 
out by multiplex PCR. All Ghr insertion sites were confirmed by site-specific PCR. 
For most insertion sites the distance to the transcription start site (TSS) of the 
nearest gene is shown, except in the case of Ghr insertions because this gene 
uses several TSS. The locations of HV vector insertions into the Ghr are shown 
in Figure 4.4. Ori indicates whether the vector insertion occurred in the same (+) 
or in the opposite (-) orientation as the gene’s transcript. Predicted gene function 
is shown where known. The number of appearances in the retroviral tagged 
cancer gene database (RTCGD) of each insertion site locus is shown where 
applicable.
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| L2Prom) L2 Exon 1
Clone Position
HVA2 3.452.579
HV14 3.423.438
HV82 3.423.359
HV77 3.420.819
HV24 3.416.415
HV43 3.414.174
HV41 3.411.498
HV3 3.409.827
HV32 3.409.089
HV49 3.408.558
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Figure 4.4. Location of HV vector insertions into the growth hormone receptor (Ghr) locus in 10 
IL-3 independent mutants.
All 10 HV vector insertions occurred in the same orientation as Ghr gene transcription and were in the 
125 kilobasepair region upstream of exon 2, the first coding exon of the Ghr. The three alternative 
promoters and associated first exons used by the Ghr, are also shown. ATG indicates the start codon in 
exon 2. The table shows the position on mouse chromosome 15 where each vector integration 
occurred.
161.
4.2.4.4. All Ghr insertional mutants express the Ghr transcript
To investigate whether the Ghr transcript was expressed in the IL-3 independent
mutants that had HV vector insertions into the Ghr locus, reverse transcriptase 
(RT) PCR for the Ghr transcript was performed (Figure 4.5.a.). The Ghr transcript 
was indeed expressed in all 10 mutants; in addition it was also produced by 
mutants HV10, HV25, HV26, HV42 and HV43. Not all HV vector integration sites 
in these mutants were cloned out by inverse PCR; presumably they also have 
vector insertions into the Ghr. Insertional activation of the Ghr therefore seems to 
be the most common mechanism whereby the HV lentiviral vector transforms 
BAF3/BCL15 cells to IL-3 independence. The Ghr transcript is not expressed by 
the parental cells, mock mutants M8 and M53 and mutant HV48. However, 
mutant HV48 does express the IL-3 transcript, as do the two mock mutants 
(Figure 4.5.b). Activation of IL-3 gene expression seems to be a mechanism 
whereby BCL15 cells spontaneously become IL-3 independent.
4.2.4.5. Ghr-insertional mutants express the Growth Hormone 
Receptor on the cell surface
Insertional activation of the Ghr leads to expression of a functional GHR on the 
cell surface of IL-3 independent mutants. Cell surface staining for the GHR was 
performed on mutants HV3 and HV14 from experiment LV2. Unlike the parental 
cells, the mutants express GHR on the cell surface (Figure 4.6.). Dr E.F. Gevers 
at the National Institute for Medical Research in Mill Hill demonstrated that the 
GHR on these mutants was functional by performing intracellular staining for 
phosphorylated STAT5 (Data not shown). STAT5 was phosphorylated in parental 
cells and mutants following stimulation with IL-3; bGH stimulated STAT5 
phosphorylation in mutants only.
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Figure 4 .5 . All 10 m utants th a t contain an HV vector insertion into the Ghr locus, express the Ghr 
transcript.
a. A reverse-transcriptase (RT) PCR for expression of the Ghr transcript was performed on parental cells 
and IL-3 independent m utants from  experim ents LV1-3. A forward primer in exon 4 and a reverse 
prim er in exon 8 were used to  am plify a 552b p  section of the GHR transcript Mouse liver RNA was 
used as a positive contro l.The 10 m utants th a t were found to have HV vector insertions into the  Ghr, all 
express the  Ghr transcript. M utants  H V10, HV25, HV26, HV42 and HV72 also produce the  Ghr transcript. 
These m utants presumably have vector integrations into the Ghr, though none were recovered by 
inverse PCR. Parental BAF3 and BCL15, th e  tw o  mock mutants and m utant HV48 do not express th e  Ghr 
transcript.
b. Q u an tita tive  RT-PCR to measure IL-3 transcript levels was performed. Results are expressed as IL-3 
copies per 109 18S copies.The error bars represent the standard error o f this ratio. As positive control, 
RNA from  WEHI3B cells was used.The tw o  m ock mutants and m utant HV48 express th e  IL-3 transcript. 
This suggests that autocrine IL-3 p ro du ctio n  is a cause of spontaneous IL-3 independence in BCL15 
cells.
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Figure 4.6. M utants HV3 and HV14 from experiment LV2 express the Growth Hormone Receptor 
(GHR) on the cell surface.
Using an antibody that recognises the extracellular domain of the mouse GHR, it was demonstrated  
that unlike parental BCL15 cells (solid gray peaks) mutants HV3 and HV14 (black peaks) express the  
m ouse GHR on the cell surface. The percentage of cells to the right of the gate and the mean  
fluorescence intensity (MFI) o f the peaks are shown in each histogram.
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4.2.4.6. Ghr-insertional mutants respond to bovine Growth Hormone 
in culture
It was hypothesised that the Ghr insertional mutants obtained in the assay, 
proliferate in response to bovine Growth Hormone present at unknown 
concentration in the foetal calf serum of the culture medium. It was previously 
reported that BAF3 stably transfected with the rat GHR could proliferate in 
response to bovine Growth Hormone (Dinerstein et al. 1995; Jeay et al. 2000). 
Growth hormone signalling activates many of the same pathways as IL-3 
signalling, such as the JAK-STAT (see above), Ras-MAPK and PI3K pathways 
(Gouilleux et al. 1995; Jeay et al. 2001). Short term proliferation of mutants was 
assessed by measuring [3H] thymidine incorporation into DNA (Figure 4.7.a.). 
Unlike the parental cells, all 3 mutants tested grow in serum only without IL-3. 
They also proliferate in response to bGH alone, although to a lesser degree than 
when cultured in serum. This would suggest there are other factors present in 
serum that have an additive or synergistic effect on proliferation in combination 
with GH. Candidate factors are insulin-like growth factor 1 (IGF-1) and insulin. 
IGF-1 levels in foetal serum are very low and unable to support growth of 
parental BAF3 cells as demonstrated by their rapid apoptosis when cultured in 
serum only. IGF-1 can maintain cell viability and induce proliferation of BAF3 
cells; insulin is able to maintain BAF3 cell viability but only at very high 
concentrations (Rodriguez-Tarduchy et al. 1992).
Ghr-insertional mutants proliferate in response to bGH in a dose-dependent 
manner; proliferation is maximal at bGH concentrations of 1 pg/ml or above 
(Figure 4.7.b.). Ghr-insertional mutants are unable to proliferate in the complete 
absence of serum. Long term proliferation of mutants in response to bGH was 
also assessed by counting trypan blue excluding cells in cultures for the duration 
of one week (Figure 4.7.c). Interestingly, all 3 mutants proliferate faster in serum 
without IL-3 than in serum with IL-3; the difference in population doubling time is 
approximately two-fold.
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Both parental cells and mutants rapidly lose viability when cultured in serum-free 
medium. In contrast to the data shown in Figure 4.7.a, I could not observe an 
increase in cell number if HV A2 mutants were cultured in bGH only. Cells 
remained viable for 72 hours, followed by a decrease in cell number. This was 
also seen when HV A2 were cultured with 100 ng/ml IL-3, suggesting that neither 
signal maintains Bcl-XL expression effectively. HV3 cells cultured in the presence 
of bGH or IL-3 only, proliferated for up to 4 days at a similar rate to HV3 cells 
grown in serum plus WEHI. The total cell number slowly dropped thereafter. This 
was also seen for HV14 cells cultured with bGH or IL-3 only, though in these 
cultures the cell number dropped after 72 hours. Therefore, neither GH nor IL-3 
alone is able to sustain long term proliferation of BAF3 or BCL15 cells at these 
concentrations.
4.2.4.7. Proliferation of GHR-expressing mutants seems not to be 
mediated by IGF-1 induction
Conflicting reports exist in the literature with regards to IGF-1 production in 
response to GH signalling by GHR-expressing BAF3 cells. Proliferation of BAF3 
cells stably expressing the rat GHR was shown to be a direct effect of GH- 
signalling. Following GH stimulation of these cells, IGF-1 mRNA could not be 
detected by RT-PCR, neither could IGF-1 protein be detected in the culture 
medium (Baixeras et al. 2001). However, another study that analysed human 
GHR expressing BAF3 cells showed IGF-1 expression in these cells was 
stimulated by human GH in a dose-dependent fashion (Yoshizato et al. 2000). I 
could not detect IGF-1 gene expression by RT-PCR in my GHR-expressing 
insertional mutants that were grown in serum (Data not shown).
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Figure 4.7. Ghr insertional mutants HV A2, HV3 and HV14 respond to bovine growth hormone in 
culture.
a. Parental cells and m utants were cultured in: medium containing 10% FCS and 10% WEHI (blue); 
m edium  containing 10% FCS only (pink); serum-free medium (yellow) or serum-free m edium  
containing 1 pg/m l recom binant bGH (aqua blue).
Cells were cultured in these m edia for 24 hours before an overnight incubation in the presence o f [3H] 
thym idine. [3H] thymidine incorporation was measured by liquid scintillation counting th e  following  
day. Error bars indicate the standard error o f the mean calculated from 2 independent experim ents.
b. Parental cells and m utants w ere  incubated with serum-free m edium  containing d ifferent 
concentrations of bGH; DNA synthesis was measured as above.
Ghr insertional mutants proliferate in response to bGH (a). This response was shown to  be bGH 
dose-dependent (b). It plateaus at bGH concentrations from 1 pg/m l. Mutant proliferation in response 
to bGH alone is however less than in th e  presence of FCS (a), suggesting there are o ther mitogens 
present in serum that cause these cells to  grow.
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Figure 4 .7 .c. Ghr insertional mutants HV A2, HV3 and HV14 respond to bovine growth hormone 
in culture.
Long term  proliferation of Ghr-insertional mutants in response to bGH was assessed by counting 
trypan blue excluding cells every day for one week.
2 x 10s cells were cultured in 2ml volume in: medium containing 10% FCS and 10% WEHI (blue); 
m edium  containing 10% FCS only (pink); serum-free medium (yellow); serum-free medium containing 
10 pg/m l recom binant bGH (aqua blue) or serum-free medium containing 100 ng/ml rmlL-3 (purple). 
When the cell count approached 106 cells/ml, cells were passaged. Every two days, at 48, 96 and 144 
hours, 1 ml m edium  was replaced by fresh medium in all wells.
In the  charts, the total cell n um b er is plotted against time, taking cell passages into account. 
Exponential trendlines were fitted  to  a ll"10%  FCS plus 10% WEHI"data series. R-squared values were 
0.969, 0.9931, 0.9027, 0 .8789 and 0 .9549  for BAF3, BCL15, HV A2, HV3 and HV14, respectively. 
Exponential trendlines were also fitted  to  the "10% FCS" data series of the 3 mutants; R-squared values 
were 0 .9882,0 .9814 and 0.9875 for HV A2, HV3 and HV14, respectively.The population doubling time, 
shown in the  table, was calculated using the  formula y = c * e™, where c is the intercept (set at 2 x 105), 
e is the  base of the natural logarithm  and r is the growth constant. For the "10% FCS plus 10% WEHI" 
data series the growth constants w ere 0.0232,0.0394,0.0151,0.016 and 0.0201 for BAF3, BCL15, HV A2, 
HV3 and HV14, respectively. For the "10%  FCS" data series the growth constants w ere 0.0289, 0.0356 
and 0.0375 for HV A2, HV3 and HV14, respectively.
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Universal Amplification Primer
HV14 ------ CTACTACTAGGCC-CGCGTCGACTAGT^CGGGGGGGGGGGGGGGGTC
HV3 CTACTACTACTAGGCCACGCGTCGACTAGTACGGGGGGGGGGGGGGGGTC
HVA2 CTACTACTACTAGGCCACGCGTCGACTAGTACGGGGGGGGGGGGG TC
RACE Linker R
H V l4 TCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGA
HV3 TCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGA
HVA2 TCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGA
HVl 4 ACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTG
HV3 ACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTG
HVA2 ACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTG
R U5
H V l4 TGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTT
HV3 TGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTT
HVA2 TGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTT
' k ' k ' k ' k ' k ' J e ' k ' k J c ' k ' i c ' k ' k ' l e ' k ' k ' k ' k ' k ' J c ' k ' k J c i c ' k ' k ' k ' k ' k ' k ' k ' j c ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k
H V l4 TTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAA
HV3 TTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAA
HVA2 TTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAA
' k ' k ' k ' k ' k ' i c ' k ' k ' k ' k + r ' k ' k ' k ' k ' k ' k ' k i e ' k ' J c - k ' k ' k ' k ' k  ★ jJt ' k ' k ’k ' k ' k ' k ' k ' k ' J e ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k
U5 HIV-1 Leader
H V l4 AGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTG
HV3 AGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTG
HVA2 AGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTG
i c ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k - k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k - k ' k ' k ' k ' k ' k ' k ' k i c ' k - j c
H V l 4 AAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTCTCAGGTATGGAT
HV3 AAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTCTCAGGTATGGAT
HVA2 AAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTCTCAGGTATGGAT
' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k i e i c ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k  * 1+  • k ' k ' k - k ' k ' k ' k ' k - k ' k ' k ' k ' k ' k
MSD GHR exon 2
H V l 4 CTTTGTCAGGTCTTCTTAACCTTGGCACTGGCAGTCACCAGCAGCACATT
HV3 CTTTGTCAGGTCTTCTTAACCTTGGCACTGGCAGTCACCAGCAGCACATT
HVA2 CTTTGTCAGGTCTTCTTAACCTTGGCACTGGCAGTCACCAGCAGCACATT
' k ' k ' k ' k ' k ' k ' k i c - k ' k ' k i e ' k ' k ^ c i c ' i r ' k i c ' k ' k ' k ' k ' k ^ e ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k ' k i e i c ' k ' k i c ' k ' k ' k ' k ' k ' k ' k ' k
H V l4 TTCTGGAAGTGAGG
HV3 TTCTGGAAGTGAGG
HVA2 TTCTGGAAGTGAGG
★ *•*■■ *•****** + **•*»
Figure 4.8.The Ghr transcript in the mutants originates from the HIV-1 5'LTR of the vector.
To amplify the 5' end of the Ghr transcript present in the mutants, Dr S.L. Stephen in the Collins lab performed 
5' rapid amplification of cDNA ends (5' RACE) on mutants HV A2, HV3 and HV14. cDNA was synthesised from 
total RNA using a Ghr-specific reverse primer that anneals in exon 5. An oligo-dC tail was added to the 3'end 
of this cDNA using the enzyme terminal deoxynudeotidyl transferase (TdT). Nested amplification of tailed 
cDNA was performed using universal forward primers whose 3'sequence is complementary to the oligo-dC 
tail and Ghr-specific reverse primers in exon 4. A 590bp 5' RACE product was cloned and sequenced. An 
alignment of the first 414bp of the 5'RACE product is shown.
The RACE linker cassette is 46bp; the GHR transcript starts at the HIV-1 R region. It contains 289bp of HV 
vector sequence, before it splices from the HIV-1 major splice donor to the splice acceptor of GHR exon 2.The 
start codon in Ghr exon 2 is highlighted in bold.
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4.2.4.8. Analysis of the Ghr transcript in IL-3 independent mutants
To identify the mechanism whereby HV vector insertion activates Ghr gene
expression, we needed to analyse the Ghr transcript in the mutants. This work 
was carried out by Dr S.L.Stephen in the Collins lab. To investigate where the 
Ghr transcript originates from, 5’RACE was performed. This specialised form of 
RT-PCR allows amplification of the 5’ends of rare mRNA species. 5’RACE on 
mutants HV A2, HV3 and HV14 yielded a single pre-dominant PCR product of 
approximately 600bp in size. This 5’RACE product was cloned and sequenced. 
An alignment of the sequences is shown in Figure 4.8. The Ghr transcript starts 
at the beginning of the HIV-1 R region; it further contains the 5’LTR U5 region 
and HIV-1 leader sequence up to the HIV-1 major splice donor (MSD); the Ghr 
transcript splices from the HIV-1 MSD to the splice acceptor of Ghr exon 2. 
Further RT-PCR analysis by Dr S.L.Stephen failed to detect Ghr transcripts that 
contained any of the three known alternative first exons (L2/L1 and L5) or the 
HIV-1 U3 region (Data not shown). Hence, the predominant Ghr transcript in Ghr- 
insertional mutants is a vector-Ghr fusion transcript that seems to originate from 
the HIV-1 5’LTR.
4.2.5. The frequency at which Ghr insertional mutants are 
obtained from an HV vector transduced population can be 
increased by selecting cells in serum plus additional growth 
hormone
So far, Ghr insertional mutants were only obtained following selection according 
to the standard selection protocol, whereby cells were grown in 24 well plates in 
complete medium without IL-3 for one week; then rescued by adding IL-3 back to 
the medium; then washed of IL-3 again for a second selection round for IL-3 
independence. Ghr insertional mutant clones were unable to grow out without IL- 
3 rescue when selected in 24 well plates in complete medium, even though 
established mutants proliferate very well in this medium. We were wondering 
whether cells in which the HV vector had activated the Ghr could expand when 
selected in complete medium containing additional bGH. A modified protocol 
whereby cells are selected in 24 well plates in complete medium containing 1
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|jg/ml bGH was first tested in experiment LV3. Its efficiency in selecting for Ghr 
insertional mutants was compared to that of the standard selection protocol. 
Equal numbers of HV transduced target cells in experiment LV3 were selected 
according to each method. 26 out of 100 wells containing growing cells were 
scored after selection in serum plus bGH. After elimination of “sibling” clones, 
another 18 independent mutants with the HV vector were obtained. This was at a 
cell and integrant frequency of 3.6 x 10'7 and 9.5 x 10“8, respectively (Table 4.3.). 
No mock mutants were obtained in this experiment. All these new “GH HV” 
mutants were able to proliferate in complete medium only without the need for 
additional bGH once they had become established clones. We wanted to 
determine whether any of the same Ghr insertional mutants were picked up after 
selection with additional GH compared to standard selection. Southern blots on 
the 18 “GH HV” mutants were performed (Figure 4.9.) and compared to the 
Southern blots shown in Figure 4.2. of the LV3 standard selection mutants. No 
mutants which shared band patterns could be seen. It therefore looks like 31 
unique mutants were obtained from the initial HV-transduced population in 
experiment LV3. HV vector integration sites in the “GH HV” mutants were not 
identified, but all expressed the Ghr transcript (Figure 4.10.a) and none 
expressed the IL-3 transcript (Figure 4.10.b). Selecting HV vector transduced 
cells in complete medium with additional GH is therefore an effective way to 
select for Ghr insertional mutants.
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Table 4.3. HV lentiviral vector mutagenesis frequencies after standard selection and 
selection in foetal calf serum plus 1 pg/ml bovine growth hormone (LV3).
Selection
Type Target Cell
Mock Mutants HV Vector Transduced Mutants
Mutant
Number
Cell 
Frequency a
Mutant
Number
Cell 
Frequencya
Integrant 
Frequency b
Standard BCL15 2 4.0x1 O’8 13 2.6 x 10'7
CD 
-w
 
00 
00
 
X 
X
p 
o
oo
FCS + bGH BCL15 0 < 2.0 x 10"8 18 3.6 x 107 2.5 x 107 9 .5 x 10'8
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Table 4.3. Experiment LV3. HV lentiviral vector mutagenesis frequencies 
after standard selection and selection in foetal calf serum plus 1 pg/ml 
bovine growth hormone.
In experiment LV3, 5 x 107 BCL15 target cells were transduced with HV lentiviral 
vector at MOI 3.77 (Q-PCR). Cells were cultured in the presence of IL-3 for 48 
hours following transduction. By day 3 of the experiment, target cells had 
expanded 8-10 fold in cell number. 108 cells were washed thrice in complete 
medium without IL-3. 5 x 107 cells each were selected in one of two ways:
a. Selection according to the standard protocol as described in Table 4.1. Briefly, 
cells are plated in 24 well plates at 5 x 105 cells per well in 2ml complete medium 
without IL-3. Cells are rescued by adding IL-3 back to the medium on Day 10. 
Any growing cells are washed off IL-3 again to subject them to a second 
selection round for IL-3 independence.
b. Selection in complete medium supplemented with 1 pg/ml bGH in 24 well 
plates at 5 x 105 cells per well in 2ml medium. Wells are fed once a week by 
replacing 1ml old medium for 1ml fresh medium containing bGH. Plates were 
screened by visual inspection for cells growing out.
a The cell frequency was calculated by dividing the number of mutants by the 
total number of target cells in the experiment. The difference between the 
observed cell frequencies in the mock and HV arms of the experiment was 
significant: LV3 standard selection p < 0.001, X2 = 161; LV3 FCS + bGH 
selection p < 0.001; X2 = 360.
b The integrant frequency was calculated by dividing the number of mutants by 
the total number of integrants in each experiment.
The number of “GFP” integrants was calculated by multiplying the number of live 
target cells by the MOI. The MOI was determined by flow cytometry for GFP 
expression at 48h to 72h post-transduction. The GFP integrant frequency is 
shown in green.
The average number of vector copies per cell in experiment LV3 was also 
determined by Q-PCR. This number was multiplied by the number of target cells 
to obtain the number of “Q-PCR” integrants. The Q-PCR integrant frequency is 
shown in black.
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Figure 4 .9. Southern blots of IL-3 independent m utants obtained in experim ent LV3 following  
selection in foe ta l calf serum supplem ented w ith  1 pg/m l bGH.
Southern blots w ere perform ed as described in Figure 4.2. Band patterns were examined to determ ine  
clonality o f the m utants and HV vector copy number per genome. Blots from LV3 were exposed to  
autoradiography film . Irrelevant lanes on blots were removed. The num ber o f bands seen on the  
Southern blots o f each m u tan t is shown in the table below the blot.
Southern b lot band patterns o f LV3 m utants selected in complete medium plus bGH (shown in this 
figure), were com pared to  those o f LV3 mutants obtained by standard selection (shown in Figure 4.2.). 
No band pattern similarities could  be seen, suggesting unique mutants were picked up by both  
selection methods.
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Figure  4 .10 . IL-3 independent m utants that express the Ghr transcript, are obtained following  
selection o f an HV  vector transduced population in serum plus additional bovine GH.
RT-PCR for expression o f th e  Ghr transcript (a) and quantitative RT-PCR to measure IL-3 transcript levels 
(b) was perform ed as described in Figure 4.5.
IL-3 independent m utants from  exp erim ent LV3 that were selected in serum plus additional bGH all 
express the Ghr transcript (a); none express the IL-3 transcript (b).
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4.3. Discussion
4.3.1. Summary of achievements
• It was established that the BAF3 cell line was not robust enough for use in
insertional mutagenesis experiments, so we switched to a Bcl-2 over­
expressing derivative cell line, BCL15.
• IL-3 independent mutants of the BCL15 cell line could be obtained with the 
HV lentiviral vector at an average integrant frequency of 4.3 x 10"8 (LV2 
and LV3). The protocol still involves rescue with IL-3, 7 days after initiation 
of IL-3 starvation.
• All mutants obtained with the HV lentiviral vector, except HV48, were 
found to contain independent vector integration sites into the Ghr locus.
• Ghr gene expression was activated by HIV-1 5’LTR promoter insertion; 
activity of the HIV-1 5’LTR in the cells in the absence of Tat was 
unexpected and is potentially interesting for the study of HIV-1 latency.
• Ghr-insertional mutants can be efficiently selected in serum supplemented 
with bGH. This can be used to screen HV vector variants.
Each of these points shall be discussed in greater detail below.
4.3.2. Need for suitable target cell in mutagenesis experiments
In the previous chapter, two problems were addressed: firstly the asynchronous
cell death of parental BAF3 cells upon IL-3 withdrawal, and secondly the inability 
of IL-3 independent mutants to expand from amidst a large pool of dead or dying 
cells, necessitating rescue with IL-3. This chapter started by outlining a third 
problem, namely the inability to generate IL-3 independent mutants of the BAF3 
cell line with a lentiviral vector that had been shown in a pilot experiment to be 
able to transform this cell line. Several variables were tested: selection in T25 
flasks versus 24 well plates; cell density during selection; whether or not to 
rescue by adding IL-3 back and if IL-3 rescue was performed, what is the best 
time to do this following initiation of IL-3 starvation. However, no IL-3 independent 
mutants of the BAF3 cell line could be obtained.
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At the time this left us with several possibilities: It could be that the HV lentiviral 
vector was not so mutagenic after all; alternatively the BAF3 cell line was not the 
most suitable target cell. This latter possibility was explored first.
A suitable target cell in mutagenesis experiments must allow selection for a 
phenotype, in this case IL-3 independence. It was thought a two to three day 
expansion of cells in the presence of IL-3 was sufficient to allow deregulation of 
cellular gene expression by proviral insertion. However, what seemed to happen 
was that upon IL-3 withdrawal, BAF3 cells died too rapidly before the selectable 
phenotype could take over in mutants. The role of the anti-apoptotic protein Bcl-2 
expression in cancer cells is to prolong cell viability, allowing other mutations to 
accumulate. Bcl-2 over-expressing BCL15 cells remain viable for longer after IL- 
3 withdrawal and did allow IL-3 independent mutants to emerge, but again only 
after rescue with IL-3.
With the HV lentiviral vector, IL-3 independent mutants were obtained at a Q- 
PCR integrant frequency of 4.3 x 10'8 and cell frequency of 2.3 x 10'7 in 
experiments LV2 and LV3 combined. For mutants to grow out without rescue, the 
cell frequency needs to be at least KT6 (See section 3.2.2.), meaning greater 
than 20 fold more integrants would have to be screened. This is not feasible, so 
in all other experiments a protocol that involved rescue with IL-3 was used.
4.3.3. Ghr gene activation in HV insertional mutants
The HV lentiviral vector is able to transform BCL15 cells to IL-3 independence. It
seems to do so uniquely through activation of the Ghr gene. 15 out of 16 mutants 
obtained through standard selection express the Ghr transcript and independent 
HV vector integration sites in the Ghr locus were recovered in 10 mutants. As 
mentioned previously, the Ghr is a retroviral common insertion site, Evil24. The 
Ghr was a target of retroviral integration by endogenous Murine Leukaemia Virus 
(Akv) in 6 independent (B cell) leukaemias/lymphomas (Suzuki et al. 2002; 
Suzuki et al. 2006). In these two studies by Neal Copeland’s group retroviral 
insertional mutagenesis was used with the objective of identifying new cancer 
associated genes. Ghr insertions in these tumours suggest that GH supports 
survival and/or proliferation of these cells in vivo. All insertions were clustered
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within 5.5 kb up- or downstream of the L2 promoter, which drives transcription of 
the predominant Ghr transcript in mouse adult liver. Four out of 6 insertions were 
in reverse orientation as Ghr gene transcription, and would be expected to 
activate transcription from the L2 promoter by enhancer insertion.
All 10 identified insertions in my IL-3 independent mutants occurred in intron 1-2 
in the same orientation as Ghr gene transcription. In contrast to wild type 
retrovirus insertions, none of the HV vector insertions were near the L2 promoter. 
All, except the insertion in mutant HV A2, were in the 15 kb region upstream of 
exon 2, near the L1 and L5 promoters. The most likely mechanism whereby HV 
vector insertion activated Ghr expression was considered to be enhancer 
activation by the HIV-1 or SFFV enhancers in the vector of one of the three 
endogenous promoters. However it was intriguing that all 10 identified HV vector 
insertions were in the same orientation as Ghr gene transcription. Generation of 
a read through transcript from the SFFV promoter was another possibility. This 
would necessitate inadequate polyadenylation at the 3’LTR.
4.3.4.HIV-1 promoter insertion results in the generation of a 
vector -  Ghr fusion transcript
HIV-1 5’ LTR activity in BAF3/BCL15 cells in the absence of the Tat 
transactivator protein was not anticipated. However, the HIV-1 major splice donor 
interacted with the splice acceptor of Ghr exon 2 to generate a vector-Ghr fusion 
transcript. Similar cases of promoter insertion were reported in wild type Mo-MLV 
induced rodent haematopoietic tumours. MLV insertions in the same orientation 
upstream of c-myb were found in mouse myeloid tumours (Shen-Ong et al
1986). Transcripts were initiated from the 5’LTR and use a cryptic splice donor 
present in gag to splice to the splice acceptor of a downstream c-myb exon.
MLV promoter insertion activated expression of a cytokine receptor, namely the 
prolactin receptor (PRLR) in a rat T cell lymphoma (Barker et al. 1992). Proviral 
insertion occurred upstream of the Prlr gene. Transcripts were initiated from the 
proviral 5’LTR. The MLV splice donor upstream of the gag gene interacted with a 
cryptic splice acceptor in exon 1 of Prlr.
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4.3.5. Why is the HIV-1 LTR active in BAF3/BCL15 cells?
In wild type HIV-1 infected cells basal LTR activity is required to re-activate
viruses from latency. The transcription factors involved in basal transcription from 
the HIV-1 LTR include Sp1 (Jones et al. 1986) and NFkB (Nabel and Baltimore
1987). We hypothesise these transcription factors are active in BAF3 cells and 
initiate transcription from the HIV-1 LTR. Sp1 transcription factors are 
ubiquitously expressed, whereas NFkB is inducible upon antigen stimulation and 
cytokine signalling. The importance of these two transcription factors in HIV-1 
LTR promoter activity in BAF3 cells was demonstrated when HIV-1 LTR 
luciferase reporter gene constructs were transfected into BAF3 cells expressing 
the human GM-CSF receptor (Watanabe et al. 2002). Maximal luciferase 
expression was seen in an HIV luciferase construct that contained the complete 
U3 region and the first 25bp of the R region. NFkB and Sp1 binding site deletion 
mutants displayed much reduced luciferase expression, highlighting the 
importance of these transcription factors in GM-CSF induced LTR activity.
The tissue specific transcription factor GATA-2 was also shown to be important in 
HIV-1 LTR promoter activity (Towatari et al. 1998). Luciferase expression in 
BAF3 cells from an HIV-1 LTR construct in which the GATA-2 binding sites were 
mutated was reduced by 60% compared to wild type. GATA-2 is phosphorylated 
by a MAPK-dependent pathway in BAF3 cells in response to IL-3 signalling 
(Towatari et al. 1995).
The role of the trans-activator protein Tat, encoded by wild type HIV-1, is in HIV-1 
LTR transcriptional initiation and elongation. Tat is not expressed in BAF3 target 
cells and elongation of transcripts initiated from the HIV-1 5’LTR would expected 
to be very inefficient. A recent paper examined the role of NFkB activity in latent 
HIV-1 gene expression (Williams et al. 2007). NFkB is not only a strong inducer 
of HIV-1 transcriptional initiation; its sustained expression can induce 
transcriptional elongation. The RelA subunit of NFkB is thought to recruit P-TEFb, 
which phosphorylates serine 2 of the C-terminal domain of RNA polymerase II. In 
wild type HIV-1 infected cells these elongated transcripts code for small 
quantities of Tat, leading to efficient elongation of HIV-1 transcripts.
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In the same way as GM-CSF, IL-3 signals through the common (3 chain and one 
would expect many of the same pathways to be activated by IL-3 and GM-CSF 
signalling in BAF3 cells. Following transduction, BAF3 cells are cultured in the 
presence of IL-3 for 2-3 days. IL-3 signalling at this time could activate HIV-1 LTR 
activity. IL-3 was shown to induce NFkB activity in BAF3 cells (Nakamura et al. 
2002). Once the GHR is expressed on the cell surface of Ghr-insertional mutants, 
GH signalling itself induces NFkB activity (Jeay et al. 2000) and could in that way 
sustain its own expression. Future work will investigate the role of different 
transcription factors on HIV-1 LTR activity in BAF3 cells.
4.3.6.Why does HV vector transformation only work via 
activation of Ghr expression?
Assuming HIV-1 LTR activity is not just restricted to the Ghr locus, it should have 
the potential to activate other genes by promoter insertion. However, in this 
assay we only observed activation of the Ghr by this mechanism. The Ghr is 
unique in that it has a very large (125kb) first intron preceding the first coding 
exon. For this mechanism of promoter insertion to work, vector insertion needs to 
occur in the same orientation as gene transcription and there needs to be a 
splice acceptor upstream of the coding region that can interact with the splice 
donor of the vector. This implies that candidate target genes cannot have a 
coding first exon, unless there is a cryptic splice acceptor present upstream of 
the start codon in exon 1. This long list of prerequisites for this mechanism of 
gene activation to work, probably explains why we do not see activation of other 
candidate genes such as IL-3, Igf1, Pdgfr, Fgfrl and Bcl-X, that could also 
potentially transform BAF3 cells to factor independence. IL-3 is a very small gene 
of just over 2 kb, whose first coding exon is exon 1. The Igf1 gene is much larger 
at 56kb, but again exon 1 is the first coding exon. Looking at the structure of 
genes encoding growth factor receptors whose ligands are present in serum, all 
transcripts contain at least one non-coding exon. The Pdgfr expresses 2 
transcripts; translation starts at exon 2; the first introns are small at 457bp and 
14.6 kb. The first coding exon of Fgfrl is exon 2, but again the first intron is small 
at 13 kb. HIV-1 LTR promoter insertion might well activate expression of these
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receptors, but their ligands might not be present at sufficient concentrations in 
serum or the resulting phenotype is not robust enough to survive the selection 
protocol. Retroviral vectors can activate Bcl-XL expression (Thomas et al. 1998). 
The Bcl-X (Bcl2l1) gene is 64 kb in size. Four different transcripts are expressed 
from this gene. Exon 2 is the first coding exon in all of these transcripts. Intron 1- 
2 varies in size from 283 to 1500bp, so again is relatively small. BCL15 cells 
already over-express Bcl-2, so B c I-X l insertional activation would be unlike to 
affect the phenotype of such a cell. As discussed previously, Bcl-XL over­
expression alone in BAF3 cells does not result in IL-3 independent growth, but 
only prolongs viability. If we had many integrants per cell, we could select for Bcl- 
X insertions cooperating with insertions in a genes encoding mitogens. However, 
the MOI in these experiments was presumably too low for that. Finally, another 
reason why we might only pick up Ghr insertional mutants, is because the Ghr is 
a preferred integration site for HIV-1. Regional hotspots of HIV-1 integration have 
been reported (Schroder et al. 2002). However, in parental cells, the Ghr is not 
expressed and HIV-1 integrates preferentially but not uniquely in active genes 
(Schroder et al. 2002).
4.3.7. Why does the GH selection protocol work?
Ghr-insertional mutants are unable to expand when selected in serum alone
without rescue with IL-3. However, in the final part of this chapter it was 
demonstrated that Ghr-insertional mutants could grow out when selected in 
serum supplemented with additional growth hormone.
It is difficult to estimate the bGH concentration in serum. Also, the issue of other 
factors present in serum that could synergise with bGH remains unresolved. It is 
thought very low levels of GH are sufficient to stimulate GH signalling. It could be 
that during the first 10 days after transduction, GHR-expression levels by Ghr- 
insertional mutants are still very low and this is why higher concentrations of bGH 
are needed during selection. This was demonstrated in BAF3 cells engineered to 
express the IL-2 receptor (Collins etal. 1994). The IL-2 concentration needed to 
support survival and proliferation of BAF3 clones expressing different levels of IL- 
2 receptor on the cell surface was compared. In clones that expressed low levels
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of IL-2 receptor, high concentrations of IL-2 were needed, presumably to induce 
maximal receptor occupancy. As Ghr-insertional mutants become established, 
GHR expression levels might increase, allowing them to grow in serum without 
additional bGH.
Slightly more mutants (18 versus 13) were picked up after selecting the same 
transduced cell population in serum plus bGH, as opposed to standard selection. 
Interestingly, these were all independent clones. A total of 30 Ghr-insertional 
mutants were obtained after screening 1.9 x 108 integrants in experiment LV3. 
Overall, in mutagenesis experiments with the HV lentiviral vector in the BCL15 
cell line 3.1 x 108 HV vector integrants were analysed. Assuming random 
integration, this means roughly one HV vector integrant per every 10bp of the 
genome. Intron 1-2 must have been hit 1.25 x 104 times and half of these 
integrants should be in the same orientation as Ghr gene transcription. This 
resulted in 33 Ghr insertional mutants, meaning approximately 1 in 200 integrants 
in the locus could result in a mutant.
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Chapter 5
5. Insertional mutagenesis by a self-inactivating 
lentiviral vector
5.1. Introduction
In chapter 4, a frequency at which IL-3 independent mutants of the BCL15 cell 
line were obtained with the wild type HIV-1 LTR lentiviral vector HV, was 
established. The mechanism by which this vector transforms BCL15 cells was 
analysed. Insertional activation of the Ghr gene by the HV vector was found to 
have occurred in IL-3 independent mutants. A vector-Ghr fusion transcript 
originating from the HIV-1 5’LTR was found in these mutants. Activity of the HIV- 
1 LTR in the BCL15 cell line was unexpected.
Self-inactivating (SIN) lentiviral vectors should theoretically be less mutagenic in 
the BCL15 cell line, because they lack HIV-1 LTR promoter and enhancer 
activity.
In this chapter, the ability of the self-inactivating lentiviral vector CSGW 
(Demaison et al. 2002) to transform BCL15 cells to IL-3 independence was 
analysed. The SIN LTR in CSGW is derived from pHR SIN (Zufferey et al. 1998), 
described previously in section 1.3.4. of the introduction. It has a 400bp deletion 
of the U3 region and residual HIV-1 promoter activity by the 5’LTR should be 
negligible. The questions that were addressed were as follows:
• Is a SIN lentiviral vector, otherwise identical to the HV lentiviral vector 
used in chapter 4, still able to transform BCL15 cells to IL-3 independence 
and if yes, at what frequency?
• By what mechanism(s) does this SIN lentiviral vector transform BCL15 
cells?
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5.2. Results
5.2.1. The integrant frequency at which IL-3 independent mutants 
are obtained with a SIN lentivector is almost 10 fold lower than 
with a wild type LTR lentivector
Two experiments with the SIN lentiviral vector CSGW were performed. BCL15 
cells were transduced with the CSGW lentiviral vector and selected according to 
the standard selection protocol, which involved rescue with IL-3 after an initial 
week of IL-3 starvation. In experiment LV4, 3 mutants were obtained in the vector 
transduced population versus one mock mutant (Table 5.1). This was at an 
integrant frequency of 9.8 x 10'9 by Q-PCR. The same transduced target cell 
population was also selected in serum plus bGH. In contrast to experiment LV3 
with the HV lentiviral vector (Table 4.3.), this did not result in an increase in the 
number of vector transduced mutants that were obtained. More mutants were 
obtained from the mock than the vector transduced population (3 versus 2). In 
experiment LV5, 5.4 x 108 CSGW integrants were screened; almost twice the 
number of integrants analysed in experiment LV4. No long term IL-3 independent 
mutants were obtained after either standard selection or selection in serum plus 
bGH. The difference between the observed cell frequencies in the mock and HV 
arms of the experiment in LV4 and LV5 combined was not significant in either the 
standard or serum plus bGH selections.
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Table 5.1. Mutagenesis frequencies with the self-inactivating lentiviral vector CSGW
Experiment Target Cell
Mock Mutants
Mutant
Number
CSGW Vector Transduced Mutants
IntegrantCell Mutant Cell
I Frequency 3 Number I Frequency3 1
Standard selection
LV4
LV5
BCL15
BCL15
2.0 x 10' 6.0 x 10'
0 < 2 . 0 x  10' 0 < 2.0 x 10'
3.3 x 10 
9.8 x 10-9
< 1 0 x 1 0 '  
< 1.9 x 10'9
Selection in foetal calf serum plus 1 p g / m l  b o v in e  growth hormone
LV4
LV5
BCL15
BCL15
4.0 x 106.0x1 O'8
< 2 . 0 x  10<2.0x1  O'8
2.2 x 10' 
6.5x1 O'9
< 1.0 x 10'
< 1.9 x 10'9
Table 5.1. Mutagenesis frequencies with the self-inactivating lentiviral 
vector CSGW
In experiments LV4 and 5, 5 x 107 BCL15 target cells were transduced with the 
self-inactivating lentiviral vector CSGW. Cells were cultured in the presence of IL- 
3 for 48 hours following transduction. By day 3 of the experiment, target cells had 
expanded 8-10 fold in cell number. 108 cells were washed thrice in complete 
medium without IL-3.
5 x 107 cells each were selected in one of the ways, as described in Table 4.3.
a The cell frequency was calculated by dividing the number of mutants by the 
total number of target cells in the experiment.
The difference between the observed cell frequencies in the mock and HV arms 
of the experiment in LV4 and LV5 combined was significant in neither the 
standard nor FCS + bGH selections: standard selection p = 0.0015, X2 = 10; FCS 
+ bGH selection p = 0.1572; X2 = 2.
b The integrant frequency was calculated by dividing the number of mutants by 
the total number of integrants in each experiment.
The number of “GFP” integrants was calculated by multiplying the number of live 
target cells by the MOI. The MOI was determined by flow cytometry for GFP 
expression at 48h to 72h post-transduction. The GFP integrant frequency is 
shown in green.
In experiments LV4 and LV5, the average number of vector copies per cell was 
also determined by Q-PCR. This number was multiplied by the number of target 
cells to obtain the number of “Q-PCR” integrants. The Q-PCR integrant frequency 
is shown in black.
186.
5.2.2.The same two subclones seem to have been picked up 
following standard selection and selection in serum plus bGH
IL-3 independent mutants from experiment LV4 were analysed by Southern blot
(Figure 5.1.) to determine clonality and vector copy number. Mutants carried 3 to 
5 copies of the vector each. Analysis of the band pattern of standard selection 
mutants revealed that CSGW12 is the only unique mutant. The band patterns of 
CSGW91 and CSGW94 look similar; the top double band in CSGW91 is not very 
clear and there is a fifth band below the top double band. This would suggest 
CSGW91 and CSGW94 are subclones. Interestingly, the same two subclones 
seem to have been picked up by selection in serum plus bGH. The band patterns 
of bGH CSGW1-1 and bGH CSGW2-4 look similar to that of CSGW91 and 
CSGW94, respectively.
5.2.3.The SIN lentiviral vector mutants do not express the Ghr 
transcript, nor do they respond to bGH in culture
Before proceeding to analyse the integration sites in these mutants, I first
assessed by RT PCR whether any of them were likely to be Ghr insertional 
mutants. None of the CSGW mutants produce the Ghr transcript (Figure 5.2.a). 
Because of the comparatively high number of mock mutants in experiment LV4 
(4 versus 5 CSGW mutants), IL-3 expression levels were also analysed by Q-RT- 
PCR. All mock mutants and mutant CSGW12 express the IL-3 transcript (Figure 
5.2.b). The two subclones CSGW91 (= GH CSGW 1-1) and CSGW94 (=GH 
CSGW2-4) express neither Ghr nor IL-3 transcript. This is a unique phenotype, I 
had not seen before. For this reason, I decided to focus my integration site 
analysis on these two mutants.
None of the CSGW mutants respond to bGH in culture (Figure 5.3.). Interestingly, 
no difference in the ability to grow in serum free medium can be seen between 
the mutants that express IL-3 (Mock60, CSGW12) and the others that do not.
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Figure 5 .1. Southern blots of IL-3 independent mutants obtained in experiment LV4 following  
standard selection and selection in foetal calf serum supplemented with 1 pg/ml bGH.
15pg genom ic DNA o f each m utant was digested with BamHI.This enzyme cuts only once inside the 
vector at the  same position as in the HV vector (See Figure 4.2.). Blots were probed with the cDNA for 
eGFP. Blots from  LV4 were exposed to a phosphorscreen. Irrelevant lanes on blots were removed.
Band patterns w ere exam ined to determ ine clonality of the mutants and CSGW vector copy number 
per genome. The num ber o f bands seen on the Southern blots and the number o f integrations sites 
cloned out by LM-PCR for each m utan t are shown in the table below the blot.
The band pattern o f CSGW12 is unique compared to the other two mutants picked up in the standard 
selection.There was less DNA in th e  CSGW91 lane. However, on closer inspection the band patterns of 
mutants CSGW91 and CSGW94 are similar, except that CSGW91 has a fifth band.
Furthermore, CSGW91 and GH CSGW1-1 show a similar band pattern on Southern blot, as do mutants 
CSGW94 and GH CSGW2-4. This suggests the same clones were picked up by standard selection and 
selection in FCS plus bGH.
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Figure 5.2. None of the CSGW mutants express the Ghr transcript.
a. A reverse-transcriptase (RT) PCR for expression of the Ghr transcript was performed on parental cells 
and IL-3 independent m utants from  experiment LV4. A forward primer in exon 4 and a reverse primer 
in exon 8 were used to am plify a 552bp  section of the GHR transcript. Mutant HV A2 RNA was used as a 
positive control. None o f the CSGW mutants express the Ghr transcript.
b. Quantitative RT-PCR to measure IL-3 transcript levels was performed. Results are expressed as IL-3 
copies per 109 18S copies. The error bars represent the standard error of this ratio. As positive control, 
RNA from WEHI3B cells was used. All four mock mutants as well as mutant CSGW12 express the IL-3 
transcript.
M utants CSGW91 and 94, and m utants  GH CSGW1-1 and 2-4, express neither the Ghr nor IL-3 
transcripts.
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BCL15 M60 C SG W  C SG W  C SG W  GH GH HV14
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1-1 2-4
Figure 5.3. The m utants obtained with the CSGW lentiviral vector do not respond to bGH in 
culture.
Parental BCL15 cells and CSGW m utants were cultured in: medium containing 10% FCS and 10% WEHI 
(blue); m edium  containing 10% FCS only (pink); serum-free medium (yellow) or serum-free medium  
containing 1 pg/m l recom binant bGH (aqua blue).
Cells were cultured in these m edia for 24  hours before an overnight incubation in the presence of [3H] 
thym idine. [3H] thym idine incorporation was measured by liquid scintillation counting the following  
day.
Ghr insertional mutant HV14 was a positive control in this experiment. The three mock mutants 
obta ined  in the selection in serum plus bGH were not analysed. Error bars indicate the standard error 
of th e  m ean calculated from 2 in d ep end en t experiments.
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5.2.4.Integration site analysis confirms two subclones were 
picked up, but does not fully reveal their genotype
SIN lentiviral vector integration sites were cloned out by linker-mediated PCR
(LM PCR). The principle of this method is shown in Figure 5.4. In short, genomic 
DNA was digested with a restriction enzyme that has a 4bp recognition 
sequence. A linker compatible with the overhang generated by this enzyme was 
ligated to DNA fragments. Nested amplification was performed using U5 region 
and linker specific primers to amplify out the 3’LTR junction. LM PCR products 
were size separated, gel extracted, cloned into a plasmid vector and sequences. 
Analysis of lentiviral vector integration sites in GH CSGW1-1 and GH CSGW2-4 
confirmed we were dealing with two subclones. GH CSGW1-1 and GH CSGW2-4 
shared 3 integration sites. The integration into Zfp407 on chromosome 18 was 
unique to GH CSGW1-1. I was unable to clone out the fourth integration shared 
by GH CSGW1-1 and GH CSGW2-4, despite performing LM PCR with 3 different 
enzymes. Insertional activation of the genes at the integration sites identified so 
far, would not easily explain transformation to IL-3 independence of these 
mutants.
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Figure 5.4. a, b and c.
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Figure 5.4. CSGW lentiviral vector integration sites in IL-3 independent mutants from  
experiment LV4 were cloned using the linker-mediated PCR technique.
Linker-mediated PCR (LM-PCR) was performed as described by Wu et al to amplify genomic DNA 
flanking the 3'LTR of the vector. Duplicate samples of genomic DNA from GH CSGW1-1 and GH CSGW
2-4 were digested with 4 base pair cutters Nlalll, Taql or Mspl. On one out of two samples a second 
digest with EcoRI (for Nlalll and Mspl initial digests) or Sacl (for Taql initial digest) was performed, to 
destroy the "internal band" which is otherwise amplified from the 5'LTR.
a. Overview of the linker-mediated PCR technique. The CSGW vector is shown as a provirus. LM-PCR 
primers were designed in the HIV-1 LTR U5 region, to amplify DNA flanking the 3'LTR. An Nlalll site is 
present at unknown distance downstream of the 3'LTR. The Nlalll site downstream of the 5'LTR in the 
vector is also shown, as is the EcoRI site used to eliminate the internal band (I). Genomic DNA is 
digested with Nlalll (plus/minus EcoRI) (II). Nlalll digested DNA is then ligated to an Nlalll compatible 
linker (III). Vector genome junction sequence is amplified using primers recognising the HIV-1 U5 
region and the linker (IV).
b. Approximately 10Ong of template was used in the first round of amplification; but no bands could be 
seen when this PCR reaction was run out on a gel. One hundredth of the first round product was used 
in nested amplification.This 2% agarose gel shows LM PCR products obtained from GH CSGW1-1 and 
GH CSGW 2-4 after nested amplification. Genomic DNA was digested with Nlalll (plus/minus EcoRI) as 
indicated. Amplification of the internal band is expected to be inefficient because of its large size (1.8 
kb). Hence, the internal band cannot be seen, even in lanes in which template was digested with Nlalll 
only. More bands than expected from Southern blots were observed. Sequence analysis revealed 
genomic DNA was incompletely digested in some cases; in other cases concatamers of DNA fragments 
had formed during ligation. LM-PCR products were gel extracted, cloned into a plasmid vector and 
sequenced.
c.The sequence of 223 bp LM PCR product obtained from GH CSGW1-1 and GH CSGW 2-4 is shown 
here. It contains 69 bp of HIV-1 U5 region (in green) and 21 bp of linker sequence (in black). The 
primers used in nested amplification are shown. The 133 bp of mouse genomic DNA sequence (in 
blue) mapped to the Cnot4 gene on chromosome 6.The Nlalll site which is reformed upon ligation of 
the linker is underlined.
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Table 5.2. CSGW lentiviral vector integration sites in IL-3 independent 
mutants (LV4)
Clone SB LM-PCR
In
Gene
(Y/N)
Gene
Name
Entrez
Gene
ID
Chr Distance to TSS Ori
Predicted Gene 
Function RTCGD
LV4
GH
CSGW
1-1
5 4
Y Zfp407 240476 18 23kb Intron 1-2 +
Y Cnot4 53621 6 32kb Intron 1-2 -
CCR4 NOT Transcription 
Complex, subunit 4
Y Gmeb2 229004 2 26kb Intron 4-5 -
Glucocorticoid 
modulatory element 
binding protein 2
Y Wipi2 74781 5 12kb Intron 2-3 +
WD repeat domain, 
phosphoinositide 
interacting 2
GH
CSGW
2-4
4 3
Y Cnot4 53621 6 32kb Intron 1-2 -
CCR4 NOT Transcription 
Complex, subunit 4
Y Gmeb2 229004 2 26kb Intron 4-5 -
Glucocorticoid 
modulatory element 
binding protein 2
Y Wipi2 74781 5 12kb Intron 2-3 +
WD repeat domain, 
phosphoinositide 
interacting 2
Table 5.2. CSGW lentiviral vector integration sites in IL-3 independent 
mutants (LV4)
LM- PCR was performed on mutants GH CSGW1-1 and GH CSGW 2-4 using 
three different restriction enzymes, Nlalll, Taql and Mspl. PCR products were gel 
extracted, cloned into a plasmid vector and then sequenced. Vector-genome 
junction sequences were blasted against the mouse genome, released August 
2007 (www.ensembl.org/Mus musculusV
SB indicates vector copy number in the mutant determined by Southern blot. LM- 
PCR indicates the number of insertion site loci identified in the mutant by linker 
mediated PCR. All insertion sites shown in this table were confirmed by site- 
specific PCR. The distance to the transcription start site (TSS) of the nearest 
gene is shown. Ori indicates whether the vector insertion occurred in the same 
(+) or in the opposite (-) orientation as the gene’s transcript. Predicted gene 
function is shown where known. None of the integration sites obtained from GH 
CSGW 1-1 and 2-4 were common insertion sites listed in the RTCGD.
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5.3. Discussion
5.3.1. Summary of achievements in this chapter
In this chapter, it was firstly demonstrated that IL-3 independent mutants of the
BCL15 cell line could still be obtained with a SIN lentiviral vector. The integrant 
frequency at which mutants were obtained was approximately 10 fold lower than 
with the HV vector. The difference in cell frequencies at which mutants were 
obtained from the mock and vector transduced populations was hardly 
significant. Secondly, it was shown that the SIN lentiviral vector transforms 
BCL15 cells by a different mechanism than the HV lentiviral vector. No Ghr 
insertional mutants were obtained with the SIN vector, which is consistent with 
the hypothesis that an active HIV-1 5’LTR promoter is required for this 
mechanism of transformation to work. Thirdly, the role of the vector in 
transformation of mutants to IL-3 independence could not convincingly be 
demonstrated.
5.3.2.Anaiysis of mutants obtained with a SIN lentiviral vector
Two IL-3 independent mutants that are subclones, were obtained with the CSGW
lentiviral vector. These mutants express neither the Ghr nor the IL-3 transcripts, a 
phenotype that has not been seen previously. Presumably these two subclones 
expanded considerable during the 2 day bulk culture in the presence of IL-3, as 
they were both picked up following standard selection as well as selection in 
serum plus bGH. As these mutants do not express the GHR or respond to GH in 
culture, that means they were able to expand from amidst dead cells following 
unbiased selection, without the need for rescue with IL-3. This is unique as this 
type of mutant was never picked up before. Unfortunately, lentiviral integration 
site analysis of these mutants is incomplete, with one shared integration site still 
unidentified. The integration site might well hold the key to elucidating why these 
subclones are IL-3 independent. It is not obvious how activation of the genes 
found near the integration sites identified so far could result in IL-3 
independence. There remains a possibility that these subclones are spontaneous 
mutants that happen to carry vector insertions, like mutant HV48 from experiment
195.
LV3 in the last chapter. So far, we have only seen mock mutants that had 
spontaneously activated IL-3 expression. However, this need not be the only 
mechanism by which BCL15 cells can become spontaneously IL-3 independent. 
For example, point mutants in the IL-3 receptor, resulting in ligand independent 
signalling, could also do this.
5.3.3. Further analysis of which elements in the HV vector are 
required for Ghr insertional activation
The mutagenesis experiments described in this chapter show that SIN lentiviral 
vectors are unable to activate Ghr gene expression. This means HIV-1 promoter 
activity is effectively silenced in these vectors, and they should be safer to use in 
the clinical setting than wild type LTR lentiviral vectors.
We still do not know why the wild type HIV-1 LTR is active in BCL15 cells and 
able to drive transcription of elongated transcripts. For this reason, it would be 
interesting to perform a more detailed analysis of exactly which transcription 
factor binding sites in the HIV-1 U3 region are necessary for promoter activity. In 
chapter 4, it was speculated that NFkB, Sp1 and/or GATA-2 transcription factors 
might be important in HIV-1 LTR activity (Towatari et al. 1998; Watanabe et al. 
2002) in BCL15 cells. HV vectors in which one of more binding sites for these 
transcription factors have been mutated could be tested for their ability to activate 
Ghr expression.
Transcription from the HIV-1 5’LTR in the Ghr insertional mutants is Tat- 
independent. It would be interesting to investigate whether the TAR loop is still 
required. It was recently reported that in a Tat-independent HIV-1 variant 
dependent on doxycycline for transcription, the TAR loop could be completely 
deleted without affecting transcription starting at the U3/R junction (Das et al. 
2007).
Also, possible interactions between the internal elements within the HV vector 
cassette and the HIV-1 5’LTR would need to be investigated. An HV vector 
derivative lacking the Woodchuck post-transcriptional regulatory element 
(WPRE) is currently being tested, as is a construct in which the SFFV LTR 
promoter has been replaced by ubiquitously active cellular promoter.
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The other obvious “mutagenic” component of the HV lentiviral vector is the HIV-1 
major splice donor (MSD), because it allows interaction with the splice acceptor 
of Ghr exon 2. An obvious solution to further improve the safety profile of this 
vector would be to mutate the MSD. However, a functional MSD is required for 
inactivation of the poly(A) site in the 5’LTR (Ashe et al. 1995). The factor 
responsible for this was shown to be the U1 snRNP which interacts with the 
MSD, and in some way inhibits activity of poly(A) factors at the poly(A) site (Ashe 
et al. 1997). Mutating the MSD in lentiviral vectors would result in premature 
polyadenylation in the 5’LTR during vector production, resulting in low titre vector 
preparations.
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Chapter 6
6. Retroviral vector mutagenesis in the BCL15 cell line
6.1. Introduction
In chapter 4, I demonstrated that a wild-type HIV-1 lentiviral vector could 
transform BCL15 cells to IL-3 independence via activation of Ghr gene 
expression. This was at an average integrant frequency of 4.3 x 10'8 by Q-PCR.
In this chapter, I assayed two retroviral vectors for insertional mutagenesis in the 
BCL15 cell line. The integrant frequencies at which mutants are obtained were 
compared to that of the HV lentiviral vector. I investigated whether the same host 
genes were targeted in mutants transformed by lentiviral versus retroviral 
vectors.
The two retroviral vectors tested were CNCG and MFG.S eGFP. The CNCG 
retroviral vector (Soneoka et al. 1995) was used in experiments RV1 and RV3. 
CNCG has two wild type Moloney MLV LTRs and contains an internal CMV 
promoter driving GFP expression. The MFG.S retroviral vector (Riviere et al. 
1995) was tested in experiment RV2. This vector backbone was used in the X- 
SCID trials to deliver yc to target cells. The GFP reporter gene in this construct is 
expressed from the 5’LTR.
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6.2. Results
6.2.1. Retroviral vector mutagenesis experiments in the BCL15 
cell line
5 x 107 target cells each were transduced in RV1 and RV3. In the standard 
selection, 6 IL-3 independent mutants (C10, C40, C57, C96, C59 and C94) were 
obtained with the CNCG vector; versus zero in the mock transduced arm of the 
experiment (Table 6.1.). This was at a combined integrant frequency of 9.5 x 10'8 
by Q-PCR and 9.0 x 10'8 by GFP. CNCG-transduced target cells in experiment 
RV3 were also selected in FCS plus 1pg/ml bovine GH. However, this method of 
selection did not result in any mutants. Ghr insertional activation is therefore not 
the main mechanism whereby CNCG transforms BCL15 cells.
One mutant, “G18”, was obtained with the MFG.S vector in experiment RV2 at an 
integrant frequency of 1.8 x 10'7 by Q-PCR and 5.9 x 10'8 by GFP. The Q-PCR 
integrant frequency in RV2 is higher than the GFP integrant frequency. 
Surprisingly, the number of integrants determined by Q-PCR was 3 fold lower 
than that determined by GFP, whereas normally the reverse is seen. Single cell 
clones were cloned out of this MFG transduced population. Only 14% of the 
clones were GFP positive. This is consistent with the Q-PCR data which gave an 
average of 0.11 vector copies per cell in this experiment.
6.2.2. Characterisation of the retroviral vector mutants
The number of vector copies in these 7 retroviral vector mutants was determined
by Southern blot (Figure 6.1.). On Southern blots of mutants C40, C96, C59 and 
G18 only a single band could be seen. Mutant C94 is most probably a 
spontaneous mutant: it does not show any bands on Southern blot. (It does not 
express GFP determined by flow cytometry; neither could integrated GFP copies 
be detected by Q-PCR (Data not shown)).
Mutants C10 and C57 seem to both contain several copies of the vector, but 
exactly how many could not be clearly made out. All mutants in RV1 and RV3 
were independent clones.
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Table 6.1. Retroviral vector mutagenesis frequencies after standard selection and selection in 
foetal calf serum plus 1 pg/ml bovine growth hormone
Cvn Target
Cell
Mock Mutants Retroviral Vector Transduced Mutants
txp vector Mutant
Number Cell Frequency3
Mutant
Number Cell Frequency3
Integrant 
Frequency b
Standard Selection
RV1 CNCG BCL15 0 < 2.0 x 10"® 4 8.0x10-®
1.2x10“' 
7.0 x 10 ®
RV2 MFG.S BCL15 0 < 2.0 x 10"® 1 2.0x10-®
5.9 x 10 ® 
1.8 x 1 0 7
RV3 CNCG BCL15 0 < 2 .0 x1 0 '8 2 4.0 x 10-®
5.9 x 10 ® 
1.2 x 10'7
Selection in foetal calf serum plus 1 pg/ml bovine growth hormone
RV3 CNCG BCL15 0 <2.0x10-® 0 <2.0x  10-®
< 2.9 x 10 
<5 .9x  10-®
2 0 0 .
Table 6.1. Retroviral vector mutagenesis frequencies after standard 
selection and selection in foetal calf serum plus 1 pg/ml bovine growth 
hormone.
5 x 107 BCL15 target cells were transduced with the CNCG (RV1 and 3) or 
MFG.S eGFP (RV2) retroviral vectors. Cells were cultured in the presence of IL-3 
for 48-72 hours following transduction. Cells were washed of IL-3 on day 3/4 of 
the experiment. In experiment RV1 and 2, 5 x 107 cells were selected only 
according to the standard selection protocol as described in Table 3.1. In 
experiment RV3, 5 x 107 cells each were subjected to either the standard 
selection protocol or selection in foetal calf serum plus 1 pg/ml bGH, as described 
in Table 4.3.
a The cell frequency was calculated by dividing the number of mutants by the 
total number of target cells in the experiment. The average cell frequency at 
which mutants were obtained with CNCG was 6 x 10'8 (experiment RV1 and 
RV3). The difference between the observed cell frequencies in the mock and 
CNCG arms of the experiment was significant: RV1 and RV3 standard selection 
p < 0.001, X2 = 60; RV2 standard selection p < 0.001; X2 = 20.
b The integrant frequency was calculated by dividing the number of mutants by 
the total number of integrants in each experiment.
The number of “GFP” integrants was calculated by multiplying the number of live 
target cells by the MOI. The MOI was determined by flow cytometry for GFP 
expression at 48h to 72h post-transduction. The GFP integrant frequency is 
shown in green.
In experiments LV4 and LV5, the average number of vector copies per cell was 
also determined by Q-PCR. This number was multiplied by the number of target 
cells to obtain the number of “Q-PCR” integrants. The Q-PCR integrant frequency 
is shown in black.
The average integrant frequency at which mutants were obtained with CNCG 
was 9.0 x 10-8 (GFP) and 9.5 x lO-8 (Q-PCR).
201.
a . Hindi 11
CNCG
BamHI
?
U3
SD Neo CMV
MFG.S eGFP 
b.
RV1 RV3
LO
CO i -
oOzoQ.
Csl «
<  I]- o 4 - - ^ o o h - c D C T ) ^ r ^  r o < 0 ' - ^ i f i G i n o ) > 0- j c o c Q o o o o o o x m
____ U3 as SD y, SAr 1
GFP
U3 E
]  Probe
BamHI
GFP i U3 E
1 Probe
RV2
mco
O
LL
S
CL
in<D
■S Li. —I 00 —ITO <  o  J- O
_ l  CO CD O  CD
8
Hindlll
i
SB 1 1 1 0 1
IPCR 10 1 4 1 0 0 1
Southern Blot 1
Inverse PCR 2
Figure 6.1. Southern blots o f IL-3 independent mutants obtained in experim ents RV1 -  3.
a.The retroviral vectors CNCG and  MFG.S eGFP are shown as proviruses.The unique Hindlll (CNCG) and 
BamHI (MFG.S eGFP) sites used in Southern blotting are indicated. Blots were probed with the cDNA  
for GFP.
b. 15pg genomic DNA of each m u ta n t was digested with Hindlll (RV1 and 3) or BamHI (RV2). Blots were  
exposed to  autoradiography film. The tables below each blot show the estimated vector copy num ber 
and th e  num ber of integration sites in each mutant that were cloned out by inverse PCR.
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6.2.3.Integration sites analysis of iL-3 independent mutants 
obtained with retroviral vectors
Retroviral vector integration sites were cloned by inverse PCR, as illustrated for 
lentiviral vector integration sites in Figure 4.3. Mutant genomic DNA was digested 
with Mspl. Divergently oriented primers in the MLV LTR U3 region were used to 
amplify genomic DNA flanking the 5’LTR. An MLV-derived retroviral vector was 
used to introduce human Bcl2 into BAF3 cells to establish the BCL15 cell line 
(Collins et al. 1992). The BCL15 cell line in use in our lab is a single cell clone of 
a BAF3 cell population transduced with this vector. It is not known at how many 
copies the human Bcl2 expressing vector is present in the BCL15 cell line. The 
integration site(s) of this vector in parental BCL15 cells and mutants might 
therefore be amplified by inverse PCR. For this reason, any interesting 
integration sites cloned out by inverse PCR were confirmed by site-specific PCR 
for their presence only in the mutant and not in parental BCL15 cells. However, 
the integration site of the human Bcl2 vector in BCL15 cells was never identified. 
Vector integration sites were successfully obtained from all mutants (Table 6.2.), 
with the exception of RV3 mutant C59. Out of the 18 retroviral integration sites 
(RIS) identified, 10 (56%) were within 5 kb of transcription start sites of genes. 
This is consistent with the reported preference for MLV integration near promoter 
regions. If these vector insertions were to affect gene expression, this would most 
likely be because of enhancer insertions: 6/10 RIS were downstream of 
transcription start sites, of the remaining 4, 3 were upstream but in reverse 
transcriptional orientation.
Significantly, no integration sites into the Ghr locus were identified in any of the 
retroviral vector mutants.
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A RIS 2.6 kb downstream of the IL-3 gene transcription start site was identified in 
mutant G18. The GM-CSF (Csf2) gene transcription start site is located 17.4 kb 
downstream of the IL-3 gene; therefore, the MFG.S RIS was also 14.8 kb 
upstream of the GM-CSF gene in the same orientation as GM-CSF gene 
transcription.
In mutants C40 and C96, that each contained just a single copy of the vector, 
RIS near common insertion site (CIS) loci were identified. CIS are loci that were 
targets of wild type retrovirus integration in multiple independent mouse tumours 
and are likely to encode a cancer associated gene (Akagi et al. 2004).
In mutant C40, the CIS associated oxysterol binding protein like 3 (Osbpl3) gene 
was 46 kb downstream of the vector integration site. The RIS in mutant C96 
occurred within the second intron of the Rps16 gene; the Evi24 CIS locus (Zfp36/ 
Plekhg2) is 20-30 kb downstream of this site. In mutant C57, four RIS were 
recovered. One of these was in semaphorin 4b (Sema4b), which is a CIS, 
Evil67. Furthermore, a RIS within a gene encoding a well known transcription 
factor GATA-1 was found. 10 RIS were recovered from mutant C10, but none of 
these were in CIS. The insertion site from mutant C59 was not recovered.
It is not immediately evident by which mechanisms, insertional dysregulation of 
the genes near the RIS in the CNCG mutants results in IL-3 independence of 
these mutants. The possible significance of insertions near CIS loci will be 
discussed later.
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Table 6.2. Retroviral vector integration sites in IL-3 independent mutants 
(RV1-2)
Clone SB IPCR
In
Gene
(Y/N)
Gene
Name
Entrez
Gene
ID
Chr Distance to TSS Ori
Predicted Gene 
Function RTCGD
RV1
C10 10
Y Slc36a3 215332 11 3539bp intron 3-4 +
Proton amino acid 
transporter
Y Mamdc2 71738 19 96kb intron 8-9 -
N 16
N 4
Y Psma6 26443 12 685bp intron 1-2 +
Endopeptidase/hydrolase
activity
N 13
N Zdhhc4 72881 5 165bpupstream -
Zinc ion binding; 
acetyltransferase activity
N 4
N Mvd 192156 8 1030bpupstream -
Diphosphomevalo-nate 
decarboxylase activity
N Dusp6 67603 10 4740bpdownstream
Dual specificity 
phosphatase 6
C40 1 1 N Osbpl3 71720 6* 46kbupstream +
Lipid transport; 
steroid metabolism 2
C57 4
Y My 14 17896
11*
802bp intron 
1-2 + Motor activity
N Cdc27 217232 1067bpupstream - Cell division
Y Sema4b 20352 7* 21kb Intron 2-3 +
Cell differentiation; 
nervous system 
development
Evil 67 
5
N 9*
Y Gatal 14460 X* 4241 bp Intron 1-2 +
Transcription factor 
activity
C96 1
Y Rps16 20055
7
779bp 
Intron 2-3 +
Structural constituent of 
ribosome
N Zfp36/Plekhg2 101497
21kb
downstream -
Guanyl nucleotide 
exchange factor activity
Ev/24
9
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Clone SB IPCR
In
Gene
(Y/N)
Gene
Name
Entrez
Gene
ID
Chr Distance to TSS Ori
Predicted Gene 
Function RTCGD
RV2
G18 1 2
N II3 16187 11* 2607bpdownstream +
Cytokine/growth factor 
activity
N Fbxo9 71538
9
3183bp
upstream +
Ubiquitin-protein ligase 
activity
N Ick 56542 5744bpupstream -
Protein kinase activity; 
signal transduction
Table 6.2. Retroviral vector integration sites in IL-3 independent mutants 
(RV1-3)
Inverse PCR was performed on IL-3 independent mutants from RV1-2 using the 
restriction enzyme Mspl. PCR products were gel extacted, cloned into a plasmid 
vector and then sequenced. Vector-genome junction sequences were blasted 
against the mouse genome, released August 2007 
(www.ensembl.org/Mus musculus). No RIS were obtained from RV3 mutants 
C59 and C94.
SB indicates vector copy number in the mutant estimated by Southern blot. IPCR 
indicates the number of insertion site loci identified in the mutant by inverse PCR. 
The asterisks in the chromosome column indicate that the integration site found 
in this locus was verified by site-specific PCR. Site-specific PCR was not 
performed on any of the integration sites found in mutant C10. The integration 
site in mutant C96 and the integration site in chromosome 9 in mutant G18 could 
not be confirmed by site-specific PCR.
The distance to the transcription start site (TSS) of the nearest gene is shown. 
Ori indicates whether the vector insertion occurred in the same (+) or in the 
opposite (-) orientation as the gene’s transcript. Predicted gene function is shown 
where known. The number of appearances in the retroviral tagged cancer gene 
database (RTCGD) of each insertion site locus is shown where applicable.
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6.2.4. None of the IL-3 independent retroviral vector mutants 
express the Ghr transcript; all except one express the IL-3 
transcript
To confirm that retroviral insertional mutagenesis did not occur through activation 
of the Ghr gene, RT-PCR for the Ghr transcript was performed. None of the 7 
mutants obtained with CNCG or MFG.S expressed the Ghr transcript (Figure 
6.2.a). Mutant G18 would be expected to express the IL-3 transcript, as it has a 
RIS downstream of the IL-3 gene. A normal size transcript encompassing the 
complete coding region could be detected by RT-PCR (Data not shown).
Earlier experiments suggested that activation of IL-3 gene expression was a 
mechanism whereby BCL15 cells could spontaneously become IL-3 
independent. IL-3-Q-RT-PCR was therefore performed on all mutants by Mustafa 
Ceylan, an MSc student in the lab (Figure 6.2.b). Only mutant C59 did not 
express the IL-3 transcript. Mutant C94, which does not contain any copies of the 
vector, is a mock mutant that has spontaneously activated IL-3 expression. 
Mutant G18, which has a RIS downstream of IL-3, expresses the IL-3 transcript 
at very similar levels to C94. All mutants from experiment RV1 also express the 
IL-3 transcript, but at somewhat lower levels than G18 and C94. These mutants 
have either spontaneously activated IL-3 gene expression or insertional 
activation of genes near the retroviral integration sites resulted in IL-3 gene 
expression.
Mustafa Ceylan also measured expression levels of genes near RIS in mutants 
C40 (Osbpl3), C57 (Sema4b and Gatal) and C96 (Plekhg2 and Zfp36). He found 
no difference in expression levels of these genes between parental BCL15 cells 
and mutants (Data not shown).
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Figure 6 .2 .The IL-3 independent mutants obtained with retroviral vectors in experiments RV1-3 
do not express the Ghr transcript; all but one of them express the IL-3 transcript.
a. A reverse-tran scr ip tase  (RT) PCR for exp ress ion  o f  the Ghr transcript w as perform ed on  parental cells  
a n d  IL-3 in d e p e n d e n t  m u ta n ts  from  ex p er im en ts RV1-3. A forward primer in exon  4  and  a reverse  
prim er in exon 8 were used to am p lify  a 5 5 2 b p  section o f  th e  GHR transcript. M ouse liver an d  m u ta n t  
HV A2 RNA w a s u se d  a s a p o s it iv e  con tro l. N one o f th e  m utants ob ta in ed  w ith retroviral v ec to rs  
ex p ress th e  Ghr transcrip t. D ata for th e  tw o  RV3 mutants is not show n.
b. Q uantitative RT-PCR to  m e a su r e  IL-3 transcript levels was perform ed. Results are ex p ressed  as IL-3 
c o p ie s  per 109 18S co p ies . T he error b ars represen t the standard error o f  this ratio. As p o sitiv e  control, 
RNA from  WEHI3B cells w as u se d . O n ly  m u ta n t C59 from experim ent RV3 d o e s  n o t p ro d u ce  th e  IL-3 
tran scr ip t. M utant C94 from  e x p e r im e n t  RV3 appears to  b e  a sp o n ta n e o u s  m u tan t, a s  it w a s  
e s ta b lis h e d  by Southern b lo t a n d  Q-PCR th a t it does not contain  an y  c o p ie s  o f  th e  vector . C 94  
e x p r e s s e s  th e  IL-3 transcript a t sim ilar  le v e ls  to  m utant G18, which has an MFG vecto r  in tegration  s ite  
ju st d o w n str e a m  o f th e  IL-3 g e n e .  All m u ta n ts  obtained in ex p er im en t RV1 a lso  ex p ress  th e  IL-3 
transcript.
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6.2.5. Phenotypical characterisation of IL-3 independent mutants
I previously established that mock mutant M60 from experiment LV4 could
proliferate, at least short term, in serum free medium (Figure 5.3. in chapter 5). 
To be able to differentiate between mutants on a phenotypical basis, RV1 and 
RV2 mutants were tested for their ability to proliferate in serum-free medium 
(Figure 6.3). Short term proliferation was measured by [3H] thymidine 
incorporation and long term proliferation was measured by counting trypan blue 
excluding cells.
Mutant C96 and G18 display the most robust mutant phenotype seen so far. 
They are able to proliferate in serum-free medium. Figure 6.3.a shows they 
proliferate almost as well in serum free as complete medium; the difference is 
less than the 10 fold seen for mutant M60 in Figure 5.3. Although mutant C40 
expresses similar levels of IL-3 as C96 (Figure 6.2.b), it is unable to proliferate in 
serum free medium. Mutants C10, C40 and C57 are IL-3 independent, but lose 
viability at a similar rate to parental BCL15 cells in serum free medium.
6.2.6.Conditioned medium from mutant G18 is able to support 
growth of parental BCL15 cells
To establish whether an autocrine factor was secreted from the cells, I tested 
whether supernatants harvested from mutants could support the growth of 
parental BCL15 cells. Surprisingly, only the supernatant from mutant G18, but not 
C96, was able to support growth of parental BCL15 cells (Figure 6.4.). 
Supernatant from mutant C96 was as ineffective as supernatant from mutant HV 
A2, which acted as a negative control. Supernatant from mutants C10, C40 and 
C57 supported growth of parental BCL15 somewhat at a concentration of 50%. 
The readings are lower at 100% for all supernatants; this is because at this data 
point cells were re-suspended in neat supernatant. As the cells were quite dense 
when the supernatant was harvested, it presumably contained some inhibitory 
factors that were diluted out at other data points.
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Figure 6.3. Mutants C96 and G18 are able to proliferate in serum-free medium.
a. Parental BCL15 cells and mutants from experiments RV1 and RV2 were cultured in: medium 
containing 10% FCS and 10% WEHI (blue); medium containing 10% FCS only (pink) or serum-free 
medium (yellow). Cells were cultured in these media for 24 hours before an overnight incubation in the 
presence of [3H] thymidine. [3H] thymidine incorporation was measured by liquid scintillation 
counting 48 hours after the start of the experiment. Error bars indicate the standard error of the mean 
calculated from 2 independent experiments.
b. Long term proliferation of BCL15 parental cells and the 5 IL-3 independent mutants in these media 
was assessed by counting trypan blue excluding cells every day for 6 days. 105 cells were cultured in 
2ml volume. When the cell count approached 106 cells/ml, cells were passaged. Every two days, 1ml 
medium was replaced by fresh medium in all wells. In the charts, the total cell number is plotted 
against time, taking cell passages into account. Exponential trendlines were fitted to all "10% FCS plus 
10% WEHI" data series. R-squared values were 0.9852,0.98,0.9809,0.9896 for BCL15, C10, C96 and G18, 
respectively. Exponential trendlines were also fitted to the "10% FCS" data series of the 3 mutants; 
R-squared values were 0.9839,0.9933 and 0.9906 for C10, C96 and G18, respectively.
Mutants C10, C40 and C57 died at a similar rate to parental BCL15 cells in serum free medium; only the 
data for mutant C10 is shown here. Mutants C96 and G18 on the other hand were able to proliferate in 
serum free medium with a doubling time of approximately 40 hours.
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Figure 6.4. Supernatant from mutant G18 only is able to support growth of parental BCL15 cells.
Supernatants were collected from  m utants w hen they were at a cell density o f 106 cells per ml. Two 
fold serial dilutions o f supernatant, starting at 100%, were plated out on 2 x 104 cells in a total volume  
o f 2 0 0 pi. Cells w ere cultured in these conditioned media for 24 hours before an overnight incubation  
in th e  presence o f  [3H] thym idine. [3H] thym idine incorporation was measured by liquid scintillation 
counting 48  hours after the  start o f th e  experim ent.
Supernatant from  WEHI3B cells acted  as a positive control. Two fold serial dilutions o f recom binant 
mouse IL-3, starting at a concentration o f 0.1 pg/ml, served as a second positive control. Supernatant 
from  m utan t HV A2 served as a negative  control.The mean value of triplicate wells is shown.
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6.3. Discussion
The two retroviral vectors tested can transform BCL15 cells to IL-3 
independence. With retroviral vectors IL-3 independent mutants were obtained at 
an average integrant frequency of 1.2 x 10'7 by Q-PCR. This is almost three fold 
higher than the average integrant frequency with the HV lentiviral vector of 4.3 x 
10'8. Retroviral vectors transform BCL15 cells to IL-3 independence by a different 
mechanism compared to the HV lentiviral vector. No activation of Ghr gene 
expression was found in any of the retroviral vector mutants. A vector integration 
site near the IL-3 gene was found in the mutant obtained with MFG.S. Five out of 
6 mutants obtained with CNCG, also expressed IL-3. A role of vector insertion(s) 
in stimulation of IL-3 production or transformation to IL-3 independence in these 
mutants was not demonstrated.
6.3.1. IL-3 gene expression by mutants obtained with retroviral 
vectors
All mutants obtained with retroviral vectors, except mutant C59 from experiment 
RV3, express the IL-3 transcript. In addition, in previous chapters it was shown 
that a common mechanism whereby BCL15 cells spontaneously become IL-3 
independent is by activation of IL-3 gene expression.
At this point, it would be useful to briefly discuss regulation of murine IL-3 gene 
expression, on a transcriptional and post-transcriptional level. I shall then 
proceed to consider the implications of this on IL-3 gene expression by the 
mutants.
6.3.1.1. Regulation of murine IL-3 gene expression
As mentioned in the introduction to chapter 3, IL-3 is normally only expressed by
activated T cells, NK cells, mast cells and some megakaryocytic cells (Blalock et 
al. 1999). The murine IL-3 promoter is considerably less well studied than the 
human IL-3 promoter. The two promoters share 59% sequence homology 
(Osborne et al. 1995). Cytokine (CK) 1 and 2 elements, GATA, AP-1 and core 
binding factor (CBF) binding sites are found in both promoters. The TATA box of 
the mouse IL-3 gene is located 30bp upstream of the transcription start site. A
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critical transcription factor involved in the regulation of IL-3 gene expression is 
Nuclear Factor of Activated T cells (NFAT) (Osborne et al. 1995; Ko et al. 2007). 
NFAT is activated following TCR signalling in T cells and Fes crosslinking on 
mast cells. Phosphorylated NFAT is localised in the cytoplasm; upon calcium 
signalling it is dephosphorylated by calcineurin and subsequently translocates to 
the nucleus. Cyclosporin inhibits calcineurin and NFAT mediated IL-3 gene 
expression was found to be cyclosporin sensitive. In the mouse IL-3 gene locus 
three NFAT binding regions were identified. The first one is in the IL-3 promoter 
region (between -293 and -150bp); the second one is in intron 1-2 of the IL-3 
gene (Ko et al. 2007). NFAT binding sites were also identified in an enhancer 
located 11 kb downstream of the IL-3 transcription start site (Osborne et al. 1995). 
This enhancer activates transcription of both the IL-3 and GM-CSF genes. The 
latter is located 14kb downstream of the IL-3 gene on chromosome 11. 
Post-transcriptional regulation of IL-3 gene expression is regulated by an AU-rich 
element (ARE) in the 3’UTR of the IL-3 transcript (Gillis and Malter 1991). This 
element binds hnRNP-D, which destabilises IL-3 mRNA, resulting in rapid 
turnover of IL-3 transcripts.
In the IL-3 expressing mutants C10, C40, C57 and C96 that do not contain vector 
integration site near the IL-3 gene, we could measure the levels of transcription 
factors regulating IL-3 gene expression.
6.3.1.2. Activation of IL-3 gene expression by transposable elements 
and retroviral vectors
In the WEHI3B mouse myelomonocytic cell line, an IAP insertion upstream of the 
IL-3 gene resulted in constitutive IL-3 expression by the cells. IAP insertion 
occurred in reverse orientation with respect to IL-3 transcription, so IL-3 
activation is a result of enhancer insertion (Ymer et al. 1985; Ymer et al. 1986). 
Disruption of the 3’UTR ARE by IAP insertion results in increased IL-3 mRNA 
stability as well as IAP enhancer mediated activation of gene expression (Mayo 
etal. 1995).
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6.3.1.3. Mechanism of IL-3 gene activation in mutant G18
In the G18 mutant from experiment RV2, the MFG.S retroviral vector insertion
site (RIS) occurred downstream of the IL-3 gene. The insertion occurred 2.6kb 
downstream of the IL-3 transcription start site and did not disrupt the 3’UTR ARE. 
Since an endogenous enhancer is located 11 kb downstream of the transcription 
start site, it is not surprising that a retroviral vector 2.6 kb downstream is able to 
activate transcription. This vector insertion also has the potential to activate GM- 
CSF gene expression by an enhancer mechanism. However, I was unable to 
demonstrate this by RT-PCR.
6.3.1.4. Possible mechanisms of IL-3 gene activation in the other four 
retroviral mutants
In four other mutants obtained with the CNCG retroviral vector, IL-3 gene 
expression was also activated, yet no RIS in or near the IL-3 gene were identified 
in the mutants. Several possibilities exist by which these mutants activated IL-3 
gene expression to become IL-3 independent.
Firstly, I explored whether activation of CIS genes or other genes near RIS could 
result in activation of IL-3 gene expression. The following CIS insertions were 
found in mutants C40, C57 and C96:
Mutant C40
The integration site in mutant C40 is intergenic. The nearest transcription start 
site is 46 kb downstream, that of the Osbpl3 (oxysterol binding protein like 3) 
gene. The Osbpl3 locus is listed as a CIS in the RTCGD database. In a mouse 
model of pre-B cell leukaemia, the rate of which could be accelerated by Mo-MLV 
induced insertional mutagenesis, two RIS sites in this locus were identified (Bijl et 
al. 2005). Genes that collaborated with the E2a-PBX1 fusion protein were 
identified using this approach. 18% of integrations in these pre B cell leukaemias 
were found in the Hoxa locus on chromosome 6. The Hoxa locus, itself a CIS 
(Evi7), encodes homeobox transcription factors expressed in haematopoietic 
cells. The Hoxa locus is 2 Mb upstream of Osbpl3. Instead of representing a new 
proto-oncogene, RIS in the Osbpl3 locus are thought to also act via Hoxa gene
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up-regulation in pre-B cell leukaemias. We have not looked at expression levels 
of Hoxa genes in mutant C40.
Mutant C96
The integration site in mutant C96 is in a gene dense region. It is located in intron 
2-3 of Rsp16s (ribosomal protein 16S). However, this RIS is also 21/ 28 kb 
downstream of the Plekhg2/ Zfp36 transcription start sites. Plekhg2, also known 
as Clg, encodes a guanine nucleotide exchange factor and is a CIS, Evi24 
(Himmel et al. 2002). Insertions upstream of this gene activate Plekhg2 
expression in B cell and myeloid leukaemias.
Mutant C57
In mutant C57, four RIS were found. One of these was in semaphorin 4b 
(Sema4b), a CIS (Evi167). The insertion was in the same transcriptional 
orientation in the second intron of Sema4b. Out of the 5 RIS found in mouse 
tumours in this locus, 3 occurred upstream of the gene; the other ones were in 
intron 1 and exon 2, which is the first coding exon of this gene.
The RIS in Gatal, though not a CIS, is also potentially interesting as it occurred 
upstream of the first coding exon 2 in the same transcriptional orientation. Upon 
IL-3 signalling in BAF3 cells, the transcription factor GATA-1 is phosphorylated 
on serine 26 by a MAPK-dependent pathway. It is then mediates transcription of 
the survival gene E4bp4, which is itself a transcription factor, and B c I-X l (Yu et al. 
2002; Yu ef al. 2005). The same group showed that BAF3 over-expressing 
GATA-1 maintained cell viability for longer upon IL-3 withdrawal (Yu et al. 2002).
216.
It was hypothesised that CIS gene activation could somehow up-regulate activity 
of transcription factors controlling IL-3 gene expression. However, we were 
unable to demonstrate CIS gene up-regulation in these mutants when cultured in 
the absence of IL-3; neither could up-regulation of GATA-1 transcription factor 
expression be demonstrated in mutant C57. It remains possible that retroviral 
vector insertion alters CIS gene expression for example on initial IL-3 removal.
It would be interesting to analyse RIS in a few random, IL-3 dependent clones, 
that were transduced with retroviral vectors, but were not selected for IL-3 
independence. If RIS in CIS loci were found in these random clones, that would 
suggest they were probably not significant in transformation to IL-3 
independence of our mutants and the recovery of RIS in CIS in them was just an 
incidental finding. It is also possible that retroviral vector insertion could have 
affected expression of genes much further a field than we investigated. These 
genes could be responsible for the activation of IL-3 expression. Large scale 
analysis of gene expression in these mutants by microarray would have to be 
performed to identify such genes.
There is no data to suggest that either Hoxa, Plekhg2 or GATA-1 gene up- 
regulation will activate IL-3 gene expression. However, up-regulation of 
expression of these genes in haematopoietic cells in combination with IL-3 is 
possible. In this model, insertional activation of genes near CIS is not responsible 
for activation of IL-3 gene expression per se, but cooperates with IL-3 in cells that 
have switched on low level expression of this cytokine, to produce an IL-3 
independent phenotype.
Lastly, retroviral vector insertion might not have been involved in transformation 
to IL-3 independence of these mutants at all. In previous experiments, it was 
observed that activation of IL-3 gene expression was a common mechanism by 
which BCL15 cells spontaneously became IL-3 independent. The mechanisms by 
which this can occur will be discussed below.
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6.3.1.5. Mechanisms of spontaneous activation of IL-3 gene 
expression
In the introduction to chapter 3, a study was cited in which mutants of the IL-3 
dependent cell line FDC-P1(M) were selected for activation of GM-CSF alpha 
chain expression following retroviral vector transduction (Laker et al. 2000) (See 
Table 3.1). In 40% of the GM-CSF alpha chain expressing mutants analysed, 
gross chromosomal rearrangements of the GM-CSF alpha chain locus were 
found to have occurred. It is conceivable that this mechanism could also be 
responsible for spontaneous transformation to IL-3 independence of BCL15 cells. 
We have not looked for deletions, insertions or chromosomal translocations 
involving the IL-3 locus in any of our IL-3 expressing “mock” mutants from 
experiments LV3 and LV4 or the CNCG mutants C10, C40, C57 and C96. 
Epigenetic changes could also be responsible for activation of IL-3 gene 
expression in these mutants. It was shown that site-specific demethylation of the 
IL-3 promoter is associated with IL-3 gene expression in activated mouse CD8+ T 
cells (Fitzpatrick et al. 1998). We have not analysed the methylation status of the 
IL-3 promoter in our mutants, but demethylation could result in spontaneous IL-3 
gene expression in these cells.
Lastly, it was shown that intracisternal A particle (IAP) transposition is a common 
mechanism of spontaneous transformation to IL-3 independence in the mouse 
IL-3 dependent D35 and FDC-P cell lines (Stocking et al. 1988; Heberlein et al. 
1990; Wang et al. 1997). lAPs are transposable elements present in the genome 
of Mus musculus at 1000 copies per haploid genome (Lueders and Kuff 1980). 
They are expressed in embryonic and transformed mouse cells. lAPs are 
defective in envelope protein synthesis, and are retained in the endoplasmic 
reticulum of the cell (Perk and Dahlberg 1974). The IAP activity in BAF3 cells is 
not known, but could account for spontaneous transformation to IL-3 
independence of these cells.
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6.3.2. Phenotypical characterisation of the retroviral vector 
mutants
Mutant G18 that has a RIS near the IL-3 gene, and the spontaneous mutant C94, 
expressed the highest levels of IL-3 transcript. The lower levels at which the IL-3 
transcript was expressed by the four IL-3 expressing CNCG mutants varied less 
than 10 fold.
We tested which of the 5 mutants from RV1 and RV2 were able to proliferate in 
serum free medium. Only mutants C96 and G18 were able to do so.
Conditioned medium from these 5 mutants was assayed for its ability to induce 
proliferation of parental BCL15 cells. An interesting finding was that only 
conditioned medium from mutant G18, but not C96, was able to support growth 
of parental BCL15 cells. The conditioned medium experiment suggests IL-3 is not 
secreted by mutant C96. It could be that this mutant proliferated independently of 
exogenous IL-3, because endogenously produced IL-3 binds the IL-3 receptor 
intracellularly. This has been reported for IL-3 that was engineered to be retained 
in the endoplasmic reticulum (Dunbar et al. 1989).
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6.3.3. Why do retroviral vectors not transform BCL15 cells via 
Ghr activation?
Four fold more HV lentiviral (3.1 x 108 by Q-PCR) than retroviral (8.0 x 107 by Q- 
PCR) vector integrants were screened in the BCL15 cell line. Assuming random 
integration, this means there were fewer retroviral than lentiviral vector hits in the 
Ghr locus. This might be one explanation why no Ghr insertional mutants were 
obtained with retroviral vectors.
As was discussed at the end of chapter 4, the main mechanism whereby 
endogenous MLV (Akv) seemed to activate Ghr expression in a mouse model of 
pre-B cell leukaemia, was by enhancer insertion (Suzuki et al. 2002; Suzuki et al. 
2006). The six RIS in the Ghr locus in these tumours clustered around the L2 
promoter and two thirds were in reverse orientation to Ghr gene expression. The 
LTRs present in the vectors used in this study were derived from exogenous 
MLVs -  Mo-MLV and MPSV. The enhancers contained within the LTRs of these 
vectors might not be able to trans-activate Ghr expression from the L2, L1 or L5 
promoters. Another reason why Ghr enhancer activation was not observed, could 
be because vector integration in the BCL15 cell line did not occur near the L2, L1 
and L5 transcription start sites.
The main mechanism whereby HV activates Ghr gene expression was shown to 
be by HIV-1 promoter insertion. Retroviral vectors integrated in the first intron of 
the Ghr in the same transcriptional orientation as Ghr gene transcription, should 
theoretically also be able to activate its expression by promoter insertion and 
generation of a spliced transcript. Even though MLV promoter insertion was 
described previously (Shen-Ong et al. 1986; Barker et al. 1992), it is expected to 
work less efficiently than HIV-1 promoter insertion, because the retroviral splice 
donor is less potent. Only -30% of MLV primary transcripts are spliced to 
generate the env transcript. In comparison, in HIV-1 over 40 different mRNA 
transcripts are generated by alternative splicing from a single pre-mRNA 
transcript. All these transcripts are spliced from the major splice donor to multiple 
splice acceptors. Full length unspliced HIV-1 transcripts are only maintained once 
Rev is produced.
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Chapter 7
7. Final discussion and future directions
The work described in this thesis was initiated following the news in 2002 that 
several recipients of gene therapy for X-SCID had developed leukaemia. Vector 
induced activation of known T cell proto-oncogenes was believed to be the 
driving force behind this process. In the light of these complications, the 
development of safer vectors for use in future gene therapy clinical trials was of 
the utmost importance. However, at the time no assay systems existed that 
allowed a quantitative assessment of the mutagenic potential of different vectors. 
Simple in vitro assays that would enable quick initial screening of such vectors 
were particularly desirable.
In this thesis I aimed to establish such an assay using the immortalised pro-B cell 
line BCL15, which is dependent on IL-3. The rate at which these cells became IL- 
3 independent following transduction with different vectors was measured. Below,
I will discuss the general implications of the findings in this thesis. The assay will 
be compared to the Baum lab in vitro assay (Modlich et al. 2006; Zychlinski et al. 
2008), discussed in section 1.5.2.3. of the introduction. Table 7.1. summarises 
the main differences between these two assays. Ways to improve our assay will 
be suggested. Lastly, adaptation of this assay into an in vivo screening tool for 
insertional mutagenesis will be considered.
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Table 7.1. Comparison of the Collins versus Baum lab in vitro assays to 
measure insertional mutagenesis
Collins Lab Assay Baum Lab Assay
Target cell IL-3 dependent mouse pro-B 
lymphocyte cell line
Lin' bone marrow from C57BI6
# of target 
cells 5 x 107 105
MOI 4 - 1 2  (LV); 0 . 1 - 1  (RV) 20 (RV)
Selectable
Phenotype
IL-3 independence Acquisition of serial replating 
ability
Selection
Protocol
2-3 day bulk culture with IL-3 
Standard selection:
• Wash of IL-3 on day 3/4
• Add back IL-3 on day 10/11
• Withdraw IL-3 day 13-14
• Score positive flasks 
Modified selection:
• Wash of IL-3 on day 3/4
• Select in FCS plus bGH
• Score positive wells
• 2 week bulk culture
• Plate cells in 96 well plates 
at 100 cells/well I
• Score positive wells after 2 
weeks
Vectors 
tested & 
Integrant 
frequencies
Standard Modified Modlich Zychlinski
HV
CSGW
CNCG
4.3x1 O’8 
4.9 x 10'9 
9.5 x 10'8
9.5x1 O'8 
3.3x1 O'9 
< 5.9 x 10'8
WTSFFV 
SIN SFFV 
SIN SFFV 
cHS4 
SIN EF1a
2.76x1 O'3 
2.30x1 O'4 1.19 x10‘3
4.70x1 O'4 
0
Target
genes
Lenti: Ghr 
Retro: IL-3/ Bcl-XL Retro: Evil
Benefits • No animal, recombinant 
cytokine cost
• Assay scores independent 
I clones
• Sensitive assay for LV 
vector mutagenesis
• 1° cell is more relevant
• Convenient readout
• 104 fold more sensitive in 
detecting transforming 
events
• Sensitive comparison 
between RV vector 
configurations
Limitations • Lower sensitivity
• Inconvenient standard 
selection protocol
• RV vector mutagenesis 
assay not very robust
• Limited # of transforming 
target genes
• Long bulk culture phase
• Assay does not score 
independent clones
• Limited # of transforming 
target genes
RV = retroviral; LV = lentiviral; # = number
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7.1. Insights into the mechanisms of insertional 
mutagenesis by different vectors
At the outset of this project a number of target genes in the BAF3/BCL15 cell line 
had been identified in other studies whose activation could transform these cells 
to IL-3 independence. A gain of function assay for insertional mutagenesis 
should ideally screen as many loci as possible. The immortalisation of primary 
bone marrow cells by retroviral vectors in the Baum lab assay selects for Evil 
insertional mutants. In our assay, we similarly found targeting of specific genes 
by lentiviral versus retroviral vectors.
The main mechanism whereby the wild type HIV-1 LTR lentiviral vector HV 
transforms BCL15, is by activation of the Ghr. HV vector integration in these 
mutants invariably occurs in the first intron of this gene. A fusion transcript is 
present that originates from the HIV-1 5’LTR then splices from the HIV-1 major 
splice donor to the splice acceptor of Ghr exon 2. Ghr insertional mutants 
express the GHR on the cell surface and respond to GH in culture. This finding 
allowed the introduction of a modified, more sensitive selection protocol (See 
section 7.2.)
Activity of the HIV-1 5’LTR, which drives this mechanism of mutagenesis, is likely 
to be a phenomenon specific to the BAF3 ceil line, which we plan to further 
investigate as discussed at the end of chapter 5. The HIV-1 LTR is unlikely to be 
active in the absence of Tat in most target cells of gene therapy. The clinical use 
of HIV-1 LTR-driven lentiviral vectors is likely to be restricted to gene therapy 
directed against HIV-1 infection. In the first clinical gene therapy trial using a 
lentiviral vector, the antisense against HIV-1 env was expressed in T cells in a 
Tat-dependent manner from the HIV-1 LTR (Levine et at. 2006). Use of such a 
vector in HIV-1 gene therapy to transduce more primitive long lived cells such as 
HSC might be more dangerous. In most gene therapy settings use of a SIN 
lentiviral vector will be far more desirable; especially as these can be produced 
transiently to similar titres as their wild-type counterparts. As demonstrated in this 
assay, the SIN configuration readily abolishes the promoter insertion mechanism 
of insertional mutagenesis. The residual transforming potential of SIN lentivectors
223.
will largely depend on the choice of internal promoter, as demonstrated for SIN 
retroviral vectors in the Baum lab assay (Zychlinski et al. 2008). Unfortunately, 
characterisation of the CSGW mutants is incomplete, and the mechanism by 
which they gained IL-3 independence is unknown.
The mechanisms of transformation in IL-3 independent mutants obtained with 
retroviral vectors in this assay were not as clear-cut. In one mutant, a RIS near 
the IL-3 gene was found and activation of this gene presumably occurred via an 
enhancer effect. In the majority of retroviral vector mutants however, a role of the 
vector in transformation was not demonstrated, although insertional activation of 
genes that activate IL-3 expression remains a possibility.
7.2. Quantitation, Reproducibility and Applicability of 
the assay
Two experiments each were performed with the HV, CSGW and CNCG vectors. 
In some experiments mock mutants were obtained. The average frequency at 
which BCL15 cells spontaneously became IL-3 independent was 1.1 x 10'8. IL-3 
independent mutants were obtained at cell frequencies significantly over 
background with the HV and CNCG vectors. The average integrant frequencies 
at which mutants were obtained with the HV, CSGW and CNCG vectors were 4.3 
x 10'8, 4.9 x 10'9 and 9.5 x 10'8, respectively. These frequencies were obtained 
from scoring independent clones. This is in contrast to the Baum lab assay; it 
was reported many of their clones were genetically identical and shared RIS. 
Ideally, more repeat experiments for each vector would need to be performed to 
confirm these frequencies are reproducible and to determine variability in 
frequency between experiments. This was not possible, due to the labour­
intensiveness of the standard selection protocol. A higher throughput selection 
protocol, see section 7.3., might make this feasible.
The current numbers allow us to conclude that the wild type HIV-1 LTR vector 
has a greater potential for insertional mutagenesis than the SIN vector CSGW; 
the numeric difference is 9 fold. Mechanistically, this is supported by the fact that 
none of the CSGW mutants activated Ghr expression. The difference in integrant 
frequencies between HV and CSGW was even greater (29 fold) after selecting
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BCL15 cells transduced with these vectors in serum plus GH. This modified 
selection protocol is biased towards picking up Ghr-insertional mutants and is 
very sensitive in doing so; making it particularly suitable for screening safety 
optimised variants of HV vectors. The readout of this modified protocol is simple. 
A frequency can be calculated assuming that at least 70% of wells contain 
independent mutants. Another 1.9 x 108 HV integrants were recently screened by 
Abinav Gupta, a BSc student in the lab. 15 wells were scored. These clones have 
not been characterised yet, but IL-3 independent mutants were obtained at an 
integrant frequency of at least 5.5 x 10'8 in this experiment.
Four fold fewer retroviral than HV lentiviral integrants were screened. The 
average integrant frequency for CNCG was 9.5 x 10"8, 2 fold higher than for HV. 
The CNCG integrant frequency is close to the 2 x 10'7 integrant frequency at 
which an MPSV retroviral vector transforms TF-1 cells to factor independence 
(Stocking et al. 1993). As discussed above, no one clear mechanism whereby 
retroviral vectors transform BCL15 cells to IL-3 independence was identified. So 
in contrast to HV mutagenesis, no tailor-made selection protocol that allowed 
rapid screening of different retroviral vector configurations could be introduced.
As shown in Table 7.1., the strength of the Baum lab assay is that it allows a 
direct comparison between the transforming potentials of different retroviral 
vector configurations (non-SIN versus SIN; different internal promoters within a 
SIN vector). Currently it is not possible to detect such differences in our cell line 
assay. Also going by the Baum lab assay numbers, we would have to screen 10 
to 100 fold more retroviral integrants.
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7.3. Towards a more high throughput selection protocol
At present only our modified selection protocol that is biased towards picking up 
Ghr-insertional mutants, has a convenient readout. This is much like the Baum 
lab assay where wells containing replating cells are scored 2 weeks after 
seeding. Our current standard selection protocol is time-consuming and limits the 
number of cells that can be screened in each experiment. This necessitates 
transduction at high MOI to screen a sufficient number of integrants. Resulting 
mutants contain several copies of the vector, increasing the number of vector 
integration sites that need to be cloned per mutant and complicating identification 
of the transforming gene. This was especially of practical importance in the early 
stages of the project, because we were interested in analysing the mechanisms 
of transformation. Ideally, more cells with on average one vector copy per cell 
could be screened. We need an unbiased selection protocol that allows mutants 
to grow out when grown in serum only without IL-3.
I started this thesis by testing assay conditions to facilitate selection for IL-3 
independent mutants of the BAF3 cell line. X-irradiation was used as a strategy 
to eliminate more effectively parental BAF3 cells, so these would not be rescued 
upon re-addition of IL-3 to the media, which was needed to allow the expansion 
of IL-3 independent mutants from amidst dying cells. This strategy has not yet 
been tested on BCL15 cells. Bcl-2 expression should somewhat protect BCL15 
cells from irradiation-induced apoptosis in the absence of IL-3 (Ascaso et al.
1994). Activation of cytokine or growth factor receptor expression should offer 
additive or synergistic protection to mutants. Currently, IL-3 independent mutants 
are selected in liquid medium. Selection cultures contain 5 x 105 cells, initially per 
well of a 24 well plate and later in a T25 flask. So far, I have never seen more 
than one clone growing out of a population of 5 x 105 cells. Selection in semi­
solid media, such as soft agar or methylcellulose, would allow immediate 
selection for single cell clones. Outgrowth of mutants without the need for rescue 
with IL-3 might be possible in this setting, as this might not now be inhibited by 
the presence of large numbers of dead cells in the immediate vicinity. Similar to 
the current modified selection protocol, there would still need to be an initial
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determination of the number of independent clones because the cells are grown 
as bulk culture for 3 days following transduction.
Another way to make the assay more sensitive is to introduce more biased 
selection, specifically for insertional mutants that have activated expression of 
receptors or subunits thereof. Selection of such mutants is at present limited by 
the availability of ligand of these receptors in serum. For example, selection in 
serum plus GM-CSF picked up retroviral insertional mutants of the FDC-P1(M) 
cell line that had activated expression of the GM-CSF receptor alpha chain 
(Laker et al. 2000). As demonstrated in the introduction to chapter 3, signalling 
by many other interleukin or growth factor receptors in BAF3 can substitute for IL- 
3.
7.4. Towards an in vivo assay
Neither parental BAF3 nor BCL15 cells are tumourigenic in vivo (Palacios and 
Steinmetz 1985). We have not established yet whether any of our IL-3 
independent mutants are tumourigenic in vivo when injected into nude or 
syngeneic mice. In one study, wild-type MPL (WT-MPL) and a constitutively 
active mutant of MPL (Mu-MPL) were expressed in BAF3 cells (Alexander et al.
1995). WT-MPL cells were dependent on IL-3 or TPO for growth, whereas Mu- 
MPL cells grew independently of any growth factors. In another study, a different 
MPL mutant conferred serum-independent growth onto BAF3 cells (Onishi et al.
1996). In both studies WT-MPL and Mu-MPL expressing BAF3 cells were 
injected into BALB/c mice. Only mice that received Mu-MPL cells developed 
tumours after 2-3 weeks. Total follow-up of these animals was 2 - 3  months.
Like MPL, the GHR belongs to the haematopoietin family of receptors. BAF3 
cells expressing GHR e.g. mutant HV A2, would therefore unlikely to be 
tumourigenic in vivo. This might be different for BCL15 cells expressing the GHR, 
as these cells have 2 oncogenic hits.
Adapting the in vitro mutagenesis assay in the BCL15 cell line to an in vivo model 
would be desirable as this is ultimately more relevant to the clinical gene therapy 
setting. BAF3 and/or BCL15 cells transduced with different vectors could be 
transplanted into nude or BALB/c mice that are then monitored for tumour
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formation. Other factor-dependent cell lines could be used such as the I n ­
dependent cell lines FDCP-mix and M-07; or IL-2 dependent cell lines CTLL-2 
and HT-2. These cell lines were not suitable for the development of an in vitro 
mutagenesis assay because they are not robust enough. It was demonstrated 
that nude and syngeneic mice injected with CTLL-2 cells transduced with a 
retroviral vector expressing IL-2, developed lymphomas (Yamada et al. 1987). 
Lastly, to develop our in vitro assay we used an immortalised cell line expressing 
human Bcl-2. In extension, we plan to select for oncogenes cooperating with Bcl-
2 by transducing factor-dependent cell lines or primary mouse bone marrow cells 
with vectors e.g. HV or MFG that encode human Bcl-2. These cells will then be 
transplanted back into mice and monitored for tumour formation. These type of 
studies have so far been performed using retroviral vectors encoding the Sox4 
(Du et al. 2005) and SV40 large T antigen oncogenes (Li et al. 2007). In the 
former study, recipients of bone marrow transduced with the Sox4 expressing 
retroviral vector developed myeloid leukaemias (Du et al. 2005). In the latter 
study, both IL-3 dependent 32D as well as mouse bone marrow was transduced 
(Li et al. 2007). SV40 large T expression in 32D cells was insufficient to confer IL-
3 independence on these cells. However, mice transplanted with these cells 
rapidly developed acute myeloid leukaemia (AML), whereas recipients of bone 
marrow transduced with the SV40 vector developed histiocytic sarcoma and 
myeloid leukaemias. As a proof of principle, in all tumours RIS in loci known to 
cooperate with SV40 large T antigen were identified.
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